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Summary
RANTES is a member of the CC chemokine family and has previously been shown to 
attract human eosinophils, memory CD45RO T lymphocytes and monocytes; cells 
which comprise the cellular infiltrate in many allergic sites. Since the guinea pig is 
frequently used in the analysis of allergic inflammation, recombinant guinea pig (gp) 
RANTES was purified and characterised and patterns of RANTES mRNA expression in 
the lung determined, in order to assess its role in this species.
In a guinea pig model of allergic lung inflammation, no differences in RANTES mRNA 
were detected between naive and ovalbumin sensitised animals after antigen challenge. 
In comparison, increased expression of MCP-1 mRNA was observed in sensitised 
animals compared to time-matched controls. In situ hybridisation analysis demonstrated 
that the macrophage was a potential source of RANTES, although bronchial epithelium 
and endothelial cells also stained positive. Furthermore, a similar cellular distribution 
was noted for eotaxin. However, neither RANTES nor eotaxin message were expressed 
in primary cultures of guinea pig lung fibroblasts, but these cells did express high levels 
of MCP-1 mRNA.
To investigate further the role of RANTES, the recombinant protein was purified and 
characterised. A high level of gpRANTES protein expression in E. coli was achieved 
by mutation of a human (h) RANTES expression construct to obtain a 68 amino acid 
protein identical to the predicted amino acid sequence, assuming an equivalent N 
terminus to hRANTES. Purified gpRANTES was an effective stimulus of human 
eosinophils as assessed by increases in intracellular free calcium in fura-2-loaded cells 
and chemotactic responses in vitro. gpRANTES exhibited similar potency and efficacy
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to hRANTES. In marked contrast, neither gpRANTES nor hRANTES were able to 
activate guinea pig peritoneal eosinophils in these assays, even in the presence of 
priming agent, IL-5. However, gpRANTES was found to be a potent stimulator of 
guinea pig peritoneal macrophages. A similar profile of activity was noted in vivo. 
Following tracheal instillation of gpRANTES, a dose dependent increase in macrophage 
numbers but not eosinophils was observed in gpBAL. Macrophage accumulation was 
detectable by 6 h and sustained for at least 48 h. Furthermore, intradermal injection of 
gpRANTES into guinea pig skin sites induced the accumulation of macrophages at 24 h. 
However, eosinophils were not detected at either 2 or 24 h post injection. These results 
indicate that RANTES has a different cellular selectivity in the guinea pig than that 
described for the human, which may be important in the use of animal models in the 
analysis of allergic disorders.
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1.1 Leukocyte migration is a primary host defence mechanism
Leukocyte migration is a primary host defence mechanism allowing the infiltration of 
phagocytes into inflammatory sites and development of an immune response. The 
Roman writer, Cornelius Celsus, defined the four ‘cardinal signs’ of inflammation as 
redness and swelling with pain and heat. The significance and explanation for these 
observations was not realised until the beginning of the 19th century in the early 
pioneering work of Cohnheim, Mechnikoff and Erlich (reviewed in Ryan & Majno, 
1997). By irritating the mesentery and skin from the tongue of frogs, Julius Cohnheim 
(1882) observed a series of vascular changes analagous to Celsus’ signs. Initially he 
noted the dilatation of blood vessels and that the blood flow increased first in the 
arteries, then the veins, and finally the capillaries. The blood flow slowed especially in 
the veins (venules) and leukocytes were noted to accumulate and adhere as a layer along 
the vessel wall before moving out of the vessel. Some years later, he suggested that the 
reduction of flow, sluggish movement of cells and concurrent swelling of the tissue 
might be due to plasma release into the surrounding tissue. The reason for white blood 
cell movement into the extravascular tissue was not fully appreciated until Metchnikoff 
(1893) suggested that these cells were capable of phagocytosing particles including 
bacteria, and in this way the offending irritant could be removed .
The conclusions of Cohnheim and Mechnikoff were surprisingly prophetic and form the 
basis of current thinking on leukocyte migration. Springer and others (1990) have 
suggested a scenario of precise co-ordinated events which mediate the extravasation of 
cells. Initially, inflammatory mediators cause leukocytes to leave the main vascular 
flow and marginate (roll) along the surface wall; an action which requires attachment to
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and detachment from the endothelium. This phenomenon is achieved by rapid binding 
kinetics (tethering) of sialyl-Lewisx (sLex) on the leukocyte surface to selectins such as 
E-selectin (Bevilacqua et al. 1987), on the endothelium. This process is low affinity and 
is replaced by high affinity leukocyte adherence between p2-integrins expressed on the 
leukocytes and members of the Ig superfamily - intercellular adhesion molecule (ICAM; 
Rothlein et al. 1986; Dustin et al. 1986) and vascular cell adhesion molecule (VCAM; 
Elices et al. 1990), on the endothelial surface. Firm adhesion is followed by 
transmigration through endothelial cell junctions and migration along a chemotactic 
gradient to the site of the stimulus for inflammation.
Mechnikoff s discovery of phagocyosis explained the reason for the existence of such a 
cascade; to allow pathogens to be rapidly cleared from the tissue. The processes of 
phagocytosis, presentation of antigen with major histocompatability complex to T cells 
and subsequent assistance of antibody production by B cells, are well documented (Male 
et al. 1989). The mechanisms by which the necessary cells are selectively recruited to a 
site of inflammation appears to involve complex networks of inflammatory mediators. 
The dissection of the role of individual mediators in various inflammatory conditions 
has been the source of much research over the past few decades not least in the search to 
identify novel therapeutic targets.
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1.2. Asthma: an inflammatory disease
The first description of clinical asthma was by Hippocrates in 4 B.C. detailing a 
condition of breathlessness and deriving the name from the Greek work meaning 
‘panting’. However, descriptions of a seasonal disorder which was treated with an 
extract of the plant Ma huang, a source of the catecholamine ephedrine, are documented 
in Chinese medicine dating between 2500-1000 B.C. (reviewed by Gould & Raffin,
1995). The association between asthma and inflammation was not recognised until 
around the turn of this century. Virchow documented that patients at status asthmaticus 
had airways obstructed by mucus plugs which contained eosinophils. At around the 
same time, Osier, in ‘The Principles and Practice of Medicine,’ 1892 (reviewed by Frew
1996) reasoned that the cause of such obstruction might be due to excessive spasm of 
the bronchial smooth muscle, inflammation of the airways or caused by abnormalities in 
neural control. It was a long held belief that bronchospasm was the basis of the 
underlying pathophysiology giving rise to the reversible limitation of airflow (reviewed 
in Keeney, 1997). Observations that some degree of bronchial inflammation was 
present in all asthmatics were not reported until the 1960s (Glynn et al 1960, Salvato 
1968) and verified by more extensive studies during the early 1980s with the advent of 
fibre-optic bronchoscopy. Of note, studies by Laitinen et a l (1985) demonstrated the 
presence of epithelial destruction and exposure of superficial intraepithelial nerves, even 
in mild asthmatics. The authors suggested that these nerves may be unprotected from 
specific and non-specific stimuli, thereby linking airways inflammation with 
hyperreactivity. It is now recognised that the underlying pathology of asthma is airway 
inflammation, and that bronchodilatory therapy offers only symptomatic, albeit rapid, 
relief.
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1.3. Clinical definition of asthma
A definition of asthma as proposed by the American Thoracic Society (American 
Thoracic Society, 1987) is widely accepted as providing a guideline of the most 
common and stereotypical features of the disease.
‘Asthma is a clinical syndrome characterised by the increased responsiveness of the 
tracheo-bronchial tree to a variety of stimuli. The major symptoms of asthma are 
paroxysms of dyspnea (breathlessness), wheezing and cough, which may vary from mild 
and almost undetectable to severe and unremitting {status asthmaticus). The primary 
physiological manifestation of this hyperresponsiveness is variable airways obstruction. 
This can take the form of spontaneous fluctuations in the severity of obstruction, 
substantial improvements in the severity of obstruction following bronchodilators or 
corticosteriods, or increased obstruction caused by drugs or other stimuli... ’
The airway obstruction associated with asthma is largely reversible and clinical 
monitoring of the severity of the disease commonly involves assessment of changes in 
the forced expiratory volume in one second (FEVi) in response to a direct acting 
bronchoconstrictor, for example metacholine or histamine (Bucca et a l 1993). 
However, enhanced responsiveness is a feature other lung diseases, such as chronic 
bronchiolitis (Pride, 1993), and even though the reversibility of constrictor responses 
may be less applicable in such cases, the diagnosis of asthma clearly rests on other 
criteria. Commonly, for example, asthma demonstrates a circadian rhythm with a 
worsening of airway function at night or in the early morning. Sensitization through the 
regular exposure to environmental stimuli has been widely implicated as the cause of 
persistent asthma, and inhalation of that stimulus is the key method of delivery since 
bronchial asthma is a disease of the upper airways (Pride, 1993).
Characterisation of stimuli allows some division within the asthmatic population. 
Allergens (usually large proteins) such as house dust mite (especially Der P 1), animal 
dander (small animal, cat, dog), pollens (grass, ragweed) and fungal spores (eg.
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Aspergillus spp.) are common precipitating factors for so-called atopic (‘extrinsic’) 
asthma describing a propensity to generate high IgE levels. The classic type I 
hypersensitivity response to injection of the allergen into skin has traditionally provided 
the clinician with a diagnostic tool. However atopy is present in only two-thirds of all 
asthmatics and is distinct from the so called ‘intrinsic’ sufferers who more commonly 
demonstrate occupational, aspirin, or smoking-associated asthma (Pride, 1993). This 
division is somewhat simplistic since Burrows et al (1989) have demonstrated that IgE 
levels peak in late childhood and decrease through adult life; age-corrected IgE levels 
correlate with the presence of asthma per se and is a more effective marker of the 
disease than skin-prick tests. In addition to the aforementioned specific stimuli, a 
number of non-specific factors exacerbate asthma and include pollutants, exercise, 
cold/dry air and stress (Pride, 1993).
The morphological analysis of asthmatic lung demonstrates characteristic hallmarks of 
the disease. Interestingly, samples from both intrinsic and extrinsic asthmatics 
demonstrate similar pathology and it has been suggested that the lung can only respond 
in a finite number of ways regardless of stimulus (Bentley et al. 1992). The gross 
features of advanced asthma include over-inflation of the lungs, and a thickening of the 
bronchi walls as well as mucus plugs in the upper airways that on closer examination 
contain shed epithelium, eosinophils, eosinophil-derived Charcot-Leyden crystals and 
cell debris. Histologically, the mucosa shows signs of oedema formation and infiltration 
of large numbers of eosinophils and to a lesser extent monocytes and T lymphocytes but 
not neutrophils (Dunnill 1960; Jeffery 1993). Furthermore there is evidence of lung 
remodelling; hypertrophy of the bronchial smooth muscle, enlargement of mucous 
glands, denudation of areas of the respiratory epithelial and thickening of the remaining 
reticular basement membrane (Laitinen et a l 1985, Jeffery 1993).
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1.4. Inflammatory response in asthma and models o f allergic inflammation
Although naturally occurring asthma exists in very few species, allergic pulmonary 
inflammation can be induced in a number of species using a sensitisation regime to 
antigen (commonly ovalbumin, OA) which generates high levels of immunoglobulin 
and hyperresponsiveness to bronchoconstrictors. However, the guinea pig has been the 
species of choice for many investigators because of an ability to closely mimic a number 
of the features of human asthma, including an allergen-induced early and late phase fall 
in lung function, bronchial hyperresponsiveness (BHR, Hutson et al. 1988), as well as 
an eosinophilic and T lymphocyte-rich infiltrate into the lungs (Dunn et al. 1987; Frew 
et al. 1990).
Much work has been undertaken to elucidate the cellular mechanisms of the 
development of asthma and allergic inflammation using antigen challenge studies in 
sensitised atopic individuals and in a variety of animal models. Two distinct phases are 
observed. The immediate phase is characteristically mast cell-driven and the release of 
preformed mediators results in bronchoconstriction within 10-20 minutes, resolving 
within 1-2 hours (Holgate et al. 1985). Such a mechanism would explain the speed of 
onset of an asthma attack. By definition, this phase is established by sensitisation 
(generation of specific IgE, or in the case of the guinea pig IgGi) following prior 
exposure to an allergen. Subsequent exposure results in the binding of that allergen to 
the IgE on the mast cell surface, the triggering of high affinity receptors FceRI (Metzger 
et al. 1986), mast cell membrane depolarisation and ultimately the release of 
biologically active substances (Plaut et a l 1989). This phase is considered a Type I 
hypersensitivity response and characterised by mucosal reddening, small vessel
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dilatation and oedema; features akin to those of the classical reddening, wheal and flare 
of Lewis’s triple response in skin (Lewis, 1927).
A number of subjects experience a second prolonged fall in lung function the onset of 
which occurs at 6-12 hours and resolves by 24-48 hours (O'Bryne et al. 1987). This is 
characterised by a marked eosinophil (De Monchy et a l 1985) and T lymphocyte 
(Azzawi et al. 1990) infiltration into the lung and bronchial lumen, the hallmarks of the 
asthmatic lung. Asthma is clearly a chronic cell mediated immune response with 
aspects of both phases following each repeated exposure to allergen. However, with 
increasing severity of disease the situation is probably complicated by remodelling of 
lung tissue (Stewart et al. 1993).
The plethora of evidence from such models points to the development of asthma 
through a complex network of communication between many cell types. The 
circumstantial evidence for cell and mediator involvement is discussed in the following 
sections.
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1.5. Cells involved in allergic inflammation
1.5.1. The mast cell and basophil
The mucosal surface of the bronchus harbours the tissue fixed mast cell which has 
traditionally be seen as pivotal in the development of an immediate allergic response 
(Beasley et a l  1989). Mast cells are differentiated from extravasated CD34+ precursors 
under the influence of c-kit ligand also known as stem cell factor and CD117 (Valent, 
1994). The predominant mature mast cells in the human lung (MT) contain tryptase but 
not chymotrypsin, characteristic of those which predominate the skin and submucosae. 
Following initial exposure to an antigen, that antigen is processed by antigen presenting 
cells (APCs) and in conjunction with major histocompatability complex (MHC) is 
presentated to T cells. The T helper cell stimulates B cell production of specific IgE 
(Male et al 1989) which binds to the mast cell surface via the high affinity receptor, 
FceRI (Metzger et a l 1986). On subsequent exposure, cross-linkage of receptor-bound 
IgE leads to tyrosine kinase phosphorylation; a key event in mast cell degranulation 
(Paterson et a l 1976; Plaut et a l 1989). A range of inflammatory mediators are 
released from mast cell granules or synthesised de novo from membrane lipids as 
summarised in diagram 1.1. The repercussion of degranulation is thus a rapid 
bronchoconstriction, an upregulation in the production of mucus and increases in 
vascular permeability, which is aided by the close proximity of mast cells to blood 
vessels (Eady et a l 1979). Furthermore, the release of chemotacic and haemopoietic 
factors encourages additional cell migration and differentiation (Plaut et a l 1989; 
Bradding et a l 1994; Wodnar-Filipowicz et a l 1989). Accordingly, increased BAL 
levels of histamine measured in allergic asthmatics are associated with BHR (Casale et 
a l 1987). Furthermore, recent work by Lukacs and colleagues (1996b) has shown that 
c-kit ligand influences both histamine levels and eosinophilia in a murine model of
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allergic inflammation and c-kit ligand may stimulate and induce the release of some 
mast cell products directly (Valent, 1994).
Membrane-derived




































Diagram 1.1 Mast cell and eosinophil products. Central box represents mediators 
common to both cell types.
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Heparin and related proteoglycans are also mast cell products and are able to bind 
histamine, cationic proteins from the eosinophil as well as the basic chemokines (Witt et 
al. 1994) by virtue of their anionic nature (Page 1991). Furthermore, heparin diminishes 
the immediate response to antigen in the skin and lung of allergic human subjects 
(Bowler et a l 1993). In addition, studies by Teixera et al. (1993) report that heparin 
suppresses eosinophil accumulation but not oedema formation, indicating that it may 
have inhibitory properties. These observations have lead to the suggestion that the mast 
cell may produce natural anti-inflammatory reagents (Page, 1991). However, binding to 
heparin does not appear to neutralise chemokines (J. Westwick, personnal 
communication) and in fact may ‘present’ them in such a way that alters their biological 
effect on a target cell (Webb et al 1993).
Histological examination of the late phase pulmonary response suggests that the 
predominant histamine-releasing cell is the basophil (Guo et al. 1994). They are 
morphologically distinct from the mast cell in containing fewer cytoplasmic granules 
and a polylobed nucleus (Wheater & Burkitt, 1987). These cells develop from different 
precusors than the mast cell, which do not express c-kit and differentiate under the 
influence of IL-3 which is enhanced by IL-4. Thus, release of IL-3 and IL-4 from mast 
cells (Plaut et al. 1989) encourages progression of the inflammatory reaction towards 
the late phase and the subsequent down regulation of c-kit ligand by IL-4 may act to 
modulate histamine release (Valent, 1994).
Both the mast cell and basophil can be activated by both IgE-dependent and independent 
mechanisms. Mediators that directly induce histamine release from basophils have 
recently been identified as the monocyte chemotactic proteins, macrophage 
inflammatory protein - l a  and RANTES; members of the CC chemokine family (Kuna
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et a l 1993; Alam et a l 1992b; Alam et al. 1994a), all of which are associated with the 
late phase of an allergic response.
1.5.2. Eosinophil
I.5.2.I. Lifecycle
Ehrlich (1879, see Weller for review) first described the eosinophil as a bilobed 
leukocyte identified by the presence of specific granules in the cytoplasm that avidly 
bind to negatively charged dyes including the brominated fluorescein compound, eosin. 
They account for only 1-6 % of leukocytes in the circulating blood - 1.3-3.5xl09 in the 
healthy human subject, although as many as 15 times that number may be present as 
precursors in bone marrow and 1 0 0  times as mature cells in tissues.
Eosinophils share the same bone marrow progenitor as neutrophils and basophils 
(myeloblast) before sequential differentiation into committed eosinophil myelocyte, 
metamyelocyte and mature eosinophil (Fischkoff et al. 1984). Differentiation is 
mediated by IL-3, IL-5 and GMCSF (Ingley & Young, 1991; Lopez et al. 1987, 
Campbell et al 1987), cytokines which are also able to prolong the survival of the 
mature cell (Rothenberg et a l 1988; Yamaguchi et a l 1988; Lopez et a l 1986). Of 
these three cytokines, only IL-5 is a specific activator of eosinophil function (Lopez et 
a l 1988). Maturation of the eosinophil within the bone marrow progresses over 2-6 
days. The lifespan thereafter is not clear; some authors suggest a half life in the blood of 
between 6-12 hours (Kay 1985), although in culture with the above cytokines, the 
eosinophil can be maintained for at least 14 days (Rothenberg et a l  1988). Furthermore 
following extravasation via the post-capillary venules, localisation within the mucosae, 
where they are particularly abundant appears to maintain survival for weeks (Kay 1985).
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The selective recruitment of the eosinophil from the blood into tissue is widely accepted 
to be at least partly mediated by the (OC4P1) integrin VLA-4 (CD49d/CD29), expressed 
constitutively on eosinophils but not neutrophils (Walsh et a l 1991; Weller et a l 1991). 
Adhesion to the endothelium is via VCAM-1 which can be upregulated by TNFa and 
IL-1 (Dobrina et a l 1991). IL-4, another cytokine implicated in the pathogenesis of 
asthma, appears to upregulate VCAM-1 selectively, but not E-selectin or ICAM-1 
(Schleimer et a l 1992). The importance of VLA-4 interactions has been verified in 
vivo. Weg et al (1993) demonstrated that pre-treatment of 11 ^ -labelled guinea pig 
eosinophils with the monoclonal antibody HP 1/2 (directed against the 0 C4 subunit of 
VLA-4) prevented their accumulation into skin sites. Since the number of circulating 
H1In eosinophils remained constant, it is unlikely that the inhibition was caused by 
mAb-induced eosinopaenia.
Whilst VLA-4/VCAM-1 provides a specific mechanism through which eosinophils but 
not neutrophils might be recruited, many investigators have suggested ICAM-1 or E- 
selectin also mediate the adhesion of eosinophils (Kyan-Aung et a l 1991; Kuijpers et 
a l 1993). However their ligands, CD11/CD18 and sLex respectively, are also present 
on a range of leukocytes including neutrophils. ICAM and E-selectin are expressed 
constitutively on the endothelium although can be upregulated by IL-1, TNFa and IFN-y 
(Pober et a l 1986). These authors reported that this upregulation varies with time; E- 
selectin peaked at 4 hours, ICAM-1 at 24 hours, and VCAM-1 at around 12 hours 
suggesting that such a mechanism might regulate leukocyte infiltration into an 
inflammatory site. Studies by Wegner and co-workers (Wegner et a l 1990; Gundel et 
a l 1991b), using chronic and acute primate models of pulmonary inflammation 
suggested that distinct time-courses of adhesion molecule expression are relevant in
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vivo. Repeated exposure to antigen increased ICAM expression and the associated 
eosinophilia and BHR could be reduced by pre-challenge treatment with anti-ICAM-1 
mAb (Wegner et al. 1990). However, a single exposure to antigen increased E-selectin 
but not ICAM-1 expression and administration of anti-E-selectin mAb decreased the 
observed neutrophil accumulation (Gundel et al. 1991b).
I.5.2.2. Activation of eosinophils
Human eosinophil activation through both IgE and and IgE-independent mechanisms is 
mediated through a number of surface receptors outlined below. The eosinophil is a 
producer of, as well as target for, many of the mediators (see diagram 1 .1 ), highlighting 
the possibility for self-perpetuating feedback mechanisms.
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MEDIATOR RECEPTOR RESPONSE REFERENCE
LTB4 Identified on guinea 
pig eosinophils
Chemoattractant Sehmi (1992a)
PAF Evidence of two PAF 
receptors on 
eosinophils







IL-3 ,IL-5, GMCSF High affinity receptors 
with common (3-chain 










C3a Likely, but not yet 
identified
Chemoattractant Daffem (1995)





CCR3 Chemotaxis, Ca2+ 
mobilisation
Daugherty (1996)
IgE FceRII; low affinity Degranulation Grangette (1989)
IgG FcyRII Degranulation Kaneko (1995)
IgA/secretory IgA FcocR Degranulation Abu-Ghazaleh (1989)
Table 1.1. Summary of receptors on the surface of the human eosinophil
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I.5.2.3. Eosinophil activity following stimulation
Increases in [Ca2+]i
Increases in [Ca2+]i can trigger a number of events in a leukocyte including cellular 
proliferation, degranulation and changes in gene expression. It is a valuable model of 
cell activation that can be easily monitored by use of Ca2+-binding fluorescent dyes such 
as fura2 (Grynkiewicz 1985). In many non-excitable cells, elevation of [Ca2+]i is 
essentially achieved by either release of Ca2+ from intracellular stores such as the 
endoplasmic reticulum or influx via transport across the lipid bilayer using receptor 
operated calcium entry. Ca2+ release from intracellular stores is widely accepted to be 
triggered by Ins(l,4 ,5 )P3 (IP3) interaction with ^-sensitive Ca2+ release channels, 
which is produced after receptor stimulation by hydrolysis of PIP2 by PLC. This 
hydrolysis also generates DAG which initiates the activation of PKC. However, influx 
is responsible for the sustained phase of elevated [Ca2+]i and to replenish intracellular 
stores. Agonist stimulated Ca2+ influx can be stimulated by second messengers such as 
IP3 , phosphatidic acid although the exact nature of this is not known. In addition Ca2+ 
influx may be induced by the emptying of intracellular stores (reviewed in Fasolato,
1994). PAF activates eosinophils using the classical pathway of HVmediated release 
from Ca2+ stores (Kemen et a l 1991) and there is evidence that PKC regulates PAF- 
induced responses (Kroegel et a l 1994). In contrast, Grix et al (1995) have suggested 
that increases in [Ca2+]i in human eosinophils induced by C5a are predominantly due to 
increased influx across the cell membrane.
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Eosinophil chemotaxis
Eosinophils share several properties with most other leukocytes, notably the ability to 
migrate towards concentration gradients of chemotacic molecules. Clearly in vivo this 
ability is utilised during extravasation, and in vitro can be demonstrated using a 
modified Boyden chamber apparatus (Falk et al. 1980). Inducers of eosinophil 
chemotaxis include PAF (Wardlaw et al. 1986), C5a, IL- 8  (Kemen et al. 1991) and 
RANTES (Rot et al. 1992) through interaction with G protein-coupled seven 
transmembrane receptors (Kemen et al. 1991). However the signal transduction 
processes that govern cell migration in eosinophils are not well defined. Studies by 
Schweizer (1994) and Kemen (1991) suggests that shape change and chemotaxis in 
eosinophils occur independently of the classical signal transduction pathway involving 
phospholipase C, increases in [Ca2+]j and protein kinase C activation. In contrast, 
Eisner et al (1996) reported that eosinophil migration could be inhibited by chelation of 
intracellular calcium. However, cell migration is dependent on the reversible 
polymerisation of globular monomeric actin into filamentous polymers of actin and is an 
immediate intracellular response after addition of a chemoattractant (Stossel 1993). In 
eosinophils, PAF induces maximal actin polymerisation by 10-15 sec and is particularly 
evident after priming with IL-5 (Schweizer et al 1994).
Alterations in eosinophil density
Some stimuli initiate a change in the phenotype and reactivity of eosinophils from an 
unstimulated ‘normodense’ to a hypodense state. Hypodense eosinophils show evidence 
of degranulation through a decrease in the number and size of granules (and hence eosin 
staining is weaker) and consequently separate at a lower sedimentation density on a 
discontinuous Percoll gradient (Winqvist et al. 1982). They are also more reactive to
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stimulants such as PAF (Yakawa et al. 1989), exhibit a higher oxygen consumption 
(Winqvist et al. 1982), generate more LTC4  in response to activation with calcium 
ionophore (Kajita et al. 1985), express increased levels of IgE low affinity receptors 
(Capron et al. 1984) and demonstrate enhanced chemotactic activity (Wardlaw et al.
1986). This state would seem to have relevance in vivo since many investigators have 
demonstrated increased numbers of hypodense eosinophils in clinical eosinophilia 
(Yakawa et a l 1989) and in the peripheral blood of asthmatic patients (Frick et al.
1989).
Release o f cationic proteins
The anti-parasitic ability of the eosinophil is achieved through the release of a number 
of basic proteins (14,000-21,000 Daltons) from the crystalloid core of the specific 
granules which are helminthotoxins. Major basic protein (MBP, Hastie 1987; Gleich et 
al. 1979) is the most abundant but is aided by the actions of eosinophil cation protein 
(ECP), eosinophil-derived neurotoxin (EDN) and eosinophil peroxidase (EPO), an 
enzyme which catalyses the formation of hypohalous acids (Weller 1991). However, 
these proteins are also detrimental to host cells and contribute to the epithelial damage 
observed in asthma by causing exfoliation, ciliostasis and cytotoxicity (Gleich et al.
1979).
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I.5.2.4. Eosinophils and bronchial hyperreactivity (BHR)
Eosinophils are a hallmark of asthma and characteristic of the late phase response. 
There has been much circumstantial evidence supporting a causative role for the 
eosinophil in the development of BHR. Patients with asthma have increased numbers of 
eosinophils in the BAL and these cells are associated with the late phase reaction (LPR) 
following allergen provocation in sensitised atopic subjects (De Monchy et al. 1985; 
Wardlaw et a l 1988). Some authors have suggested that the observed increases of 
sputum eosinophils in asthma might be a suitable prognostic marker for asthmatic 
exacerbations provided no bronchial infection was present (Ferguson et al. 1995). 
Furthermore, a number of investigators have demonstrated evidence of an inverse 
correlation between eosinophil counts in peripheral blood and specific airway 
conductance (FEVi) in patients with active bronchial asthma (Horn et al. 1975; 
Ferguson et al. 1995) but positive correlation to BHR (Durham & Kay, 1985). Such 
trends have been successfully replicated in the OA-sensitised guinea pig model (Sanjar 
et al. 1990; Frew et al. 1990).
Some authors have argued that quantification of eosinophil activation might be a more 
accurate assessment of the presence of asthma. Increases in eosinophil-derived cationic 
protein can be detected in the serum (Griffin et al. 1991), sputum (Ferguson et al. 1995), 
BAL (Wardlaw et al. 1988) and bronchial biopsy samples (Filley et al. 1982) from 
asthmatics. A number of studies correlate levels of ECP with the severity of disease 
(Bousquet et al. 1994; Zimmermann et al. 1993). Cationic proteins released from 
eosinophils are able to damage epithelium (Gleich et al. 1979) and this may result in a 
denudation of areas of the airways epithelium, thus exposing underlying nerves. 
Through this mechanism, eosinophils could cause hyperresponsiveness and Gundel et al 
(1991a) have demonstrated that human MBP induces BHR and constriction in primates.
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Furthermore, an important study by Lefort et al (1996) demonstrated that the 
neutralisation of major basic protein inhibited antigen-induced bronchial hyperreactivity 
in sensitised guinea pigs. However conflicting evidence links elevated levels of these 
proteins in vivo with the development of BHR. For example, Zimmerman et al (1993) 
detected a correlation between serum ECP levels and FEVi in symptomatic asthmatic 
children but not in asymptomatic subjects, whilst Ferguson et al (1995) reported no 
correlation between lung function (PC20 for histamine) and ECP levels for some chronic 
asthmatics. Furthermore a number of investigators have reported observations of 
hyperreactivity without inflammation and vice versa leading to the hypothesis that 
eosinophils and BHR reflect a common origin but are not necessarily causally related 
(Owaka et al. 1981). It is feasible that in some circumstances other cells might drive 
hyperresponsiveness such as the mast cell or the platelet possibly through PAF, a 
mediator able to induce the migration of human eosinophils (Wardlaw et al. 1986) and 
BHR in some subjects (Coyle et al. 1990).
1.5.3. T lymphocytes
The lymphocyte is pivotal in the recognition of foreign antigen and the T cell assists 
antibody formation, stimulates cytotoxic effects of other cells such as the macrophage 
and regulates the level of the immune response (Male 1989). CD4+ T cells are 
implicated as central to the pathogenesis of asthma by virtue of the production of a panel 
of cytokines from the so-called T helper 2 lymphocytes which favour recruitment of 
eosinophils (see reference Mosmann et a l 1986 and later sections of this introduction). 
In addition, direct evidence exists for the presence of T lymphocytes in asthma. Kay 
and colleagues identified increased numbers of activated (CD25+) T lymphocytes in the 
bronchial mucosa (Azzawi et a l 1990, Hamid et a l 1991) and in the blood of
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asthmatics (Corrigan et a l 1988). Corrigan et al (1993) have also demonstrated 
increased IL-5 levels, a product of Th2 responses in the serum of asthmatics following 
CD4+ lymphocytes activation. Furthermore T lymphocytes are specifically a feature of 
the late phase response to allergen in the human lung (Metzger et al. 1987) and mRNA 
for Th2 mediators (IL-5, IL-4, IL-10) is increased following allergen challenge in the 
BAL cells of atopic subjects (Robinson et a l 1992).
1.5.4. The alveolar macrophage
The differentiation of the blood-derived monocyte into the tissue macrophage 
(Bitterman et a l 1984) produces a cell with highly effective phagocytic (Gieser et a l
1994) and tumorocytic properties (Weissler et a l 1986), that appears to be able to 
mediate the immune response through the release of a range of inflammatory mediators.
Following release of monocytes into the blood from the bone marrow, extravasation 
occurs after 24 hours (Issekutz et a l 1993). A number of members of the chemokine 
family, notably the macrophage inflammatory proteins (Fahey et a l 1992), RANTES 
(Schall et a l 1988) and especially the monocyte chemoattractant proteins (Rollins et a l
1991) have been implicated in their recruitment into sites of inflammation. Human 
monocytes undergo differentiation upon migration, although the process occurs 
spontaneously when monocytes are culture in vitro for a few days (Kaplan & 
Gaudemack, 1982). This process confers a change in the secretory capacity of these 
cells. The extent of maturation thereafter is thought to be responsible for the large 
heterogeneity within the macrophage population, which can be observed experimentally 
by differential fractionation on Percoll gradients and cytokine release (Elias et a l 1985; 
Gessani et a l 1993).
38
The physiological role of the macrophage in the lung is to clear inhaled pathogens 
(Green & Kass, 1964) and cell debris and it is the most abundant cell in normal BAL 
fluid. They are likely to play a role in the pathogenesis of asthma since:
1. Alveolar macrophages and blood monocytes express the low affinity IgE receptor, 
FceRII, (Capron & Prin, 1986) and retain the ability to respond to antigen (Rankin et 
a l 1982). There is some evidence to suggest that expression is increased in 
asthmatic subjects (Vecchiarelli et al. 1994). Their primary location in the air spaces 
would allow exposure to antigen and trigger factors.
2. The activated macrophage releases a vast array of proinflammatory mediators which 
include the leukotrienes (Rankin et a l 1982) and PAF which are bronchospasmogens 
and chemoattractants, the early cytokines TNF (Gessani et a l 1993) and IL-1 (Elias 
et a l 1985), the haemopoietic factors GMCSF, IL-3 and IL-5 as well as chemokines 
EL-8 (Standiford et a l 1990b), M IP-la (VanOtteren et a l 1994; Berkman et a l
1995) and MCP-1 (Brieland et a l 1993). The production of some of these mediators 
by macrophages may be increased in asthmatic subjects (Damon et a l 1987).
1.5.5. Platelet
The platelet is an anucleated cell element originating from fragmentation of 
megakaryocytes in the bone marrow or possible within the capillary network of the lung. 
It normally circulates as a single entity in the peripheral blood but can adhere to exposed 
subendothelial matrix proteins using a number of surface membrane integrins (Herd & 
Page 1994). Furthermore, platelets express P-selectin through which they may bind 
leukocytes (Springer 1990).
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Activation of the platelet causes the release of a number of mediators, reviewed in 
reference Herd & Page 1994, which are known to induce bronchoconstriction (PAF, 
adenosine, TXA2), smooth muscle and fibroblast proliferation associated with lung 
remodelling (PDGF, pTGF), vasoconstriction and dilatation (5-HT, PGE2) as well as 
airway hyperresponsiveness (PAF) and eosinophil chemotaxis (PAF, RANTES). Whilst 
these are features of the acute and chronic asthmatic response during which a number of 
the mediators are upregulated, this does not provide unequivocal evidence for the 
involvement of platelets in asthma as many of these mediators are manufactured by 
other cell types (Sanchez-Crespo et al. 1980). More compelling evidence comes from 
an expression of low affinity IgE receptors FcsRII (Capron & Prin, 1986) and an ability 
to migrate following antigen challenge (Zhang et al. 1993). Furthermore platelets have 
been found in the BAL of allergic rabbits and asthmatic human subjects during late 
onset airways obstruction (Herd & Page, 1994). In vivo studies have indicated that the 
ability of PAF to induce bronchoconstriction (Vargaftig et al 1980), bronchial 
hyperresponsivness and associated eosinophilia (Coyle et al 1990) is dependent on the 
presence of platelets. Some authors (Coyle et al 1990) have suggested that this might be 
largely attributed to the actions of PAF-induced PAF release from platelets; in the 
guinea pig PAF-acether administration causes eosinophil recruitment in the lung which 
can be reduced by PAF antagonists (Lellouch-Tubiana et a l 1988). However, the 
human platelet a  granules are a rich source of pre-formed chemokines including platelet 
factor 4, platelet basic protein and derivatives CTAP-III, pTG (Holt et al 1986), PF4 
(Walz et al. 1989) as well as the CC chemokine, RANTES (Kameyoshi et al. 1992). It 
is possible that the latter, which is an eosinophil attractant (Alam et al. 1993) and other 
as yet unidentified platelet-derived chemokines, may also contribute to airways 
hyperreactivity.
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1.6. Factors which mediate allergic inflammation
It is widely accepted that distinct mediators govern the characteristic features of an 
allergic inflammatory response. Many of these substances have been identified, 
implicated on the basis of their upregulation, providing a picture of complex cell- 
mediated interactions. However, there appears to be a high level of functional 
redundancy. The use of novel therapeutic reagents and monoclonal antibodies has 
enabled some dissection of the relative importance of a given mediator in the 
development of allergy and the key lines of evidence for each are outlined below.
1.6.1. Histamine
The release of inflammatory mediators from the mast cell, most notably histamine, is 
widely accepted as the basis of the immediate allergic response (Holgate et al. 1985). 
Histamine is formed from histidine by the action of histidine decarboxylase and is stored 
within the mast cell and basophil bound to proteoglycan. Histamine is a potent 
bronchoconstrictor; inhalation of the mediator induces a response within 2-5 minutes 
lasting approximately 20 minutes. Asthmatics exhibit hyperresponsiveness towards 
histamine and this is the basis of PC20 measurement to assess airway function (Bucca et 
al. 1993). Intradermal injection of histamine induces a characteristic triple response as 
described by Lewis (1927), highlighting its ability to cause direct vasodilatation 
(erythema), increase vascular permeability and an erythematous flare through axon- 
reflex induced vasodilatation. Early antigen challenge studies in the skin by Katz et al. 
(1942) demonstrated that ragweed (antigen) could induce a similar response in 
sensitised individuals, pointing to the release of histamine. A number of subsequent 
studies have demonstrated that type I responses can be blocked by combination of Hi
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and H2 receptor antagonists (Woodward et a l 1985) although studies by Weg et a l 
(1991) suggest that oedema can only be effectively blocked with combinations of 
histamine, PAF and leukotriene antagonists (see below). However, despite the benefits 
of histamine antagonists in the relief of allergic rhinitis, they are not effective at treating 
allergic asthma. Given the number of mediators with overlapping functions released 
during chronic inflammation, it is also possible that the selective inhibition of any one 
mediator may be compensated for by others.
1.6.2. Neuropeptides
Neuropeptides, which modulate the non-adrenergic non-cholinergic (NANC) system are 
a family of proteins which share some functional characteristics of histamine. 
Substance P induces a wheal and flare reaction in skin in the immediate but not late 
phase response (Umemoto et al. 1976) and causes airways obstruction through 
bronchoconstriction and excessive mucus production (Lundberg et a l 1983). However 
vasoactive intestinal peptide, as well as the non-neuropeptide nitric oxide (Barnes,
1995), mediates NANC-bronchodilatory responses, suggesting that an alteration in the 
balance of neuropeptides could effect airway function.
Bradykinin has been implicated in allergic inflammation by virtue of increased levels in 
the upper airways of asthmatics following allergen challenge (Proud et al 1983). This 
kinin is a potent bronchoconstrictor in asthmatic but not normal controls (Fuller et a l 
1987). Since they themselves are weak constrictors of isolated airway smooth muscle, it 
is possible that their influence is exerted by neural reflexes. A number of studies have 
demonstrated that administration of bradykinin receptor antagonists prior to antigen 




Complement is an integral part of the innate immune system and consists of a number of 
plasma-derived protein mediators with pro-inflammatory activities generated through an 
amplified cascade triggered by antigen-antibody complexes. The ‘anaphylatoxin’ C5a 
can increase vascular permeability by neutrophil-dependent (Wedmore & Williams, 
1981a) and independent mechanisms, the latter through stimulating the release of 
histamine from mast cells (Gerard & Hugli, 1981; Jose et a l 1981). Histamine- 
releasing activity is abolished by the removal of the carboxy terminal arginine (C5a-des 
Arg), whilst the ability to modulate vascular permeability remains unaffected (Jose et a l 
1981). Complement can be generated by pathways other than immune complex 
deposition, which is not a feature of type 1 reactions, however little evidence exists for 
the involvement of C5a in asthma. However, it is commonly used as a control in an 
experimental setting by virtue of the potent ability to chemoattract most leukocyte types 
(Okawaera/. 1981).
1.6.4. Eicosanoids
Eicosanoids are a collection of 20-carbon fatty acids metabolised de novo from the 
membrane derived phospholipid arachidonic acid (AA). Further metabolism of free AA 
generates leukotrienes (LTs) through the action of 5-lipoxygenase and collectively 
LTA4 -E4 mediate a wide range of responses. The leukotrienes are potent 
bronchoconstrictors and are at least a thousand times more effective in this role than 
histamine (Dahlen et a l 1980). Feldberg and Kellaway first observed the actions of 
these mediators in 1938 after injecting snake venom into perfused lungs which caused a 
slow, long lasting contraction of the smooth muscle (described in Piper 1993). Later
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studies by Brocklehurst (1960) demonstrated that these ‘slow reacting substances’ 
(SRSs) were also produced during antigen-challenge in the lung. SRSs were structurally 
identified by Samuelsson et a l (1979) as derivatives of AA and specifically LTD 4  as the 
major slow-reacting substance of anaphylaxis in the guinea pig (Morris 1980).
LTC4 and LTD4 cause direct bronchoconstriction in anaesthetised guinea pigs when 
given in an aerosolised form (Brocklehurst, 1960) and a prolonged response when given 
i.v. (Piper & Samhoun, 1981) through the release of TXA2 , which has been shown to 
contract isolated trachea and increase pulmonary resistance (Piper & Samhoun, 1982). 
Such long duration of action is akin to the sustained constriction seen in clinical asthma 
although the involvement of TXA2 is questionable since indomethacin does not inhibit 
LT-induced prolonged contractions of the human bronchus (Brocklehurst, 1960). In 
addition, LTs might also mediate airways obstruction by the induction of mucus 
hypersecretion (Marom etal. 1982).
The leukotrienes are potent at inducing changes in vascular permeability and injection of 
LTC4 and LTD4 induces a wheal and flare response in human skin (Bisgaard et al 1982). 
LTC4 and D4-induced changes in vascular permeability are not dependent on the 
presence of neutrophils (Wedmore & Williams, 1981a), unlike those of LTB4 which are 
abolished in neutropenic animals. LTB4 has previously been shown to be a potent 
neutrophil (Ford-Hutchinson et a l 1980) and eosinophil (Sehmi et a l 1991) 
chemoattractant, and there is some evidence to implicate LTD4 (Spada et a l 1994) and 
LTE4 (Laitinen et a l 1993) as mediators of eosinophil accumulation. The importance of 
LTs in the development of allergic inflammation is underlined by increased levels in 
plasma (Zakrzewski et a l 1985) amd BAL (Wenzel et a l 1990) following allergen
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challenge. Furthermore, a number of LTD4 antagonists have improved lung function in 
asthmatic subjects (Spector et a l 1994).
In contrast to the predominant effects of LTs inducing changes in vascular permeability, 
prostaglandins which are derivatives of cyclooxygenase metabolism of AA, markedly 
increase blood flow (Williams & Peck, 1977). In this role they potentiate the oedematus 
response and associated pain of a number of other mediators (Ferreira 1972; Williams & 
Morley, 1973). Such a mechanism explains the paradox of high level of PGs in 
inflammatory exudates observed by Willis and yet an inability of exogenous PGs to 
induce oedema themselves. Accordingly, cyclo-oxygenase inhibitors decrease oedema 
and pain in acute inflammation (Williams & Morley, 1973). However, these inhibitors 
are of limited use in chronic inflammatory models; indomethacin does not reduce 
swelling despite a reduction in PG levels (O'Bryne et a l 1987).
1.6.5. PAF
The phospholipid, platelet activating factor (PAF) was originally identified from the 
supernatant of basophils from sensitised rabbits (Benveniste et a l 1972) and has been 
detected at increased levels in the blood (Nakamura et a l 1987) and BAL (Count et a l
1987) of asthmatics. PAF has been shown to increase vascular permeability in human, 
rabbit and guinea pig skin (Archer et a l 1984; Wedmore & Williams, 1981b; Morley et 
a l  1983) which Weg et al (1991) demonstrated could be partially inhibited with the 
PAF antagonist WEB 2086, in vivo. PAF is also able to induce bronchospasm in 
experimental animals but only in the presence of platelets implying the involvement of 
other platelet-derived mediators (Vargaftig et a l 1980). In addition, PAF is a potent 
chemoattractant of eosinophils in vitro in comparison to eosinophil chemotactic factor
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of anaphylaxis tetrapeptides, histamine and LTB4 (Wardlaw et a l 1986). However, 
Faccioli et al (1991) reported increased potency for LTB4 over PAF to induce H1In- 
eosinophil migration into guinea pig skin sites, although C5a-des-Arg was considerably 
more effective than either mediator. Studies by Little et al (1991) suggest that 
responsiveness to PAF may depend on the activation state of eosinophils since 
hypodense cells were more reactive. However as for many of these mediators, PAF is 
non selective, also attracting neutrophils and monocytes (Czametzki, 1983).
1.6.6. Early-response cytokines
The accumulation of cells at sites of inflammation has been largely attributed to a 
complex cascade of mediators of which tumour necrosis factor-alpha (TNFa) and IL-1 
have been identified as proximal cytokines. Both are produced from almost every 
nucleated cell suggesting the potential for ubiquitous release, although the 
monocyte/macrophage is a particularly rich source (Le & Vilcek, 1987). These 
cytokines have somewhat overlapping actions such as the ability to upregulate the 
production of a number of inflammatory mediators from target cells. These included 
most cytokines (notably IL-1 and TNF themselves), chemokines, lipid mediators such as 
PAF as well as prostaglandins through the stimulation of AA release and increase PLA2 
activity (Pober et a l 1986). Studies by Watson et al (1988) highlight a role for IL-1 in 
increasing vascular permeability leading to oedema.
Both TNFa and EL-1 have been widely implicated in the development of allergic 
inflammation. They are released from antigen-stimulated mast cells (Gordon & Galli,
1990) and Th2 cells (Mosmann et a l 1986) and therefore a number of target cells 
thereafter are activated, consistent with their role as inducers of the inflammatory
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cascade. Furthermore, elevated levels of TNFa and another early cytokine, IL- 6  have 
been reported from IgE-stimulated macrophages and BAL leukocytes of allergic 
asthmatics (Gosset et a l 1991; Cembryznska-Nowak et a l 1993). Similarly, local 
generation of IL-1 was detected following antigen-challenge in atopic patients (Bochner 
et al. 1990).
Using in vivo animal models, a number of workers have reported that inhibition of IL-1 
or TNF reduces leukocyte accumulation. Watson et al. (1993) demonstrated a 
protective effect in ovalbumin sensitised guinea pigs against bronchial hyperreactivity 
and the associated eosinophilia using the selective IL-1 receptor antagonist (IL-lra). 
The authors also noted reduced TNF bioactivity in the BAL. In the mouse, anti-TNF 
antibodies reduce leukocyte accumulation following IgE mediated in a model of passive 
cutaneous anaphylaxis (Wershil et al. 1991). Since these cytokines do not chemoattract 
leukocytes directly (Lukacs et a l 1995b), leukocyte recruitment in vivo may be 
associated with the TNF/IL-1-induced release of intermediary cytokines and chemokines 
(Pober et a l 1986), VCAM-1 (Dobrina et a l 1991) and ICAM-1 (Pober et a l 1986) 
expression on the endothelial cell surface.
1.6.7. Establishment of Thl/Th2 phenotypes
Activated T cells appear to be a characteristic of atopic asthma (Azzawi et a l 1990). 
The identification of distinct murine CD4+ T helper clones by Mosmann et al (1986) 
divided on the basis of selective cytokine secretions aided the understanding of the role 
of T cells in allergy. Similar specific clones have since been identified in the human 
(Wierenga et a l 1991). Termed Thl and Th2 phenotypes, Thl cells predominantly 
secrete IL-2 and IFNy whilst Th2 cells produce IL-4 and IL-5 (Mosmann et a l 1986) as
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well as IL-10 and IL-13 (Minty et a l 1993). IL-3 and GMCSF are secreted by both 
types. In mice it appears that T helper precursors pass through an intermediary ThO 
stage secreting IL-2, IL-4 and IFNy (Mosmann et al. 1986). Although IL-2 induces the 
development of all T cells (Mills et a l 1985, Cantrell et al 1984), some actions of 
Thl/Th2 cytokines are broadly antagonistic of one another, for example IL-4 induces 
IgE production from B cells which is inhibited by IFNy (Del Prete et a l 1988). It is 
possible that a shift in balance between these phenotypes could be causative of T cell- 
mediated diseases. Some of the key interactions are summarised in diagram 1.2.
Several lines of evidence point to a role for the Th2 phenotype in asthma. Robinson et 
al (1992) observed T cell mRNA expression for predominantly Th2-like cytokines in 
the BAL of atopic patients following allergen challenge which was consistent with an 
increase in activated eosinophils. The secreted panel of Th2 mediators, namely IL-5, IL- 
4 as well as IL-10, play key roles in allergy. IL-5 (as well as IL-3 and GMCSF) 
promotes the terminal differentiation of committed eosinophil precursors (Campbell et 
al 1987), selectively activates mature eosinophils (Lopez et a l 1988) and prolongs their 
survival in culture (Yamaguchi et a l 1988). Whilst IL-5 is a weak chemoattractant of 
eosinophils (Wang et a l 1989), an ability to ‘prime’ these cells augments the migratory 
responses towards potent but non-specific mediators such as PAF (Schweizer et a l 
1994). This could provide a selective mechanism for eosinophil recruitment. 
Interestingly, Sehmi et al (1992b) observed that PAF-induced eosinophil responses 
using cells from asthmatic patients could not be augmented by IL-5. The authors 
suggested that this maybe due to prior exposure in vivo possibly due to increased levels 
of this cytokine. In support of this, a number of studies have demonstrated an 
upregulation of IL-5 in allergic inflammation. Hamid et al (1991) reported a correlation 
between IL-5 mRNA levels in human bronchial biopsies and EG2+ eosinophils and
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CD25+ lymphocytes; markers used to assess severity of asthma. Van Oosterhout (1993) 
demonstrated that pretreatment using anti-IL-5 antibodies reduced BHR and eosinophil 
accumulation in the guinea pig lung following antigen challenge. This might be 
explained by the identification of DL-5 as the predominant eosinophil-active cytokine 
during the LPR following segmental antigen challenge, at least in the human lung 
(Ohnishi et a l 1993).
Mast cells are also a source of IL-5, released during degranulation following IgE 
crosslinking by antigen (Plaut et a l 1989). The growth and regulation of mast cells and 
synthesis of IgE from B cells through Ig isotype switching is driven by IL-4, another 
Th2 cytokine (Finkelman et a l 1990). From studies using IL-4 knock-out mice, Kopf 
and colleagues (1993) reported that IL-4 favoured the conversion of naive CD4+ T cells 
to the Th2 phenotype both in vitro and in vivo and was essential for CD4+-derived EL-5 
and the IL-5-induced eosinophilia in this model. IL-4 also modulates other aspects of 
eosinophil activity, specifically extravasation through the upregulation of adhesion 
molecule VCAM-1 on the endothelial surface (Schleimer et al. 1992). IL-4 (as well as 
IL-5) appears to be upregulated in allergic asthmatics as assessed by increased 
expression in CD2+ T cells and protein levels in BAL (Robinson et a l 1992; Walker et 
a l 1992). However, recent work by Krug and colleagues (1996) indicated that most T 
cells from the BAL of asthmatics produce IFNy when stimulated ex vivo whilst those 
secreting IL-4 accounted for less than 2 %. This work suggests a selective increase in 
IFNy production during asthma and underlines the fact that the application of the 
















The chemotactic cytokines or ‘chemokines’ are a family of 8-10 kD, basic proteins, each 
of which is able to attract distinct subsets of leukocytes (Lindley et al. 1993a). For this 
reason, they are widely proposed to be responsible for the selective leukocyte 
recruitment of inflammation. The chemokines were originally separated into two main 
families on the basis of structure and function. The division is made on the position of 
the first two of four cysteine residues being either adjacent (CC) or juxtaposed with 
another amino acid (CXC, Lindley et a l 1993b). However, it would seem that other 
subfamilies also exist; lymphotactin contains only one N terminal cysteine and probably 
represents a member of the so-called ‘C’ family, of chemokines (Kennedy et al. 1995), 
whilst the recent characterisation of ‘fractalkine’ by Bazan (1997) suggests that 
chemokines can bear a CX3C motif. At the time of writing, 11 human CXC chemokines 
and 9 human CC chemokines had been characterised. Whilst some were identified as 
biological activity secreted by cells, in tissues or biological fluids (e.g. IL-8 , eotaxin), 
many others were discovered by the cloning of genes expressed in selected cell types 
(e.g. RANTES).
CXC chemokines such as IL- 8  and MGSA, are broadly chemotactic for neutrophils and 
T lymphocytes, whereas CC chemokines attract monocytes, T lymphocytes, eosinophils 
and activate basophils (Lindley et al 1993b). Accordingly, the genes for each family are 
located on separate chromosomes; CXC on q 12-21 of human chromosome 4 (Richmond 
et al. 1988) and CC on the ql 1-21 region of 17 (Irving et al. 1990) where the individual 
loci for each CC chemokine have been designated Syca 1-9 or small incucible cytokine a
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(reviewed in Youn et a l 1995). It has been suggested that the two families diverged 
many millions of years ago from a single ancestral gene.
Despite the separation into the subfamilies, many features are common to most 
chemokines:-
Functionally: all chemokines stimulate the directional migration of selected cell types 
and many induce other features of cell activation such as calcium mobilisation, enzyme 
release, respiratory burst and adherence to endothelium.
Structurally: most chemokine cDNAs encode a protein of 92-99 amino acids, which 
includes a cleavable hydrophobic amino acid sequence (approximately 2 0  residues) at 
the N terminus. Furthermore the chemokines show striking conservation of exon/intron 
gene organisation. CXC chemokines assume a 4 exon/3 intron configuration whilst CCs 
are arranged as 3 exons/2 introns, with the first exon encoding most of the leader 
sequence and the second and third, the mature protein (Schall, 1991). Chemokine 
production is mediated at the transcriptional level and the amount of mRNA is 
influenced by the regulation of its stability. Many chemokines harbour AU rich 
sequences at the 3'-end, non-translated region, the presence of which has been shown to 
be a rate defining step in the degradation of mRNA (Brewer & Ross, 1988).
In terms of protein structure, the basic nature of chemokines allows binding to 
negatively charged proteoglycans including heparin (CC chemokines MUM a  and (3 are 
an exception since they are acidic although still bind heparin (Wolpe et a l 1988)). This 
has lead to the idea that chemokines might be mobilised along the extracellular matrix 
and in this way could provide a solid phase chemotactic gradient toward a site of 
inflammation; so-called haptotaxis (Witt, 1994). In this respect, the standard assay to
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characterise the chemokines in vitro, namely chemotaxis using some form of Boyden 
chamber, may be somewhat flawed since cells migrate along a fluid phase (Falk et a l
1980). However, it is possible that chemokines are mobilized to the polycarbonate 
filters through which the cells migrate.
The presence of the four cysteine motif is crucial for both CC and CXC chemokines 
allowing the formation of disulphide bridges between cysteines 1-3 and 2-4 which is 
essential for biological activity (Matsushima & Oppenheim, 1989). It is unclear how 
this picture might accommodate the ‘C’ chemokine, lymphotactin, which lacks cysteines 
1 and 3 but still retains lymphoattractant activity (Kelner et a l 1994). Overall sequence 
homology between the CXC and CC families is low (20-40 %) (Oppenheim et al. 1991) 
and in this respect is it curious that they form similar monomeric tertiary structures; a 
single C-terminal a  helix packed against a three-stranded antiparallel p sheet (Wells et 
al. 1996). It has been suggested that hydrophobic sequences on the monomer surface 
are conserved in both families but that the exact distribution of these residues conveys 
receptor selectivity for ligands. In contrast, dimeric structures are very different 
between the two families (Wells et al. 1996), and so the assessment of quaternary 
structure at physiological concentrations (<100 nM) is important. It has been suggested 
that the monomeric form is the active form, since the concentration of most chemokines 
in vivo is within the nanomolar range (Paolini et a l 1994). In support of this, the IL- 8  
analogue N-Methyl-Leu-25 is unable to dimerise and yet has a similar potency to wild 
type IL- 8  in vitro (Wells et a l 1996).
53
1.6.8.2. CXC chemokines
The first chemokine to be identified and characterised was IL- 8  by Yoshimura et al 
(1987a) as a major neutrophil chemoattractant component from IL-1-stimulated human 
monocytes. However, some years earlier Deuel et al (1977) reported the sequence of 
platelet factor 4 (PF4), which was later described as a neutrophil and monocytic 
chemoattractant activity (Deuel et a l 1981). Although structurally this chemokine is 
indeed a member of the CXC subfamily, the studies performed by Deuel used purified 
and not recombinant PF4. It is possible that these samples were contaminated with 
other chemokines since recombinant PF4 does not attract these cell types (J. Westwick, 
personal communication). Moreover, PF4 lacks the ELR motif seemingly required for 
neutrophil migration (see below).
Monocytes are rich sources of CXC chemokines; as well as IL-8 , IP 10 (Luster et al. 
1985) and monokine induced by IFNy (mig-y, Farber 1993) were identified as products 
of IFNy-stimulated macrophages. Other members of the family include MGSA/gro a  
(Richmond et a l 1988), gro p, gro y, (Haskill et a l 1990; Iida & Grotendorst, 1990), 
NAP-2 and CTAP-IH which arise from the N terminal processing of platelet basic 
protein (Walz et a l 1989), endothelial-cell-derived neutrophil-activating protein (ENA- 
78, (Walz et a l 1993) and granulocyte chemotactic protein-2 (GCP-2, Proost et a l
1993).
A feature of the CXC chemokines is that N terminal modifications are common place, 
for example IL- 8  is predominantly secreted as a 77 amino acid protein from endothelial 
cells, denoted [ala-IL-8 ]77, where as monocytes and T lymphocytes release the N- 
terminally reduced [ser-IL-8 ]7 2  form. Both proteins are able to stimulate neutrophils but 
full activation of IL- 8  requires cleavage by thrombin to the 72 amino acid form (Hebert
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et a l 1990) which induces chemotaxis (Yoshimura et al. 1987b), calcium mobilisation 
and, in the presence of cytochalasin B, azurophil granule release at nanomolar 
concentrations (Peveri et a l 1988). Colditz et al (1989) demonstrated relevance in vivo 
as oedema and neutrophil accumulation were evident at 4 hours post-intradermal 
injection of rhIL- 8  into rabbits. The neutrophil chemoattractant ability of EL-8 requires 
the presence of the N-terminal tripeptide sequence Glu-Leu-Arg (E4L5R.6) preceeding 
the first cysteine (Hebert et a l 1991).
There is some evidence to suggest that IL- 8  plays a role in allergic inflammation. This
9 4 -chemokine can induce small but significant increases in [Ca ]i in normal human 
eosinophils (Kemen et a l 1991) and possesses weak chemoattractant activity (Erger & 
Casale, 1995). This response is increased using eosinophils from asthmatic subjects 
(Warring et a l 1993) which may be a result of IL-5 priming of the cells in vivo since the 
preincubation of normal eosinophils with IL-5 in vitro potentiates IL-8 -induced 
stimulation (Schweizer et a l 1994). IL- 8  also causes the migration of selective T 
lymphocytes in vitro at picomolar doses (Larsen et a l 1989, Bacon et al 1989). Many 
of these observation are supported by in vivo evidence. Leonard et al (1990) observed 
basophil, lymphocyte and neutrophil accumulation in dermal-injected sites, whilst 
Burrows et al (1990) reported lymphocyte and eosinophil accumulation in the BAL of 
guinea pigs given intraperitoneal injections of IL-8 . However, Collins et al (1993) 
observed that accumulation of 11 ^ -labelled eosinophils into IL- 8  injected skin sites in 
the guinea pig was delayed until 1-2 hours post injection. This compared to an 
immediate accumulation in ZAP-injected sites suggesting that an intermediary player 
released by IL-8 , and not IL- 8  alone, may be mediating eosinophil migration. IL- 8  is 
released by numerous cell types that are associated with allergic inflammation, including 
alveolar macrophages (Carre et a l 1991), pulmonary epithelial cells (Standiford et a l
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1990a) and notably, the eosinophil (Braun et a l 1993) suggesting the establishment of a 
positive feedback mechanism.
1.6.8.3. CC chemokines
The CC chemokines have been extensively studied in association with allergic asthma 
by virtue of their preferential recruitment of eosinophils, monocytes, basophils and a 
variety of T cell subsets. In particular, RANTES, eotaxin, MCP-1 and 3, M IP-la have 
been widely implicated (Lukacs et a l 1996a) and a summary of their activities is 
provided below.
CC Chemokine Human target cell Reference
RANTES Eosinophil (Rot 1992)
Monocyte (Schall 1990)
T lymphocyte (CD4+/CD8+) (Schall 1990) 
(Turner 1995)
Basophil (Kuna 1993) 
(Bacon 1994)
Eotaxin Eosinophil (Jos ee ta l .  1994b)
MCP-1 Monocyte (Yoshimura 1989b)
Basophil (Alam 1992b)
T cell (Taub 1995)
MCP-3 Eosinophil (Weber 1995)




M IP-la Eosinophil (Rot 1992)
CD8 + T and B lymphocyte (Schall 1993),
Monocyte (Taub 1993)
Table 1.2. Summary of CC chemokines implicated in cell recruitment in allergic 
inflammation. All induce chemotaxis of their respective cell types, except for basophils 
which undergo histamine release.
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Monocyte chemotactic proteins (MCP)
The CC chemokines were originally described as attractants of monocytes but not 
neutrophils (they lack the ELR motif of the neutrophil attracting CXC chemokines) and 
in this respect, the monocyte chemotactic peptides are prototypes (Oppenheim et al.
1991). MCP-1 was identified by Matsushima et al (1989) and Yoshimura et al (1989b) 
in supernatant from stimulated PBMCs and a monocytic cell line respectively and 
assumed to be the homologue of the previously reported murine protein JE from PDGF- 
stimulated 3T3 fibroblasts (Cochran et al 1983, Rollins et al. 1988). In 1992, Van 
Damme and colleagues (1992) purified two related chemokines with identities of 62 and 
73% to MCP-1 from an osteosarcoma cell line, labelled MCP-2 and MCP-3 
respectively. MCP-1 is a potent stimulator of chemotaxis (Yoshimura et al. 1989a), 
calcium influx and respiratory burst in human monocytes and also regulates adhesion 
molecule expression in these cells (Jiang et al. 1992). In comparison to other CC 
chemokines however, MCP-1 is not a chemoattractant for eosinophils (Rot et al. 1992).
MCP-1 is one of the most potent mediators of histamine release from basophils being 
active at nanomolar concentrations and comparable to anti IgE or C5a (Alam et al. 
1992b). RANTES, and to a lesser extent M IP-la and (5, CTAP IQ and the related NAP- 
2 can also stimulate a similar response (Kuna et al. 1992, 1993). Alam and colleagues
(1988) described the presence of a substance produced by mononuclear cells that 
inhibited histamine release from basophils, later identified as IL- 8  by Kuna et al (1991) 
which does not have any significant histamine-releasing ability. Alam et al (1992a) also 
reported RANTES as having a similar inhibitory activity towards MCP-1-induced 
histamine (Alam et al. 1992a). One explanation for these inhibitory effects could be 
that pretreatment of basophils with a certain chemokine will desensitise the histamine-
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releasing capacity of another (Kuna et a l 1992). It is also noteworthy that MCP-1 and 
RANTES induce the migration of basophils in vitro (Bischoff et a l 1993).
Macrophage inflammatory protein-1
Macrophage inflammatory protein-la and (3 were originally isolated from the LPS 
stimulation of a mouse macrophage cell line (Wolpe et a l 1988; Davatelis et a l 1988) 
although the cDNA to the human homologue of M IP-la (LD78) had actually been 
cloned a few years earlier from PMA-treated tonsillar lymphocytes by Obaru et al
(1989). It would now appear that both forms of MIP are expressed in T cells, B cells, 
and activated neutrophils (Kasama et a l 1993). M IP-la is able to stimulate chemotaxis 
and degranulation of human eosinophils over a nanomolar range and is particular potent 
at inducing changes in [Ca2+]i compared to RANTES or IL- 8  (Rot et a l 1992). M IP-la 
also demonstrates chemotactic activity for B cells (Schall et a l 1993) as well as CD4+ 
and CD8 + T lymphocytes (Taub et a l 1993), and upregulates EL-1, TNFa and IL- 6  
production from macrophages (Fahey et a l 1992). It can induce increases in [Ca2+]i in 
neutrophils, but this does not appear to translate into a functional role such as migration 
(McColl et a l 1993). Subcutaneous injection of M IP-la into the footpads of mice 
induces an immediate swelling followed by a long-lasting monocytic infiltrate (Alam et 
a l 1994b). Despite the fact that hMIP-lp bears 70% amino acid homology to hM IPla 
and is structurally very similar, MDMp does not stimulate human eosinophils (Rot et a l
1992). The discrepancy between homology and activity of these two proteins is further 
supported by their ability to attract different lymphocyte populations (Schall et a l
1993).
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The MIP proteins are somewhat distinct from other CC chemokines since they have a 
number of other roles in addition to chemoattraction. M IP-la induces pyrogenic 
activity in the rabbit which is prostaglandin independent and cannot be blocked by 
cyclooxygenase inhibitors (Davatelis et al. 1989). Furthermore, M IP-la is reported to 
inhibit haematopoiesis by preventing colony formation of immature progenitors, 
although IL- 8  and MCP-1 may also induce similar effects (Broxmeyer et al. 1990).
RANTES
Schall et al (1988) originally identified RANTES (an acronym for Regulated on 
Activation Normal T cell Expressed and Secreted) in 1988 as a product of IL-2 
dependent, antigen-driven human T cell clones during a search to identify novel cDNA 
clones present in T cells, but not B cells. The cDNA encodes a 91 amino acid protein 
that includes a cleavable 23 amino acid hydrophobic signal sequence at the N-terminus 
and a mature secreted protein of 7.9 kDa (Schall et al. 1988). The RANTES protein is 
highly basic (pi of around 9.5) and contains no sites for N-glycosylation. A murine 
RANTES cDNA has also been cloned and encodes a mature protein with 85 % amino 
acid homology to its human counterpart (Schall et a l 1992).
RANTES was distinct from the early so called ‘sis’ or (small inducible, secreted) 
proteins in showing an inverse pattern of transcript regulation in T cells (ie. RANTES 
expression decreased in activated T cells whilst MDP-la increased) (Schall et al. 1988; 
Oppenheim et al. 1991). Studies of the SycaS gene encoding mRANTES suggest that 
these differences in inducibility may be explained by the absence of a 1 0  nucleotide core 
sequence in the promotor region of the RANTES gene which is present in other CC 
chemokines (Danoff et al. 1994). It is interesting that RANTES also lacks AU rich
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sequences in the 3' untranslated region of its mRNA (Schall et a l 1988), the presence of 
which has been shown to reduce the half life of other cytokines (Brewer & Ross, 1988).
The biological activity o f RANTES
The characterisation of human RANTES suggested that it might play a pivotal role in 
the pathogenesis of allergic inflammation. The protein attracts eosinophils over a 
nanomolar range (Kameyoshi et a l 1992, Rot et a l 1992; Alam et a l 1993), as well as 
CD45RO T cells (primed T helper cell involved in memory function) and monocytes 
(Schall et a l 1990); a profile which mirrors the infiltrate found in the asthmatic lung 
(Azzawi et a l 1990). Rot et al (1992) ascribed a number of other eosinophil functions 
to RANTES including the ability to increase [Ca2+]i, and stimulate the release of ECP 
from cytochalasin B-treated cells although there was no evidence of LTC4 formation. 
Furthermore RANTES induces respiratory burst in these cells (Rot et a l 1992, Kapp et 
a l 1994, Bourne et a l  1992). However, M IP-la is more potent on a molar basis at 
inducing changes in [Ca2+]i and ECP but less potent as a chemoattractant (Rot et a l
1992) whilst reports conflict on its ability to cause respiratory burst (Rot et a l 1992; 
Kapp et a l 1994, Bourne et a l 1992). Alam and colleagues (1993) demonstrated the 
ability of RANTES to induce a state of hypodensity, a feature of eosinophils from 
asthmatic subjects (Frick et a l 1989) and to upregulate the expression of C D llb  at the 
same concentrations required to induce eosinophil chemotaxis. Later studies by 
Eibsawa (1994) could not reproduce this effect, although the authors did observe 
eosinophil transendothelial migration induced by RANTES which could be inhibited by 
antibodies against the (32 integrin, CD18. RANTES is also able to induce histamine
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release from basophils (Kuna et a l 1992) and basophils from atopic patients 
demonstrate an increased responsiveness compared to nonatopics (Kuna et a l 1993).
The original characterisation of RANTES by Schall (1990) highlighted a role for 
RANTES as a chemoattractant of human monocytes and lymphocytes. These findings 
have since been supported by observation from a number of groups. RANTES-induced 
increases in [Ca2+]i were reported by Vaddi et al (1994) in both human blood monocytes 
and the monocytic cell line THP-1, although MCP-1 was a more potent agonist. 
However, whilst monocytes readily underwent chemotaxis, THP-1 cells were prevented 
through an inability to achieve actin polymerisation and cell polarisation.
RANTES appears to mediate a number of lymphocyte cell functions. The CD4+ T cell 
attractant activity of the protein has been described by a number of groups (Schall et a l 
1990) although Taub and co-workers have suggested that CD8 + subsets also migrate in 
vitro (Taub et a l 1993) and observed equal numbers of CD4+ and 8 + T cells in 
RANTES injected murine skin sites (Muiphy et a l 1994). Studies by Turner et al 
(1996) indicate that RANTES is more than a lymphoattractant; this chemokine is able to 
induce T cell proliferation. Furthermore, important work by Dragic (1996) 
demonstrated that RANTES can inhibit HIV entry into CD4+ T cells by blocking the 
CCR5 receptor. RANTES does not seem to be associated exclusively with either Thl or 
Th2 phenotypes. Schrum and colleagues (1996) suggested that RANTES release from T 
cells was predominantly from Thl clones secreting IL-2 and IFNy. However, Kimata 
and colleagues (1996) have recently reported the ability of RANTES to induce IgE and 
IgG4 production from B cells, an event associated with Th2 mediated responses (Del 
Prete et a l 1988). These immunoglobulins are selectively elevated in atopic subjects 
(M enetetal. 1984).
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Cellular and tissue sources o f RANTES
RANTES has been identified in a number myeloid cells such as T lymphocytes (Schrum 
et al. 1996) and monocytic cells (Devergne et al. 1994). However, studies by 
Kameyoshi et al (1992) demonstrated that thrombin-stimulated human platelets are a 
rich source of biologically active RANTES. Purification of the supernatant from these 
platelets and assessment of the eosinophil-chemotactic activity of resulting fractions 
identified two peaks which on sequencing were both found to be RANTES; one product 
with a slightly higher molecular weight due to glycosylation. This work allowed 
analysis of the native form of human RANTES. In addition, a number of authors have 
reported RANTES in a number of parenchymal/stromal cells, the expression of which in 
vitro frequently requires TNFa stimulation. These include dermal (Noso et al. 1995) 
and synovial (Rathanaswami et al. 1993) fibroblasts, smooth muscle cells (Jordan et a l 
1995), epithelial (Kwon et a l 1995) and endothelial cells (Marfaing-Koka et a l 1995), 
epidermal and oral keratinocytes (Li et a l 1996), and human (Robson et a l 1995) and 
murine messangial cells (Wolf et a l 1993). Given the array of cells that produce 
RANTES, it is not surprising that mRNA for the protein is found in a number of whole 
tissues/biological fluids. These include the lung and BAL (Alam et a l 1996), kidney 
(Heeger et a l 1992) and the peritoneal fluid from subjects with endometriosis where the 
RANTES concentration correlated with the severity of disease (Khorram et a l 1993).
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I.6.8.4. Chemokine receptors
It would appear that there is some functional overlap between the CXC and CC 
chemokines, for example eosinophil migration can be induced by IL- 8  in some 
circumstances as well as by RANTES and M IP-la. However redundancy between the 
families is minimised by distinct receptors for which the ligands do not cross-compete. 
In contrast, many investigators have observed intra-family sharing of receptors. 
Experimentally these patterns have been identified using radioligand binding 
displacement studies and calcium desensitisation profiles. The combined use of these 
techniques has proved useful since there are many examples where chemokine binding 
affinity does not predict functional activity of the cell.
In the case of the CXC chemokines, two receptors have been identified denoted IL-8 - 
RA and IL-8 -RB (Holmes et a l 1991; Murphy & Tiffany, 1991) and share an amino 
acid sequence homology of 77 % (Cerretti et a l 1993). EL-8 -RA specifically binds IL- 8  
with high affinity, whilst IL-8 -RB binds IL-8 , MGSA/gro a  and NAP-2 with equal 
affinity (Cerretti et a l 1993). The aforementioned ELR motif is thought to be essential 
for binding to these receptors and Clarke-Lewis et al (1993) have demonstrated that N 
terminal modification of PF4 to substitute ELR for the natural DLQ, allows binding to 
the IL- 8  receptors and activation of neutrophils.
At the time of writing of this thesis, five human CC chemokine receptors each with 
murine homologues had been cloned This compares to one CC receptor at the 







































Table 1.3. Summary of the characterised CC chemokine receptors. Adapted from 
Power and Wells et al (1996).
Cloning of the first CC receptor (CCR1) from HL60 libraries was reported by Neote et 
al (1993) and Gao et al (1993) in close succession. When expressed in either human 
embryonic 293 cells or Xenopus oocytes, binding of RANTES and M IP-la was 
observed but not to any CXC chemokines. M IP-la was able to displace and abolish 
[Ca2+]i responses induced by RANTES but RANTES was only able to reduce M IP-la 
responses, suggesting partial desensitisation of the receptor by RANTES. Surprisingly 
this receptor binds M IP-la with high affinity but RANTES with a much lower affinity, 
and yet these ligands induce [Ca2+]i in transfected cells over a similar range (1-100 nM). 
Furthermore MCP-1 and MIPl-p only induce [Ca2+]i changes at much higher doses, but 
bind the receptor with greater affinity than RANTES. Clearly the binding affinities of 
this receptor do not parallel the ability of the ligand to signal (Neote et al. 1993).
Neote (1993) and Gao (1993) reported a similar distribution for CCR1 on the myeloid 
presursor cells HL60, U937 and monocytic cell line THP-1, human B lymphocytes as 
well as dibutyryl cAMP-treated neutrophils and neutrophils from peripheral blood 
although its presence is unclear given the inability of either ligand to induce neutrophil 
migration. Furthermore the desensitisation of [Ca2+]i responses in human eosinophils 
using M IP-la and RANTES by Rot’s group provided the first evidence of a shared 
receptor on these cells (Rot et al. 1992).
CCR1 demonstrates 32% identity with receptors for IL- 8  and the orphan clone 
HUMSTSR (also known as fusin, LESTR and CXCR4), in comparison to 23% with the 
C5a receptor. In addition, an open reading frame, US28, of the human cytomegalovirus 
(CMV) also shares 33% identity with the MIP-la/RANTES receptor which increases to 
56 % over the acidic N terminal region. CMV is known to infect myeloid and lymphoid 
cells that might also express the chemokine receptor. It has been suggested that CMV 
infection could alter the immune response (thereby providing a more favourable 
environment for the virus) by competing for chemokine binding (Neote et al. 1993; Gao 
etal. 1993).
The notable exception to receptor exclusivity between the chemokine families is a 
receptor on the erythrocyte apparently identical to Duffy blood-group antigen which 
binds the malarial parasite Plasmodium vivax. This so-called Duffy antigen receptor 
(DARC) binds most chemokines with Kd values of 20-50 nM. Clearly there is no 
requirement for extravasation of erythrocytes, leading investigators to speculate that this 
receptor clears excess amounts of chemokines thus limiting leukocyte stimulation. 
However, this receptor is not restricted to erythrocytes, expression has also been 
detected on endothelial cells and T cells (Horuk et al. 1993).
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All chemokine receptors identified are seven transmembrane spanning; a formation that 
allows the extracellular exposure of four conserved cysteine residues in the receptor 
sequence which are postulated to form disulphide bonds, an extracellular N terminus 
and intracellular C terminus. A highly conserved motif, DRYLATVHA, within the third 
transmembrane domain 3 is present in all chemokine receptors, except DARC but not in 
other chemoattractant receptor such as C5a or fMLP (Neote et a l 1993). The two-step 
binding principle adopted by C5a to its 7TM receptor may be an applicable model of 
ligand/receptor interactions for the chemokines. The core of the ligand (region beyond 
first disulphide bond) binds the outer surface of the receptor, the N-terminus which may 
dictate receptor specificity. This interaction is probably stabilised through charge- 
charge interactions given the highly acidic nature of N-terminus of the chemokine 
receptors (which is uncommon in other G protein coupled receptors (Gao et a l 1993)) 
and the basic regions of the chemokine protein. Once orientated, the flexible amino 
terminus of the chemokine can position itself inside the receptor (as reviewed in Wells 
e ta l  1996).
All chemokine receptors (except DARC) are coupled to GTP-binding proteins and so 
cellular responses induced by binding of their ligands are pertussis toxin-sensitive 
(Sozzani et a l 1991). Most signalling through such receptors occurs via dissociation of 
the a  subunit from the (3y subunits of the G-protein thus activating phospholipase Cp2- 
The subsequent generation of inositol 1,4 ,5-triphosphate IP3 and diacylglycerol (DAG) 
from phosphatidylinositol 4,5-bisphosphate (PIP2) allows a rapid and transient calcium 
release from intracellular stores as well as a cascade of phosphorylation and activation 
steps involving PKC and phospholipase D (Sozzani et a l 1994). The signal ultimately 
conveys to the cell motility, mediator production and/or oxidant production. Studies by 
Turner et al (1996) indicate that such a pathway does indeed exist and demonstrate
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MCP-1-induced IP3 generation in the monocytic cell line THP-1. However, earlier 
studies by Sozzani and colleagues (1993) failed to identify IP3 or evidence of PIP2 
turnover in similar studies using human blood monocytes. Instead, they observed Ca 
transients which could be blocked by Ni2+, suggesting that increases in [Ca2+]i were 
achieved through influx across the cell membrane. It is possible that chemokines also 
utilise other pathways. Turner et al (1995) demonstrated that RANTES-stimulation of 
human peripheral blood T lymphocytes induces increases in PI3 kinase but observed no 
changes in [Ca2+]i.
Following the binding of ligand, receptors are internalised and are later recycled back to 
the surface of the cell (Kelvin et al. 1993). The response following cell stimulation can 
also be controlled by receptor desensitisation, which can occur on rapid successive 
exposure of the same ligand or another acting at this receptor. The basis of this 
phenomenon is phosphorylation of serine/threonine residues in the C terminus, a feature 
common to all G-protein-linked receptors (Hausdorff et al. 1992).
1.7. Introductory review of the literature
The aforementioned introduction concentrated on studies performed prior to the 
beginning of the my project. Publications arising during my studies have only been 
touched upon in this section. However this work is discussed fully in the context of my 
findings, in chapter 6 .
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1.8. Basis and aims of project
The use of the guinea pig as a suitable model of allergic inflammation centres around an 
ability to exhibit some of the features of the human asthmatic response and the 
development of eosinophilia in the lung. Clearly it is of great interest to assess the 
actions of chemokines and in particular, RANTES in this species. Murine RANTES 
(muRANTES) has been cloned, demonstrates 85 % amino acid identity to hRANTES 
and activates human blood monocytes (Schall et a l 1992). However there are examples 
of variations in chemokine activity between species, for example hMCP-1 is twice as 
potent at chemoattracting human blood monocytes than murine peritoneal macrophages 
(Luini et a l  1994). Furthermore, studies by Meurer et al (1993) indicate that although 
RANTES was able to induce eosinophil accumulation when injected into canine skin 
sites, no dermal responses were observed in lower species. To gain an accurate 
assessment of the role of RANTES in the guinea pig necessitates the use of the same 
species protein.
The aims of this project were therefore as follows:
1. To establish the presence of RANTES messenger RNA in the guinea pig lung
2. To determine a pattern of spatial and temporal expression of RANTES in the guinea 
pig following ovalbumin challenge
3. To purify recombinant guinea pig RANTES from transfected E. coli
4. Characterisation of the biological activity of guinea pig RANTES (gpRANTES) and 
hRANTES in vitro towards eosinophils and macrophages.
5. Characterisation in vivo to assess the migratory response towards gpRANTES in the 
guinea pig lung and skin
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CHAPTER 2. MATERIALS AND METHODS
Unless indicated, all reagents were purchased from Sigma Chemical Co., Poole, UK.
REAGENT SUPPLIER
Acrylamide mini gels 
(precast; 4-20%)
Novex, San Diego, USA
L-Agar Difco, West Molesey, Surrey, UK
Agarose MP Boehringer Mannheim, Mannheim, Germany
Anti-DIG-AP-conjugated Fab 
fragments
Boehringer Mannheim, Mannheim, Germany
Ampli Taq (with xlO buffer) Perkin Elmer, Roche Molecular Systems, NJ, US
Bacto tryptone Difco, West Molesey, Surrey, UK
Bacto yeast extract Difco, West Molesey, Surrey, UK
Bio-Rad Mini protean system Bio-Rad Laboratories, Richmond, USA
Bio-Rad protein assay Bio-Rad Laboratories, Richmond, USA
Blocking stock for nuclei 
acid hybridisation
Boehringer Mannheim, Mannheim, Germany
Boric acid BDH laboratory supplies Ltd, Lutterworth, UK
Bronchial epithelial growth 
medium
Clonetics Corporation, Walkersville, MD, USA
Calcium chloride Fisons, Loughborough, UK
Centrifuge tubes 15&50ml 
(polypropylene)
Falcon for Becton Dickinson, Franklin Lakes,USA
Chromatographic media Pharmacia Biotech, Uppsala, Sweden
Collagen- (rat tail) coated 6  
well plates
Costar, California, USA
Collagenase/Dispase Boehringer Mannheim, Mannhein, Germany
Coomassie Blue Reagent-250 Bio-Rad, Hemel Hempstead, UK
Diff-Quik Dade AG, Dudingen, Switzerland
Digitonin BDH laboratory supplies Ltd, Lutterworth, UK
DIG-11-dUTP Boehringer Mannheim, Mannheim, Germany
DNA molecular weight 
ladder(lOObp)
Gibco Life Technologies Ltd, Paisley, UK
DNA - DIG labelled DNA of 
known amount




Amersham Int. PLC, Little Chalfont, UK
E. coli Stratagene, Cambridge, UK
ELISA 96 well plates (Nunc 
‘Maxisorp’)
Gibco Life Technologies Ltd, Paisley, UK
Endoproteinase Arg C Boehringer Mannheim, Mannheim, Germany
Eotaxin cDNA labelled 
oligoprobe
R&D systems, Abingdon, Oxon, UK
Ethanol Fisons, Loughborough, UK
Ethidium bromide Sigma, Poole, UK
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Euthatal (pentobarbitone) Rhone Merieux, Dublin, Eire
FCS Gibco Life Technologies Ltd, Paisley, UK
Formaldehyde Fisons, Loughborough, UK
Formamide BDH laboratory supplies Ltd, Lutterworth, UK
Fura-2AM Calbiochem, La Jolla, US
Gentamycin Gibco Life Technologies Ltd, Paisley, UK
Glacial acetic acid BDH laboratory supplies Ltd, Lutterworth, UK
Glycerol BDH laboratory supplies Ltd, Lutterworth, UK
Guanidinium thiocyanate Fluka, Buchs, Switzerland
HBSS xlO Gibco Life Technologies Ltd, Paisley, UK
Heparin (‘Monoparin’) CP Pharmaceuticals Ltd, Wrexham, UK
Histological stains BDH laboratory supplies Ltd, Lutterworth, UK
Horse radish peroxidase- 
conjugated goat anti-mouse 
and goat anti-rabbit Abs
Bio-Rad Labs, Hemel Hempstead, UK
Horse serum Gibco Life Technologies Ltd, Paisley, UK
IFNy GlaxoWellcome, Stevenage, UK
IMS BDH laboratory supplies Ltd, Lutterworth, UK
11 indium  chloride and 
125Iodine-human serum 
albumin
Amersham Int., Bucks, UK
Interleukin-5 GlaxoWellcome, Geneva, Switzerland
Interleukin- 8 Sandoz, Vienna, Austria
JH4-Clone 1 fibroblast, 
guinea pig cell line
American Type Culture Collection, Rockville, USA
Ketamine Parke Davis Veterinary, Pontypool, UK
Lambda DNA markers Northumbria Biologicals Ltd, Cramlington, UK
LB medium Difco, West Molesey, Surrey, UK
Lymphoprep Nycomed, Oslo, Norway
Marvel non-fat milk Premier Brands UK Ltd, Stafford, UK
Methyl green histological 
stain
Vector Laboratory, Peterborough, UK
MIP-loc/p Peprotech, London, UK
M-MLV RTase Promega, Madison, US
Nitrocellulose membrane for 
protein transfer
Bio-Rad Laboratories, Richmond, USA
Nucleotides (Ultrapure dNTP 
set)
Pharmacia Biotech, Uppsala, Sweden
PAF Bachem, Bubendorf, Switzerland
Paraformaldehyde BDH laboratory supplies Ltd, Lutterworth, UK
PBS xlO (Dulbecco’s) Gibco Life Technologies Ltd, Paisley, UK
Penicillin Gibco Life Technologies Ltd, Paisley, UK
Percoll Pharmacia Biotech, Uppsala, Sweden
Phenol/chloroform Camlab, Cambridge, UK
Primers for DNA 
amplification
Perkin Elmer Cetus, manufactured by Roche 
Molecular Systems, Inc., NJ, US
Propan-2-ol (isopropanol) Fisons, Loughborough, UK
Protogel National Diagnostics, Atlanta, US
QIAquick gel extraction kit Quigen GmbH, Hilden, Germany
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Random hexamers (pd(N)6 ) Boehringer Mannheim, Mannheim, Germany
Restriction enzymes New England Biolabs, Beverly, US
Riboprobe Gemini System Promega by Roche Mol. Systems Inc, Branchburg, 
US
RNAguard-RNase inhibitor Promega by Roche Mol. Systems Inc, Branchburg, 
US
RNAsol B ams Biotechnology, California, USA
RNasin-RNase inhibitor Promega by Roche Mol. Systems Inc, Branchburg, 
US
RPMI medium Gibco Life Technologies Ltd, Paisley, UK
Sodium Bicarbonate (7.5%) Gibco Life Technologies Ltd, Paisley, UK
Sodium chloride Fisons, Loughborough, UK
Streptomycin Gibco Life Technologies Ltd, Paisley, UK
Tween-20 BDH laboratory supplies Ltd, Lutterworth, UK
Urea Fluka, Buchs, Switzerland
WEB 2086 Boehringer Mannheim, Mannheim, Germany
Xylazine Bayer, Leverkusen, Germany
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2.1. DETECTION OF CHEMOKINE mRNA IN THE GUINEA PIG LUNG
2.1.1. Preparation of digoxigenin-labelled probes
2.1.1.1. Preparation and purification of chemokine cDNA
Transformation of E. coli XL-1 Blue cells by electroporation. cDNAs encoding both 
orientations of full length guinea pig chemokines were subcloned by T. Yoshimura 
(Laboratory of Immunobiology, NCI-FCRDC, Frederick, Maryland, USA) into the 
multicloning region of pBluescriptn SK- plasmid. All subsequent procedures were 
carried out at Bath University by myself.
Sufficient E. coli to give an OD600 of 0.5-1.0 in 500 ml were pelleted by centrifugation 
at 4000 g for 15 min at 4 °C. The ionic strength of the cells was reduced by sequential 
washing in 500 ml sterile water, 250 ml sterile water and 10 ml of 10% glycerol, all at 
4°C. Final resuspension was in 0.5 ml of 10% glycerol, and aliquots (40 pi) were snap 
frozen in a dry-ice/methanol bath and stored at -70 °C. Plasmid DNA (0.5 pg) was 
mixed with a thawed aliquot of electrocompetent E. coli on ice, transferred to a sterile 
pre-chilled 0.2 cm electroporation cuvette and placed in a cuvette carrier of a Gene 
Pulser and Pulse Controller (Bio-Rad Laboratories, Richmond, CA, US). The cells were 
subjected to a single 2.5 kV pulse, with 25 p Farads capacitance and 200 Ohm 
resistance, to produce a nominal time constant for the capacitor discharge of 5 ms. 
Following electroporation, cells were allowed to recover by constant shaking in 1 ml 
recovery medium at 37 °C for 1 h. Transformed cells were selected by spreading onto 
L-agar plates containing ampicillin (100 pg/ml) and tetracycline (12.5 pg/ml) to achieve 
single-colony density, and grown at 37 °C overnight. A single colony was transferred 
using sterile technique into a 10 ml LB broth containing ampicillin (100 pg/ml) and 
tetracyclin (12.5 pg/ml) and cultured at 37 °C overnight.
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Small scale preparation o f bacterial plasmids (Miniprep). Cells from the 1 ml of 
culture were pelleted by centrifugation (13,000 g, for 1 min at 4 °C), the supernatant 
removed and DNA extracted by standard miniprep extraction according to Sambrook 
and Manniatis (1989). Briefly, the cells were resuspended in 100 |nl of solution I (see 
Appendix I) by vigorous vortexing and lysed with 200 pi of freshly prepared solution n, 
mixing by gentle inversion. The contents were placed on ice for 10 min then 150 pi of 
ice-cold solution HI was added and mixed by vortexing. The mixture was centrifugated 
(13,000g, 5 min) and the supernatant transferred to a clean 1.5 ml tube. Contaminating 
proteins were removed by two cycles of phenol-chloroform extraction (0.1 M Tris- 
saturated phenol/chloroform pH 8 ) and centrifugated at 13,000 g for 2 min. Plasmid 
DNA was precipitated from the aqueous layer by addition of 0.1 volume of 3 M sodium 
acetate, pH 5.5, and 2.5 volumes of absolute ethanol and then freezing in a dry 
ice/methanol bath. The DNA was pelleted by centrifugation (13,000g, 20 min at 4 °C) 
and washed with 70 % ethanol. Air dried pellets were resuspended in 50 pi of double­
distilled water.
Analysis by restriction enzyme digestion. Enzyme restriction of the pBluescriptll SK- 
plasmids was used to confirm the presence of chemokine cDNA inserts and thus that 
electroporation and colony selection procedures had been successful. Chemokine 
cDNA inserts were removed by digesting 1 jug of plasmid DNA with suitable restriction 
enzymes selected to cut either side, but not at points within the sequence. Each plasmid 
was digested with 0.5 pi of enzyme in a 10 pi reaction in the presence of enzyme- 
specific buffer and RNase A.
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Analysis by electrophoresis. Digestion products were separated by electrophoresis using 
Bio-Rad DNA sub-cells. Sufficient agarose for a 1 % gel in 30 ml was dissolved in 0.5x 
TBE and ethidium bromide added to a final concentration of 0.5 jug/ml before casting. 
Once set, gels were submerged in 0.5x TBE and DNA samples (0.5 pg/lane) were 
loaded with 0.2 volume 5x DNA loading buffer. Electrophoresis was carried out at 100- 
150 V for 30 min, and the DNA bands were visualised by UV light using a Hoefer 
Mighty Bright UVTM 25 transilluminator (Hoefer, San Fransisco, USA). Photographs 
were taken using Polaroid 55 film in a Polaroid CU-545 land film holder (Polaroid 
Corporation, Cambridge, MA, USA).
2.1.1.2. Preparation of full length PCR-generated cDNA probes
Plasmid DNA was amplified using a Perkin Elmer GeneAmp PCR System 2400 (Perkin 
Elmer, CA, USA). cDNA (5 pg) was added to a reaction mixture containing; xl PCR 
buffer, 200 pM each of dATP, dCTP, dGTP, 180 pM dTTP and 20 pM DIG-11-dUTP, 
1 pM of both forward and reverse primers (see sequences in section 2.2), 0.025 U/pl 
AmpHTaq DNA polymerase, and double-distilled water to achieve a final reaction 
volume of 100 pi. The reaction was initially heated to 95 °C for 1 min, pausing at 30 
sec to allow addition of 2 mM (final) of Mg2+. Cycle conditions were set as 
denaturation at 95 °C for 15 sec, annealing at 55 °C for 15 sec and extension at 72 °C for 
15 sec for 30 cycles followed by a prolonged extension at 72 °C for 6  min. DNA was 
precipitated as described above and resuspended in 100 pi of water. The amount of 
DIG-labelled probe generated was estimated by dot blot analysis and comparison to a 
sample of DIG-labelled DNA of known concentration (Boehringer Mannheim). The 
specificity of amplification of pBluescript SK- plasmids containing the required
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chemokine cDNA insert was confirmed by the presence of fragments of expected size 
using electrophoresis. Labelled probe was stored in aliquots at -20°C.
2.1.1.3. Preparation of single-stranded DIG-labelled riboprobes
pBluescriptn SK- plasmids (10 fig) containing either full length gpRANTES or eotaxin 
cDNA subcloned into the EcoRII site and EcoREXbal site respectively, were linearised 
overnight with restriction enzymes in 1 0 0  (il reactions containing the appropriate buffer 
and 5 |ig of RNase A. The enzymes were selected to allow linearisation on either the T7 
or T3 polymerase-side of the insert to enable generation of antisense (complementary to 
mRNA) or sense (identical sequence to mRNA) probes respectively.
To minimise contamination of non-linearised plasmid, digestion products were 
separated by electrophoresis using a 1.5 % agarose gel (1 jiig DNA per lane) containing 
0.5 mg/ml ethidium bromide. Gel bands containing linearised DNA were removed 
using a sterile scalpel and DNA isolated using QIAquick Gel Extraction kit purification 
columns according to the manufacturer’s instructions. DNA was precipitated as 
described above and resuspended at approximately 1 |Lig/10 j l l I  in double-distilled 
DEPC-treated water.
Purified linearised cDNA (1 fig) was transcribed using Riboprobe Gemini System. Each 
reaction contained the following: lx transcription buffer, 10 mM DTT, 0.5 mM each of 
dATP, dCTP, dGTP, 0.325 mM dUTP, 0.175 mM DIG-11-UTP, 1 fig plasmid, 50 U 
RNasin ribonuclease inhibitor, 10 U T7 or T3 polymerase and double-distilled water to 
a final volume of 50 j l l I .  The reaction was incubated for 90 min before removal of the 
template by addition of RQ1 DNase (1 U/mg of DNA) for 15 min at 37 °C. This
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reaction was quenched by 2 pi 0.5 M EDTA pH 5.5, and the cRNA was precipitated 
with 0.1 volume of 3 M sodium acetate and 3 volumes of ethanol at -70 °C for 1 h. 
cRNA was recovered by centrifugation at 12,500 g for 20 min, the pellet washed in 70 
% ethanol and resuspended in 50 pi sterile DEPC-treated water.
The efficiency of DIG-labelling was assessed by dot blot comparison with dilutions of a 
labelled DNA sample of known concentration (Boehringer Mannheim).
2.1.2. Treatment of animals and preparation of lung tissue for analysis
Dunkin Hartley guinea pigs (300-400 g, male or female) were sensitised with 10 pg i.p. 
ovalbumin (OA) and aluminium hydroxide as an adjuvant and boosted again on day 14. 
On day 24, the animals were pretreated with mepyramine (1 mg/kg i.p.) before challenge 
with aerosolised ovalbumin (0.1 %) for 30 min. Similar sensitisation and challenge 
regimes have previously been demonstrated to induce IgE production in the guinea pig 
(Andersson 1980). Animals were overdosed with Euthatal (pentobarbitone) at various 
times post-treatment and lung tissue removed from each animal immediately 
(preparation of animals by A.-M. White). Approximately 0.5 cm3 pieces were preserved 
by snap freezing in liquid nitrogen and storing at -70 °C. For in situ hybridisation and 
histological analysis, 1 cm3 sized lung segments were removed from some animals, 
fixed in formol buffered saline for 18 h and later embedded in paraffin wax using a 
Tissue-Tek VEP Processor (Tissue Tek, Hants, UK). Sections of the embedded tissue 
were cut at 5 pm using a rotary microtome (Leica Instruments GmbH, Hussloch, 
Germany) and collected on APES-precoated microscope slides. Slides were APES- 
coated by cleaning in concentrated nitric acid for 30 min, rinsing in distilled water for 2
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h and acetone for 10 min before baking at 180 °C for a further 2 h. They were then 
dipped in 2 % APES in acetone, rinsed with DEPC-treated water and air dried.
2.1.3. Isolation and growth of primary cells from guinea pig lung
The establishment of primary cells allows chemokine expression in individual cell types 
to be established and time course patterns following stimulation ex vivo to be 
determined. Fibroblasts have been grown as adherent cells that can be readily passaged 
from a number of tissues including human lung (Rolfe et a l 1992). Primary fibroblast­
like cells were grown from guinea pig lung digests. One lobe of lung was removed from 
an animal killed by an overdose with Euthatal. The tissue was bathed in DMEM with 
Ham’s F I2 supplement using sterile technique and cut into small pieces before 
incubation in collagenase at 1 mg/ml (type II from Clostridium histolyticum) in the 
same medium for 1 h at 37 °C. The digest was pipetted vigorously, and large undigested 
fragments were allowed to settle. The suspension was spun at 300 g for 10 min and the 
pellet resuspended in DMEM/Hams F I2 containing 10 % FCS, penicillin (100 p,g/ml) 
and streptomycin (100 U/ml) before plating into T25 flasks. The cells were grown to 
confluence and passaged with trypsin (0.02 mg/ml) and EDTA (0.05 mg/ml) up to 
passage 6 . For purposes of comparison, separate cultures of a guinea pig lung fibroblast 
cell line, JH4-Clone 1 (purchased from the American Type Culture Collection) were 
grown using the same medium.
Confluent cultures were stimulated with conditioned media from LPS-treated guinea pig 
peritoneal macrophages. This was prepared by the stimulation of 2xl06/ml M 0 with 1 
pg/ml LPS for 2 h, followed by the resuspension of the cells in fresh DMEM/Ham’s F I2 
medium which was harvested at 24 h for use as a stimulant. In some experiments, the
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supernatant from Con A-stimulated guinea pig spleen cells ( lx l0 7/ml cells treated with 
1 |Lig/ml Con A for 24 h) was used at a 1/10 dilution in conjunction with the macrophage 
supernatant.
Much effort was made to isolate primary lung epithelial cells since these cells appear to 
be important in chemokine production, at least in humans (Kwon et a l  1995). Tracheas 
were removed from guinea pigs killed by Euthatal overdose and washed in RPMI 1640 
medium prewarmed to 37 °C. Each trachea was immersed in 5 ml of RPMI 
supplemented with penicillin (100 flg/ml) and streptomycin (100 U/ml) and containing 
1 mg/ml collagenase (type II as before) and incubated for 30 min. The lumen of each 
trachea was repeatedly flushed through with the same medium using a 1 ml syringe and 
the cell suspension centrifuged at 350 g for 10 min. The pellet was resuspended in 
Bronchial Epithelial Cell Growth Medium (BEGM, see Appendix 2 for details) 
purchased from Clonetics Corporation (Walkersville, MD, USA). Cells were grown on 
rat tail collagen-coated wells of 6  well plates (Co-star) using one well per trachea.
2.1.4. In Situ Hybridisation methodology
2.1.4.1. Pretreatment of tissue sections
Guinea pig lung sections were analysed by in situ hybridisation based on a protocol by 
Vignaud et al. (1994). Initially paraffin-embedded sections were dewaxed by 
immersion into xylene (2x5 min) then hydrated through graded alcohols: 100% IMS 
(2x2 min), 90% (1 min), 85% (1 min) to 70% (1 min). Sections were permeabilised by 
immersion in 0.3% Triton-X in PBS for 10 min followed by a brief wash in PBS. 
Further permeabilisation was achieved by exposure to 2 mg/ml (15 units/mg) proteinase 
K solution extracted from Tritirachium album (Sigma, Poole, UK) in 20 mM Tris-HCl
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and 1 mM EDTA, pH 7.2, for 10 min at 37 °C, which was quenched by immersion in 2 
mg/ml glycine in PBS. The sections were refixed in 4 % paraformaldehyde solution for 
10 min, before incubation in a stirring bath containing 0.1M triethanolamine solution 
(pH 8 ) with 6 % v/v acetic anhydride added immediately prior to use. This step 
acetylates the sections and reduces non-specific binding due to charge interactions. 
Endogenous alkaline phosphatase activity was minimised by immersion for 15 s in 20% 
acetic acid, precooled to 4 °C. Section were rinsed in PBS before dehydration back 
though the graded alcohols to 100% IMS (2x1 min) and air-dried.
2.1.4.2. Hybridisation conditions
Section were prehybridised by addition of 100 j l l I  per slide of prewarmed hybridisation 
buffer containing 50% formamide, 5x SSC (from a x20 stock containing 3 M NaCl and 
0.3 m trisodium citrate at pH7.0), 10% dextran sulphate, 100 |ig/ml heat denatured 
salmon sperm DNA, and lx Denhardt’s solution, for 30 min. This buffer was then 
removed before replenishing the sections with 50 j l x I  of 1 ng/ml probe diluted in fresh 
hybridisation buffer and covering with a small piece of Parafilm approximately the same 
size as the section, to minimise evaporation. The slides were then incubated overnight 
at 50 °C in a sealed container lined with filter paper soaked in 2x SSC. Suitable 
stringency washing conditions for the removal of non-specific binding of probe to 
section were found to be 5x SSC (2x5 min) followed by 2x SSC (2x5 min).
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2.1.4.3. Immunological detection o f DIG-labelled probes
Section were washed in TBS containing 0.05% Tween-20 for 5 min and blocked with 
1% albumin (bovine fraction V) in the TBS/Tween buffer for 30 min. Slides were 
rinsed with 2% normal sheep serum in TBS/Tween briefly, before incubation with 7.5 
U/ml anti-DIG-AP Fab fragments for 2 h. Excess antibody was removed by sequential 
washing in TBS/Tween (2x10 min) and TBS (2x10 min), and the remaining antibody 
detected by addition of NBT/BCIP alkaline phosphatase substrate (100 pi per slide; see 
Appendix 1). After overnight incubation, the substrate was removed by washing with 
double-distilled water and the sections counterstained with methyl green for 10 min. To 
avoid removal of the counterstain, the section was blotted with damp blotting paper, air- 
dried before briefly rinsing in xylene and mounted in non-aqueous mountant using a 
Tissue Tek Automatic Coverslipper (Tissue Tek, Hants, UK).
For each lung, a separate slide was prepared and stained with haematoxylin and eosin to 
aid histological analysis. These sections were dewaxed in xylene, hydrated through the 
graded alcohols to water before immersion in alum haematoxylin (7.5 g/L) for 2-3 min. 
After a brief rinse in tap water the sections were rinsed in acid-alcohol (1% HC1 in 70% 
ethanol) to allow differentiation of the colour and stained with 1% aqueous eosin Y. 
The slides were then washed in tap water, dehydrated through the alcohols, cleared in 
xylene and mounted. All tissue and slide preparation and section staining was 
performed by myself.
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2.1.5. Northern blot analysis methodology
2.1.5.1. Extraction of total RNA
A number of methods based on work by Chomczynski and Sacchi (1987) were 
employed to isolate total RNA from whole guinea pig lung since successful 
methodology was not well documented in the literature. In initial experiments, frozen 
tissue (50 mg) was homogenised in the presence of a freshly prepared RNA extraction 
buffer (3 ml) containing 4 M guanidinium thiocyanate, 25 mM sodium citrate, 0.5 % 
sarcosyl, 0.1 M P-mercaptoethanol and precooled to 4 °C (method ‘A’). In later 
experiments frozen tissue was ground to powder using a pestle and mortar precooled 
with liquid nitrogen, homogenised with the extraction buffer until dissolved and stored 
at -70 °C for 1 h (method ‘B’). Using this buffer, protein was removed by addition of an 
equal volume of a 1 :1  solution of phenol/chloroform, followed by vigorous vortexing 
for 3 min and centrifugation at 1000 g for 7 min at 4°C. A further extraction was 
performed on the upper aqueous layer to ensure most proteins (including RNases) had 
been removed. RNA was precipitated by addition of 0.1 volume of 3M sodium acetate 
and an equal volume of propan-2-ol (HPLC grade) to the aqueous layer obtained from 
the second phenol/chloroform extraction. The mixture was vortexed vigorously, placed 
at -70 °C for 1 h and pelleted by centrifugation (30,000 g, 75 min, 4 °C). The pellet was 
washed with 75 % ethanol and air dried for 10 min before resupension in 30 jul of 
DEPC-treated water.
Later extractions of total RNA from lung were performed using RNAsol B (ams 
Biotechnology). Frozen tissue (50 mg) was ground to powder as above, dissolved in 
lml RNAsol B as recommended by the manufacturer and stored at -70°C (method ‘C’). 
Where cell cultures or isolates were used, the cells were extracted with 1 ml RNAsol B
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per 5 x 106 cells. The samples were thawed and RNA extracted b y  addition of 100 j l l I  
chloroform and centrifugation at 12,500 g for 15 min at 4 °C. An equal volume of 
isopropanol was added to the supernatant to precipitate the RNA on ice for 15 min 
which was then pelleted b y  further centrifugation at 12,500 g for 15 min. The pellet was 
washed in 70 % ethanol, dried and resuspended in 50 pi DEPC-treated water. Unless 
otherwise mentioned, all results presented in this thesis refer to extractions of total RNA 
using RNAsol B.
Where possible, the quantity of RNA in individual samples was assessed by absorbance 
at OD26o, and calculated by:
Amount of RNA (pg) = A26o x dilution factor x volume of solution (ml) x 40*
* An OD26o=1 indicates a solution of approximately 40 p,g of RNA per ml 
(OD2bo assesses the amount of protein within the sample).
2.1.5.2. Separation o f total RNA by electrophoresis
All total RNA preparations were separated using the following method as outlined by 
Jordan et al. 1995. For each sample total RNA (5-10 p,g) was denatured by addition of 
30 jul RNA sample buffer (see Appendix 1) and heating to 80 °C for 30 min. RNA was 
separated by electrophoresis through a denaturing agarose gel containing xl MOPS and
6.5 % formaldehyde, at 100 V for 90 min, using xl MOPS as running buffer. The gels 
were visualised and photographed under UV light (Polaroid film 55) to show differences 
in loading of total RNA between samples by the ribosomal RNA 18S and 28S bands. 
These bands also serve as 2 kb and 5.4 kb size markers respectively.
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2.1.5.3. Transfer and probing o f mRNA
Establishing hybridisation temperatures and buffers for the cDNA probes
Since a number of buffers are used in conjunction with DIG-labelled probes (Vignaud et 
al. 1994, Sambrook et al. 1989) the initial optimisation of hybridisation conditions was 
crucial. Total RNA was extracted using RNAsol B from 5xl06 guinea pig lung 
fibroblast JH4-C11 cells harvested at 24 h following stimulation with LPS-stimulated 
M 0 supernatant. The RNA was divided between 4 gel lanes and separated by 
electrophoresis as above. RNA was then blotted from the gel onto nitrocellulose 
membrane overnight using 20x SSC (diluted from a x20 stock containing 3 M NaCl, 
and 0.3 M trisodium citrate pH7.0) and stabilised by baking the membrane at 120 °C for 
20 min. Strips were cut from the membrane (1 lane/strip) and probed using a DIG- 
labelled cDNA for gpIL- 8  in the presence of differing buffers and temperatures as 
shown below.
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Buffer Constituents Recommended hybridisation 
temperature
A.‘Standard buffer’ 5x SSC,
0 .1 % sarcosyl, 
0.2% SDS,






0 .1 % sarcosyl, 
0.02% SDS,
1 % blocking buffer 
50% formamide 
DEPC water
6 8  °C
C.‘High SDS buffer’ 5x SSC,
0 . 1  % sarcosyl, 
7% SDS,
2 % blocking 
reagent,
50% formamide 




See Appendix I for SSC and blocking buffer constituents.
Table 2.1. Hybridisation buffers used to optimise conditions for the use of DIG-labelled 
cDNA probes in Northern blot analysis
Transfer and detection of probe
For all experiments RNA was blotted from the gel onto nitrocellulose membrane 
overnight using 20x SSC and stabilised by baking the membrane at 120 °C for 20 min. 
Unless otherwise indicated all membranes were first prehybridised at 50 °C using the 
high SDS hybridisation buffer (10 ml/50 cm2) for 1 h. This was replaced by fresh buffer 
(1.25ml/50 cm2) containing 10 ng/ml denatured DIG-labelled DNA probe (denaturation 
by heating probe at 95 °C for 5 min) and hybridised at 50 °C overnight. Non-specific
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bound probe was removed by washing the membrane twice at low stringency in 2x SSC 
containing 0.1 % SDS for 5 min and twice at high stringency in O.lx SSC/0.1 % SDS 
for 5 min. After a brief rinse in wash buffer (0.3 % Tween-20 in maleic acid buffer), the 
membrane was blocked with 1 % blocking buffer ( 1 0  % blocking stock diluted in maleic 
acid buffer) for 30 min, before detection of the bound probe by incubation with anti- 
DIG-AP Fab fragments (0.075U/ml) in 1 % blocking buffer for 1 h. Excess antibody 
was removed by wash buffer (3x10 min), and the membrane immersed briefly in 
substrate buffer before addition of CSPD chemiluminescence substrate in buffer giving 
a final concentration of 0.25 mM and allowing 500 jul/50 cm2. The membrane was 
sealed in polythene and incubated at 37°C for 30 min. The membrane was exposed to 
Kodak X-OMAT AR5 film (Sigma, Poole, UK) for 2 h, and developed.
2.1.6. Reverse-Transcription Polymerase Chain Reaction (RT-PCR)
2.1.6.1. Extraction of poly (A) RNA
Poly (A) RNA was extracted using QuickPrep Micro mRNA Purification Kit in 
accordance with the manufacturer’s instructions. Briefly, 100 mg of frozen guinea pig 
lung was solubilised in 0.4 ml extraction buffer containing guanidinium thiocyanate and 
0.8 ml elution buffer. Cell debris was removed by centrifugation (12,500 g for 1 min) 
and the supernatant mixed with oligo(dT)-cellulose for 3 min. Following another 
centrifugation as above, the pellet was washed with high salt buffer (x5) followed by 
low salt buffer (x2), transferred to a microspin column from which mRNA was eluted 
with 2 0 0  p,l elution buffer.
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2.1.6.2. Reverse-transcription reaction
Poly (A) RNA was reverse transcribed to generate cDNA. Initially, 5 pi of the 
QuickPrep column eluate was diluted to a final volume of 12.5 pi and denatured at 75 
°C for 3 min. The solution was cooled at 4 °C before addition of 7.5 jllI of RT ‘reaction 
mixture’ containing sufficient reagents for optimal concentration in 2 0  jxl; random 
hexamers (Pd (N)6) at final concentration of 1 pM, RT buffer x l, dNTPs each at 0.5 
mM, RNasin at 1 U/jliI and M-MLV RTase at 10 U/pl. Reverse transcription was 
performed at 42 °C for 60 min, followed by a denaturation at 95 °C for 2 min. The 
product was cooled on ice and underwent PCR immediately.
2.1.6.3. PCR ofRTproduct
The cDNAs for gpRANTES and gpMIP-1 were amplified in 35 cycle PCR reactions 
using a Perkin Elmer GeneAmp PCR System 2400 (Perkin Elmer, CA, USA) based on a 
method by Huang et al (1994). Each lung sample cDNA template was diluted and 
transferred to separate PCR tubes such that there were 3 tubes per sample containing 3 
p i ,  1.5 j l l I  and 0.3 pi of RT product with volumes made up to 15 pi with DEPC-treated 
water. To each tube, 8  pi of reaction mixture was added containing suitable amounts of 
constituents to deliver final concentrations of; xl PCR buffer, 200 mM each of dATP, 
dCTP. dGTP and dTTP, 1 mM each of appropriate forward and reverse primers (table
2.2) and 0.5U Taq polymerase. Primer sequences were selected so as to minimise 
primer dimerisation between pairs and with the selected house-keeping gene (p-actin) 
sequence which served as a internal standard for semi-quantitative analysis (see table
2.2). As well as RANTES and MCP-1, attempts were made to amplify eotaxin reverse
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transcripts using two primer sets; reverse 5' CAT CTC A AG CAC GAT GAT TAC 3' 
with forward primer 5' ACA CTG CAC CAT GAA AGT CTC 3', and reverse 5' TCC 
TGA ACC CAC TTC TTC TTG 3' with forward 5' CTG CAC CAT GAA AGT CTC 
CAC 3'. Where co-amplification of both chemokine and p-actin sequences was not 
possible, the PCR for each primer pair was conducted separately. Cycle conditions were 
set as before except the annealing temperature of the reaction was set at 55 °C over 35 
cycles. The PCR product was stored in aliquots at -20 °C.
To ensure that amplified DNA originated from reverse transcription and was not 
genomic DNA carried over from the original mRNA extraction, an equivalent volume 
of non-reverse transcribed mRNA was placed directly into the PCR reaction. The 
reaction mixture was analysed by electrophoresis, following 35 PCR cycles as described 
previously.
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gpRANTES R TAT GCC TCA GAT ACC ACT CC 
F GTA ATA GAA TCC ATG CCT CC
223 base pairs 55.3 °C
gpEotaxin R CAT CTC AAG CAC GAT GAT TAC 
F ACA CTG CAC CAT GAA AGT CTC
318 base pairs 56.6 °C
gpMCP-1 R CCC AAG CTT CAC TCT ACT TGT 
AGA ATT TGGA A
F CAG CCG GAT GGA GTT AAT AC
470 base pairs 57.3 °C
gpMIP-la R AAT CTT TGA TTC CTC CCA GG 
F GCT GCT TCA ACT ATG CCT CC
208 base pairs 57.0 °C
gpIL-8 R TTC ACA CCA CAC CTT TCC AC 
F GCC CTT GAT CTT AAT TTT GCT C
512 base pairs 55.7 °C
P-actin R. CTT TTC CAG CCT TCC TTC 
F. GCA GTA ATC TCC TTC TGC ATC
176 base pairs 55.1 °C
Table 2.2. Primer sequences for PCR amplification. Primers were designed using the 
‘Primer’programme of the GCG package (Daresbury Laboratory, Cheshire, UK)
2.1.7. Analysis ofRANTES protein in whole guinea pig lung using Western blotting
2.1.7.1. Assessment o f anti-RANTES monoclonal and polyclonal antibodies
A panel of 11 anti-human RANTES monoclonal antibodies was supplied by Dr. T Wells 
(Glaxo Wellcome, Geneva, Switzerland). Anti-guinea pig RANTES antisera was 
generated in rabbits by Dr. M Watson (Bath). All further characterisation of the 
antibodies was carried out by myself at Bath University.
Assessment by ELISA. Monoclonal antibodies were initially characterised for their 
ability to recognise recombinant guinea pig RANTES protein by ELISA using a method 
adapted from Harlow (1992). Serial dilutions of the chemokine (50 (il) in sodium 
bicarbonate buffer containing 20 mM Na2C0 3  and 70 mM NaHC03 at pH 9.6, were 
used to coat Nunc MaxiSorp plates (Gibco BRL) overnight at 4 °C. Plates were then 
washed with TBS containing 0.05 % Tween 20 (wash buffer) and wells incubated with 
dilutions of each monoclonal antibody for 2 h at 37 °C. Dilutions were made in the 
wash buffer containing 2 % FCS and a final volume of 50 j l l I  of antibody was added to 
the wells. Following the incubatory period, excess antibody was removed by three 
washing steps. Bound antibody was detected by incubation with alkaline phosphatase- 
conjugated rabbit anti-mouse IgG antibody (100 jil/well using a 1/15,000 dilution) for 
90 min at 37°C, washing the plate with TBS twice and addition of substrate p- 
nitrophenylphosphatase. The substrate was purchased as Sigma 104 Phosphatase tablets 
and diluted in 1 M tris pH 9.7 at 1 |Hg/ml, and 100 |xl added to each well. Colour 
development was measured after 30 min at 405 nm using a Titertek plate reader (ICN 
Biomedicals, Thame, UK).
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Dot blot analysis. Selected monoclonals and polyclonal antisera were also tested by dot 
blot analysis. Nanogram quantities of chemokine were dotted as 1 pi onto multiple 
nitrocellulose membrane strips and allowed to dry. The strips were blocked using a 
non-fat milk-based blocking buffer (5 % Marvel in TBS) overnight before incubation 
with different primary antibodies. Primary antibodies were diluted in TBS containing 1 
% Marvel. After 3 h the membranes were washed for 10 min in TBS, three times for 10 
min in TBS with 0.05 % NP-40 detergent, and finally for 10 min in TBS again. The 
membrane strips were then incubated with 1 / 1 0 , 0 0 0  dilution of alkaline phosphatase- 
conjugated secondary antibody (goat anti-mouse for monoclonals, goat anti-rabbit 
antibodies for polyclonals). Excess secondary antibody was removed by immersion of 
the membranes in TBS containing 0.05 % NP-40, threee times for 10 min and twice in 
TBS, and bound antibody detected using Enhanced Chemiluminescence (ECL) 
according to the manufacturer’s instructions.
Western blot analysis o f recombinant RANTES protein. Antibodies were also assessed 
for their ability to identify RANTES under denaturing conditions. Full methodology for 
Western blot analysis is described in the section below. Briefly, recombinant 
hRANTES and gpRANTES were run in multiple lanes of a 15 % SDS-PAGE gel using 
a Bio-Rad Mini Protean gel system. Proteins were transferred onto nitrocellulose, 
which was cut into strips such that each strip contained a sample of both rhRANTES 
and gpRANTES. Each membrane was blocked for non-specific binding and incubated 
in 1 pg/ml of a different monoclonal antibody for 3 h. Bound antibody was detected 
using alkaline phosphatase-conjugated goat anti-mouse secondary antibody and ECL as 
described above.
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2.1.7.2. Extraction and separation of protein from guinea pig lung
Frozen whole lung tissue (approximately 100 mg) was homogenised in 0.01 % triton X- 
100 containing 1 |Lig/ml leupeptin, 1 |Lig/ml pepstatin and 1 mg/ml EDTA. The 
homogenate was centrifuged at 13,000g for 2 min and supernatant stored at -20 °C. An 
assessment of the total amount of protein in each sample was obtained by comparing 
serial dilutions of each sample with a standard curve of known amounts of BSA using 
Bio-Rad Protein Assay, based on the Bradford dye-binding procedure (Bradford, 1976). 
Briefly, 10 (xl of sample or standard was mixed with 150 jil of the reagent and samples 
were read at 595 nm using a Titertek plate reader (ICN Biomedicals, Thame, UK). The 
concentration of triton-X (0.01 %) was compatible with this assay.
For each lung sample, approximately 2 mg of total protein was separated by SDS-PAGE 
on a 15 % running polyacrylamide gel under denaturing conditions (see Appendix 1 for 
details of gel composition) using a Bio-Rad Mini Protean system. The samples were run 
at 50 V for 15 min through the stacking gel (4 %) and at 150 V for 1.5 h through the 
running gel. Following electrophoresis the gels were allowed to soak in transfer buffer 
for 20 min before transfer of the protein onto nitrocellulose membrane (Bio-Rad, 
Hemmel Hempstead, UK) using 250 mA at 90 V for 40 min according to the 
manufacturer’s instructions. Membranes were blocked with blocking buffer and probed 
with optimal concentrations of primary antibodies which were detected using the 
respective secondary antibody and ECL as described above in section 2.1.7.1.
Where required, some gels were not transferred but stained with a solution of 0.2 % 
Bio-Rad Coomassie Blue Reagent-250 containing 45 % methanol and 9 % acetic acid 
for 5 h and then destained in a 10 % solution of methanol with 10 % acetic acid until the 
protein bands were clearly visible.
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2.2. PURIFICATION AND CHARACTERISATION OF RECOMBINANT 
GUINEA PIG RANTES PROTEIN
2.2.1. Cloning o f gpRANTES
Full length gpRANTES cDNA was cloned by T. Yoshimura (NCI-FCRDC, MD, USA) 
from a guinea pig spleen cell library while screening for gpMCP-1 (Yoshimura 1993). 
Briefly, poly (A) RNA was prepared from guinea pig splenocytes stimulated with 
concanavalin A (5 jig/ml, 4 h). A modification of the Gubler and Hoffman method 
(Gubler & Hoffman 1983) was used to synthesise cDNA. This was used to prepare a 
library in the ZAP II vector which was probed with a 32P-labelled oligonucleotide probe 
for MCP-1. Positive phagemids were rescued with helper phage and sequenced by the 
dideoxynucleotide chain termination method in accordance with the manufacturer’s 
instructions (Stratagen, La Jolla, US).
2.2.2. Gene expression
Successful expression of gpRANTES in E. coli was achieved by mutation of a human 
RANTES construct previously described (Proudfoot et al. 1995). The original construct 
contained the coding sequence of mature human RANTES with the addition of a N 
terminal hexapeptide ending in arginine (Arg) at the 5' end. Base substitutions were 
made by site directed mutagenesis to achieve amino acid changes at the six positions 
giving rise to the differences in primary sequence between guinea pig and human 
RANTES. Therefore, the protein produced was identical to the predicted gpRANTES 
amino acid sequence. The constructs were subcloned into the expression vector pT7-7 
and transformed into E. coli strain BL21 induced by addition of isopropylthiogalactoside 
to the medium. This work was carried out by B. Allet (Geneva Biomedical Research
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Institute, Glaxo Wellcome, Switzerland). All subsequent procedures were carried out 
by myself at Glaxo IMB, Geneva , under the supervision of Dr. A. Proudfoot.
2.2.3. Protein Purification
2.2.3.1. Extraction from inclusion body
Guinea pig RANTES was purified essentially as described for human RANTES by 
Proudfoot and co-workers (Proudfoot et al. 1995). For the purposes of comparison and 
familiarisation with the purification techniques, rhRANTES was also purified. 
Differences in the purification of the proteins are outlined below, where necessary.
Guinea pig RANTES protein was extracted from transformed E. coli (40g) by four 
rounds of homogenisation, sonication and French Press extraction in lysis buffer (Tris- 
HC1 50 mM pH 7.6, DTT 1 mM, PMSF 1 mM, DNase 20 mg/ml, MgCl2 16 mM) 
allowing the homogenate to cool at 4 °C for 5 min between each round. The extract was 
centrifuged at 10,000g for 60 min, and the hexapeptide-gpRANTES fusion protein 
identified as a component of the inclusion body by SDS-PAGE. The cell pellet was 
solubilised in 100 ml of 0.1 M Tris-HCl buffer (pH 8 ) containing 6  M guanidine HC1 
and 1 mM DTT and denatured by heating to 60 °C for 30 min before initial separation 
by size exclusion gel filtration on a Sephacryl HR S200 column (Pharmacia, Uppsala, 
Sweden) equilibrated in the same buffer. Briefly, the protein was loaded onto the 
column and eluted with the same buffer at a rate of 8  ml/min in 2 0  ml fractions. 
Aliquots (1 ml) of all fractions were dialysed against 6  M urea to allow analysis by 
SDS-PAGE and those containing protein between 5-20 kDa were pooled.
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2.2.3.2. Renaturation and further purification
The concentration of hexapeptide-gpRANTES protein in these fractions was determined 
and the solution diluted with the same Tris/guanidine/DTT buffer to achieve a final 
protein concentration of 1 mg/ml. The protein was renatured by a 20-fold dilution into 
0.1 M Tris-HCl (pH 8.5) buffer containing 1 mM oxidized and 0.1 mM reduced 
glutathione, at a rate of 1.5 ml/min with constant stirring at 4 °C overnight. Non- 
renatured protein was removed by centrifugation, and the renatured protein was then 
concentrated using cation exchange chromatography. Initially, the solution was adjusted 
with to pH 4.5 with NaOH, and diluted with distilled water to achieve a conductivity of 
10 mS before applying to a HiLoad SP 26/10 column (Pharmacia) equilibrated with 50 
mM sodium acetate, pH 4.5. Absorbed protein was eluted with a linear 0-2 M NaCl 
gradient in the same buffer over 4 h, at a rate of 8  ml/min and collected as 20 ml 
fractions. SDS-PAGE identified fractions containing the hexpeptide-RANTES protein 
which were pooled, and the protein concentration determined by absorbence at OD28o. 
The solution was frozen using a methanol-dry ice bath and the protein lyophilised.
2.2.3.3. Removal o f hexapeptide sequence and separation o f digestion products
The protein (1 mg/ml) was solubilised in 50 mM Tris-HCl (pH 8 ) and the hexapeptide 
leader sequence was removed from the RANTES protein by incubation with 
Endoproteinase Arg C at 1:300 (w/w enzyme:substrate) for 6  h at 37 °C. This length of 
incubation was optimal and determined by RP-HPLC analysis of the digestion at 1 h 
intervals from 1 - 8  h.
Products resulting from the cleavage of both hexapeptide-gpRANTES and hexapeptide- 
hRANTES underwent initial separation by cation exchange chromatography under the
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same conditions as described above with the addition of 6  M urea in the buffers and 
eluting the protein with a 0-50% gradient of NaCl over 3 h (5 ml/min in 10 ml 
fractions). This effectively separated the products of the hexapeptide-human RANTES 
digestion. However, this process only partially separated the hexapeptide-gpRANTES 
digestion. Complete recovery of cleaved gpRANTES was achieved by RP-HPLC. 
Protein (1 jig in 2 ml) was first acidified with TFA such that the final concentration of 
acid was 0.1% before injection onto a VarioPrep Nucleosil 300-7 C8  column (250 x 10 
mm, all HPLC columns from Macherey-Nagel, Diiren, Germany), equilibrated with 
0.1 % TFA in water. Protein was eluted at a rate of 4 ml/min with a gradient of buffer A 
(0.1% TFA) and buffer B (90% acetonitrile with 0.1%TFA in water) using 25-50% 
buffer B over 25 min. All buffers were filter sterilised. The peak containing cleaved 
gpRANTES was identified and the protein lyophilised in preparation for biological 
characterisation.
2.2.3.4. Analytical methods.
Protein purification and purity were followed by SDS-PAGE using 4-20 % acrylamide 
precast mini-gels (Novex) following manufacturers instructions and the gels were 
stained with Coomassie Brilliant Blue R250. All samples were denatured by mixing 
with an equal volume of x2 sample buffer and heating to 95 °C for 5 min. RP-HPLC 
was also employed using a Beckman System Gold with an Aquapore RP 300-7 C8  (220 
x 2.1 mm, Macherey-Nagel) analytical column at a flow rate of 1 ml/min using the same 
sample preparation and column conditions as described above. The purified proteins 
were quantified by the extinction coefficients of A^J° = 2 . 1  and 1 . 6  at OD28o for the 
hexapeptide-gpRANTES fusion and gpRANTES respectively, calculated from the
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predicted amino acid sequences. The amino terminus was verified by Edman 
degradation using a model 477A (Applied Systems) pulsed liquid phase sequencer. The 
amino acid composition was verified by overnight hydrolysis at 105 °C in 6  M HC1 and 
quantified using a Beckmann 6300 amino acid analyser with a SICA integrator
Bioactivity of the gpRANTES purification product was monitored by elevation of
2+[Ca ]j using the human monocytic cell line THP-1. The cells were cultured in 
suspension in RPMI 1640 medium supplemented with 10% heat inactivated FCS, 2 mM 
(L)-glutamine, 0.01 M HEPES and 0.005% gentamycin and passaged to maintain an 
optimal density of 5-8x105/ml. The cells were incubated with 2.5 pM fura-2AM for 30 
min at 37 °C, washed three times in buffer and resupended at 2xl06 cells/ml. 
Simultaneous measurements were made at an excitation of 340/380 nm and emission of 
510 nm using an LS50 Perkin Elmer spectrofluorimeter. An increase in the 340/380 
ratio was taken to indicate bioactivity.
2.2.4. Attempts to identify RANTES as a product of guinea pig platelets
In an attempt to identify a native source of gpRANTES for the purposes of sequencing, 
platelet lysates were analysed for the possible presence of the protein using a method 
adapted method from Kameyoshi et a l (1988) who isolated this chemokine from human 
platelets.
Isolation o f platelets. Approximately 30 ml of blood was collected from two Sagatal- 
anaethetised Dunkin Hartley guinea pigs (800-900 g) by cardiac puncture into 3 ml of
2.5 % sodium citrate containing 1.5 % citric acid and 2 % glucose. Platelet rich plasma 
was prepared by centrifugation of the citrated whole blood at 350 g for 15 min. The
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upper layer was collected and centrifuged further at 1 0 0 0  g for 1 0  min to pellet the 
platelets. They were then resuspended at 2xl08/ml platelets in Hepes-buffered Tyrodes 
solution (pH7.4) containing 10 mM Hepes, 145 mM NaCl, 5 mM KC1, 1 mM MgCl2, 
0.5 mM Na2HP04, 5.5 mM glucose and 0.25 % BSA.
Thrombin-stimulated platelet aggregation. Platelet activation was monitored by a 
aggregation method using a Chronolog dual aggregometer as described by Bom (1962). 
This method detects changes in light transmission through the platelet suspension as a 
result of an aggregation response to an agonist. Platelet shape change induces a 
decrease in light transmission whilst aggregation causes an increase. Light transmission 
( 0  %) was calibrated by assessing the transmission through 2 x l 0 8 platelets per ml whilst 
1 0 0  % transmission was assumed to be represented by transmission through a ten fold 
dilution of the platelet suspension (2xl07/ml). In order to assess aggregation in response 
to an agonist, 0.5 ml of platelet suspension (2xl08/ml) was stirred at 37 °C for 2 min. 
Calcium was added to a final concentration of 1 mM at t=0 min and thrombin (2U/ml) 
at t=2 min whilst continually stirring at 900 rpm at 37°C. Platelets were removed by 
centrifugation (1000 g for 5 min) at 30 min after the addition of thrombin (as described 
for human platelets by Kameyoshi et al. 1988) and the supernatant stored at -80 °C.
Assessment o f activity o f thrombin-stimulated platelet supernatant (TSPS). Thrombin- 
stimulated platelet supernatant (TSPS) was assayed for its ability to increase [Ca2+]i in 
guinea pig peritoneal macrophages using the same methods as described in sections 
2.2.5.1-2 of this thesis. Following macrophage equilibration with ImM Ca2+, various 
volumes of TSPS were used as a potential agonist. The effect of the PAF antagonist 
WEB 2086, on the changes in [Ca2+]i( was assessed by addition of a saturating dose 
(luM) to the platelet suspension at 1 min prior to addition of TSPS.
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2.2.5. In vitro biological characterisation
2.2.5.1. Cell isolation
Guinea pig peritoneal eosinophils were generated by twice-weekly intraperitoneal 
injections of horse serum over 4 weeks using 400-500 g Dunkin-Hartley guinea pigs 
(Harlan, UK) with an injection the day before harvesting (Litt 1960). Macrophages 
were elicited by one 5 ml intraperitoneal injection of thioglycollate (0.05 % w/v) and the 
cells were harvested after 3 days. Guinea pigs were killed by CO2 asphyxiation, a small 
mid-line incision made in the abdomen, and the peritoneal cavity lavaged with 2x30 ml 
HBSS pH 7.4 containing 1 mM EDTA. The cells were washed with HBSS containing
0.1% BSA (<0.1 ng endotoxin/mg) and resuspended in Percoll (1.070 g/L) containing 
1% BSA. The leukocyte populations were separated by centrifugation (1500 g for 25 
min at 4 °C) on a discontinuous isotonic Percoll gradient (Shute et al. 1990) through 
densities of 1.070, 1.080, 1.085, 1.090, 1.100 g/L. Eosinophils and macrophages 
separated at the 1.095-1.100 and 1.080-1.090 interfaces respectively. The cell containing 
fractions were carefully removed and washed three times in HBSS containing 0.1% 
BSA. In each case the cell purity obtained was >96% and the major contaminant cell 
type was monocytic with some neutrophils in the case of the eosinophil preparations, 
and neutrophilic in the case of the macrophage preparations.
Human eosinophils were isolated from peripheral whole blood using a negative 
selection technique adapted from Hansel (1989). Citrated blood (100 ml of peripheral 
blood containing 0.38 % of sodium citrate) was pelleted by centrifugation at 1865 g for 
6  min at 4 °C and the plasma removed. The red blood pellet was diluted to the original 
volume with RPMI 1640, layered onto Lymphoprep (2:1 v/v) and spun at 400 g for 30 
min at 20 °C. Peripheral blood mononuclear cells were removed and the remaining
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leukocyte/erythrocyte sediment was mixed with dextran T500 and the volume 
replenished to 150 ml with saline such that the dextran was at a final concentration of 
1%. The suspension was allowed to sediment for 30 min after which time the 
leukocyte-rich supernatant was spun (350 g, for 10 min at 4 °C). Remaining red blood 
cells were removed from the resulting cell pellet by hypotonic lysis with cold H20  and 
washing with RPMI/EDTA and the granulocytes collected by centrifugation (200 g for 
10 min at 4° C). Eosinophils were isolated by negative selection using anti-CD 16 
magnetic particles and a MACS separation system (Miltenyi Biotech, Bergisch 
Gladbach, Germany) according to the manufacturer’s instructions. Briefly, the cells 
were mixed with anti-CD 16 magnetic particles for 30 min at 4 °C (2xl08 cells/100 ml 
beads). The cells were applied to the MACS column and the eosinophils eluted with 8  
column volumes of RPMI 1640. The resulting cell purity was >96% and the 
contaminating cells were neutrophils and monocytes.
Guinea pig leukocytes were isolated from whole blood obtained from animals injected 
with recombinant human IL-5 (18.3 pmol/kg) and bled after 1 h, according to 
methodology by Collins et al. 1995. Blood was collected into sodium citrate (0.38 % 
w/v final) and sedimented with 1 % dextran as described for human eosinophils. The 
upper layer was removed and cells pelleted by centrifugation at 350g for 10 min. 
Attempts were made to separate these cells using a discontinuous Percoll gradient as 
described for guinea pig peritoneal eosinophils. Cells were then washed with HBSS 
containing 0.1 % BSA twice before resuspension in HBSS/BSA with 1 mM Ca2+ and 
Mg2+.
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2.2.5.2. Measurement o f intracellular calcium
Cells were suspended in 5 ml of HBSS/0.1% BSA containing 2.5 pM fura2-AM and 
incubated at 37 °C for 30 min. The cells were washed three times in HBSS/BSA and 
resuspended in HBSS/BSA containing 1 mM Mg2+ and 0.1 mM Ca2+ at lxlO6 cell/ml. 
Prior to each experimental run, extracellular Ca2+ was restored to 1 mM. Fluorescence 
was monitored in all cell aliquots at excitation wavelengths 340 and 380nm and 
emission at 510 nm with constant stirring at 37 °C in a Deltascan spectrofluorimeter 
(PTI inc., Surrey, UK). Baseline fluorescence was monitored for 20 sec before addition 
of agonists (10 pi). Signals were calibrated by monitoring the fluorescence change in a 
cell suspension after addition of 12.5 mM digoxigenin followed by 40 mM NaOH and 4 
mM EGTA 30 sec later, to obtain values of Rmin and Rmax. [Ca2+]i was calculated from 
the ratio of fluorescence using the excitation wavelengths according to Grynkeiwcz 
(1985):
[Ca2+], = Kd x (R-Rmin) SJ2
(Rmax-R) Sb2
Kd = the dissociation constant for fura-2 at 37 °C is 2.24x1 O'7 M 
R = Ca2+ bound/Ca2+ free flourescence 
Rm in = fluorescence ratio with zero Ca2+,
Rmax = fluorescence ratio under saturated calcium conditions
Sf2/Sb2=ratio of fluorescence values for Ca2+ bound/Ca2+ free indicator measured at the 
wavelength used to monitor Ca2+ free indicator (i.e. 380 nm).
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2.2.5.3. Leukocyte chemotaxis
Cells were resuspended at 2xl06/ml in HBSS containing 1 mM Ca2+/Mg2+ and 0.1 % 
BSA. Chemokine dilutions at 1-100 nM were prepared by dilution in the same buffer. 
Chemokines, C5a as a positive control or buffer as a negative control, were added to the 
lower wells of 48 well microchemotaxis chambers (Neuro Probe, Cabin John, US) and 
covered with a polycarbonate filter with 5 p,m pores for eosinophil experiments and 8  
Jim pores for macrophages. For each experiment, 4 replicates of each sample dilution 
were performed. Cells were added to the upper chamber and allowed to migrate for 2 h 
at 37 °C. The membrane was removed after incubation, washed, fixed and stained to 
allow visualisation of migrated cells. Results were expressed as mean ± SEM per high 
power field (all cells in the field of view using a magnification of x400) using cells 
preparations from n=3 or 4 different animals. In some eosinophil experiments, IL-5 was 
added together with chemotactic agents into the lower wells and the cells allowed to 
migrate as described.
2.2.5.4. Measurement o f hydrogen peroxide generation.
Hydrogen peroxide generation from RANTES-stimulated cells was determined by 
oxidation of the fluorescent reagent scopoletin to a non-fluorescent product at 37 °C as 
previously described by Nathan (1987). Ninety-six well flat-bottomed flexiplates were 
precoated with 150 jllI of a 3 mg/ml laminin solution for 1 h at 37 °C. The plate was 
washed with HBSS and cells resupended in HBSS containing 1.5 mM Ca2+ and Mg2+ 
were added to each well (100 jil at 2xl06 cells/ml). The following reagents were then 
added per well; 50 jil HBSS, 10 j l l I  ‘reaction mixture’ containing scopoletin (3.6 nmol;
9-i- 94-final), horse radish peroxidase (10 jig), sodium azide (150 nmol) and Ca /Mg (20
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nmol). The plate was incubated at 37 °C for 15 min prior to addition of varying 
amounts of test agonists in 10 p i  Hydrogen peroxide generation was monitored by a 
decrease in fluorescence using an excitation wavelength of 355 nm and emission of 460 
nm detected by a Titertek II plate reader (ICN Biomedicals, Thame, UK). A time zero 
reading was taken immediately after addition of test reagents and at 1 0  min intervals 
thereafter.
Calibration o f hydrogen peroxide production. A standard curve of scopoletin 
fluorescence in the presence of known quantities ( 1 - 6  nmols) of hydrogen peroxide was 
established by addition of 150 pi HBSS, 10 pi reaction mixture and 10 pi of the 
respective H2C>2 standard to blank wells. Each H20 2 standard and test reagents was 
performed in triplicate wells. The fluorescence readings from test reagent wells were 
converted to nmol of H20 2 from the fitted standard curve.
The spread sheet Excel (version 5) was used to manipulate the data and calculate the 
H20 2 generation from changes in fluorescence.
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2.2.6. Assessment of chemoattractant activity of RANTES in vivo
2.2.6.1. Tracheal instillation of gpRANTES
Dunkin-Hartley guinea pigs (350-400 g either sex) were anaesthetised with a mixture of 
ketamine (40 mg/kg) and xylazine (5 mg/kg), placed prone and tracheal instillation 
performed with the aid of a laryngoscope. gpRANTES (0.1-10 jig) was instilled as 50 
pi with saline/0.1 % BS A as a vehicle using a Gilson pipette fitted with a gel-loading tip. 
The animals were killed at 6  h, 24 h or 48 h post treatment with an overdose of 
pentobarbitone (Euthatal). The trachea was cannulated to allow attachment of a syringe 
containing 10 ml of saline with 0.1% BSA and 1 mM EDTA. This volume was 
gradually emptied into the lung so as to minimise tissue damage, and carefully syringed 
back after 10 sec. For each lung this lavage process was repeated three more times with 
fresh buffer and the lavage fluid pooled. Total cell counts were determined and BAL 
cell cytospins prepared using a Shandon cytospin (Shandon Scientific Ltd, Runcom, 
UK), stained with ‘Diff-Quik’, and differential cell counts performed. All results were 
expressed as mean±SEM cell number of n animals. Cell numbers from RANTES- 
instilled animals were compared to those from vehicle (saline with 0.1 % BSA) instilled 
animals at the appropriate time point.
2.2.6.2. Intradermal injection o f gpRANTES into naive guinea pig skin sites
A number of methods were employed to investigate the effect of RANTES on 
eosinophil accumulation in the guinea pig skin.
Accumulation o f 111 In-labelled peritoneal eosinophils. Accumulation of eosinophils in 
the guinea pig skin was monitored using a method adapted from Faccioli et al. (1991). 
Peritoneal eosinophils were generated by repeated horse serum injections using 600-
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700g ‘donor’ Dunkin Hartley guinea pigs and isolated as described above. The cells 
were labelled with in InCl3 (100 |LiCi in 100 jul) chelated with 2-mercaptopyridine-V- 
oxide (40 pg in 0.1 ml of 50 mM PBS pH 7.4) for 15 min at room temperature. 
Labelled cells were washed twice and resuspended at a density of 107 eosinophils /ml in 
Hank’s buffer pH 7.3 containing 0.1 % BSA.
‘Recipient’ guinea pigs (350-400 g) were sedated with Hypnorm (0.15 ml i.m.) and their 
dorsal skin shaved and skin sites marked. Each animal received 5xl06 labelled cells 
mixed with 2.5 pCi of 125I-albumin via the ear vein. Various mediators were injected
i.d. as 100 pi volumes into separate sites of the dorsal skin. Saline was used as a vehicle 
control whilst guinea pig zymosan activated plasma (30 % in saline) was used as a 
positive control for eosinophil accumulation and histamine for plasma leakage. Each 
animal received a duplicate of each treatment according to a randomised balanced site 
injection plan. After 2 h the animals were killed with an overdose of Euthatal (sodium 
barbitone) and a cardiac blood sample was taken immediately and plasma separated 
from cells by brief centrifugation. The dorsal skin was removed and skin sites were 
punched out with a 17 mm diameter punch and samples were counted together with 
plasma samples using an automatic gamma counter (Wallac, Milton Keynes, UK). 
Samples were also counted for 125I and corrections were made for cross-talk between the 
two isotopes.
Total m In counts for a known number of eosinophils enabled calculation of m In counts 
per eosinophil and this was used to determine m In eosinophils per skin site. Plasma
19^ 19Sleakage was expressed as pi of plasma by dividing the skin sample I counts by I 
counts per 1 pi of plasma.
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Accumulation of blood-derived cells. Dunkin Hartley guinea pigs (350-400 g) were 
anaesthetised with Hypnorm (0.15 ml i.m.) and after 5 min the dorsal skin shaved. 
gpRANTES was injected i.d. as 100 j l l I  volumes into separate sites of the dorsal skin, to 
give final amounts of either 10' 10 or 10"11 mol/site. Other sites were injected with 100 j l l I  
saline as a vehicle control or guinea pig zymosan activated plasma (30% in saline) as a 
positive control and each animal received a duplicate of each treatment following a 
randomised injection plan. The inflammatory response was assessed at 2 and 24 h («=3 
animals for each time point) by overdosing with sodium pentobarbitone (Euthatal) and 
removing the skin sites with a 17 mm punch. Samples were fixed in formal buffered 
saline overnight, embedded in paraffin wax and 8  pm sections cut to show a transverse 
view through the injected site. Mounted sections were stained by H&E to allow 
identification of dermal infiltrates.
Preparation o f zymosan-activated plasma (ZAP). Zymosan-activated plasma was used 
as a rich source of guinea pig C5a-des-Arg. Guinea pigs were killed by CO2 
asphyxiation and cardiac puncture performed to remove 10-15 ml of blood into a 
syringe loaded with heparin allowing 10 IU/ml blood. The supernatant was removed 
after sequential spinning at 1350 g for 15 min and 1950 g for 15 min. The plasma was 
incubated with zymosan (5 mg/ml) for 30 min at 37 °C with occasional shaking after 
which time the zymosan was removed by centrifugation at 3000 g for 15 min. The 
supernatant was purified using a PD10 Sephadex G-25M column to remove low 
molecular weight material, according to the manufacturer’s instructions (Bio-Rad Labs, 
Richmond, CA, US), and stored at -20 °C before use.
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2.2.6.3. Statistical Analysis
Where appropriate, statistical analysis was performed on in vivo data to identify 
statistical differences between treatments and time-matched controls. Data was 
subjected to one-way ANOVA followed by post-hoc Dunnett’s test to compare a 
number of treatment groups to one control group, whilst a Student’s unpaired t test was 
used to compare single treatment groups to their respective control groups.
Differences in standardised levels of chemokine message relative to those of the house­
keeping gene, P-actin, were compared between treatment groups using the Mann 
Whitney U test.
All statistical analysis was performed using Minitab 10.
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CHAPTER 3. RESULTS:
Detection of chemokines in the guinea pig lung
To identify the presence of chemokines in the guinea pig lung, whole tissue was 
analysed using Northern blot analysis, in situ hybridisation and RT-PCR.
3.1. Synthesis and validation of molecular probes
Since molecular probes are not currently commercially available to study chemokine 
expression in the guinea pig, all investigative tools had to initially be synthesised and 
validated initially. All this work was carried out by myself at Bath University using 
chemokine cDNA inserts in the pBluescript SK- plasmid as starting material. These 
were supplied by T. Yoshimura, NCI-FCRDC, MD, USA.
3.1.1. Synthesis ofcDNA probes for Northern blot analysis
DIG-labelled cDNA probes were successfully generated by PCR using the primer 
sequences selected. PCR cycle conditions were set as: denaturation phase at 95 °C for 
15 sec, annealing phase at 55 °C for 15 sec and extension phase at 72 °C for 15 sec. The 
amplification of 5 pg plasmid DNA over 30 such cycles generated approximately 0.2 pg 
in 100 pi (2 pg/ml) of DIG-labelled probe for all the chemokines, as assessed by dot 
blot analysis and comparison to a sample of control DIG-labelled DNA (from 
Boehringer Mannheim) of known concentration (figure 1). DIG-labelled DNA was 
detected using anti-DIG-AP Fab fragments and a chemiluminescence substrate and this 
detection system was also used as for the Northern blot analysis studies. The specificity
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of amplification for each chemokine insert was confirmed by the presence of fragments 
of expected size using electrophoresis based on the selected primer sequences (figure 2).







Figure 1. Dot blot analysis of PCR-generated DIG-labelled cDNA probes for guinea pig 
chemokines. Ten-fold serial dilutions of probes were dotted as 1 fil onto nylon 
membrane. DIG-labelled DNA was detected using anti-DIG-AP Fab fragments and 
chemiluminescence substrate. DIG-labelled probe was assessed by comparison with a 
labelled DNA sample of known concentration (Boehringer Mannheim) as shown. DIG- 
labelled probes were prepared and quantified on three separate occassions. Each 
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Figure 2. Separation of PCR products following amplification of chemokine cDNA 
sequences. cDNA were subcloned into pBluescript SK- plasmid and amplified using 
selected primer sequences to generate DIG-labelled cDNA probes. The main products 
correspond with the predicted fragment size based on the primer pairs selected; gpMIP- 
la ; 208 base pairs, gpRANTES; 223 bp, gpIL-8; 512 bp and gpMCP-1; 470 bp. 
Products were separated by electrophoresis on a 1.5 % agarose gel containing 1 mg/ml 
ethidium bromide to visualise the DNA.
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3.1.2. Preparation and validation o f single-stranded DIG-labelled riboprobes
Single stranded riboprobes are the considered to be the probe of choice for in situ 
hybridisation since they avoid the problems of competition between target tissue RNA 
and the complementary strand as is the case using denatured double-stranded DNA 
probes. Furthermore RNA-RNA hybrids are far stronger than RNA-DNA hybrids 
(Vignaud et al. 1994). Therefore, considerable time and effort was invested to generate 
labelled riboprobes.
pBluescript SK- plasmid containing gpRANTES or eotaxin cDNA was digested 
overnight with selected restriction enzymes to allow maximal linearisation. Enzymes 
were selected to allow linearisation on either the T7 or T3 polymerase-side of the insert 
to enable generation of antisense (complementary to) or sense (identical sequence to 
mRNA) probes respectively as shown in figure 3A. The linearised plasmid was purified 
by gel electrophoresis of the restriction enzyme mixture, removal of the gel band 
containing linearised plasmid (figure 3B, bands running at 4.0 kb) and extraction of the 
DNA using QIAquick columns (3C). Using electrophoresis, non-linearised and 
linearised forms of the plasmid were separable by virtue of their shape; the migration of 
the non-linearised plasmid is inhibited by its circular nature and may account for the 
faint bands running at around 21.2 kb. This purification step was found to be essential 
and during earlier attempts to synthesise riboprobes transcription using linearised, but 
unpurifed, DNA failed to yield a DIG-labelled product. In those circumstances it is 
possible that contaminating non-linearised plasmid, which would also be transcribed in 
the T7/T3 polymerase system, might have vastly decreased the amounts of free 
nucleotide as the polymerases circled the whole plasmid.
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It was found that following the restriction and gel purification steps only 1/10 of the 
starting DNA was retained. Thus a minimum of 10 (ig of miniprep plasmid DNA was 
required to generate the 1 jug of purified, linearised DNA necessary per transcription 
reaction. A number of initial attempts to synthesis riboprobes using 1-5 (ig yielded 
insufficient quantities of the riboprobe for in situ analysis.
The quantity of DIG-labelled RNA generated from the transcription of 1 jig of plasmid 
DNA was quantified by dot blot analysis and compared to a sample of DNA of known 
concentration. The transcription reaction generated approximately 50 ng/ml DIG- 
labelled cRNA for both RANTES sense and antisense probes and 25 ng/ml for both 
eotaxin probes (figure 3D).
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Figure 3. Preparation of DIG-labelled riboprobes. pBSK- plasmid containing RANTES 
(R) or eotaxin (E) cDNA was linearised with appropriate restriction enzymes either side 
of the T7 or T3 polymerase sites (A). The digests were separarted by electrophoresis
(B) and purified using QLAquick extraction cloumns to obtain pure linearised plasmid
(C) which was transcribed using with T7 or T3 RNA polymerases. Incorporation of 
DIG-11-UTP was confirmed by dotting 1 pi of serial dilutions of the probe onto 
nitrocellulose and developing using anti-DIG Fab fragments and BCDP/NBT substrate. 
This enabled quantification by comparison to control labelled DNA of known 
concentration (D).
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3.2. Northern blot analysis of whole lung tissue following OA challenge
3.2.1. Methods of extracting total RNAfrom guinea pig lung tissue
A number of methods were employed to isolate RNA from guinea pig whole lung and 
substantial time and effort were invested for this purpose. Initial attempts involved the 
extraction of RNA from frozen pieces of lung tissue using a 4 M guanidine 
isothiocyanate buffer, followed by a series of phenol/chloroform steps and propan-2-ol 
precipitation (referred to as method A in ‘Materials and Methods’). Visualisation of the 
RNA on ethidium bromide gels showed a smearing of products which is indicative of 
RNA degradation. Moreover, there was no evidence of 18 and 28 S bands. Some slight 
improvement in the purity of the RNA was observed using tissue crushed under liquid 
nitrogen, since faint 18 and 28 S bands were visible (method B).
During the course of the my studies, a number of commercial reagents became available 
to aid the extraction of RNA from tissues. RNA extracted from lung tissue crushed 
under liquid using RNAsol B proved the most successful of all methods attempted, as 
assessed by the calibre of the 18 and 28 S bands (method C). It is possible that the 
speed of RNA isolation using such commercial preparations is a major factor since the 
time the RNA is in a soluble form, when it is most susceptible to RNase activity, is 
reduced. However, considerable variation in the integrity of RNA was observed 
between experiments, even using this technique.
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3.2.2. Optimal hybridisation conditions for DIG-labelled cDNA probes
The optimal conditions for the hybridisation of RNA to DIG-labelled probes were 
assessed by probing different blots of equal quantities of the same RNA sample with a 
probe for gpIL-8 under different buffers and temperatures. Hybridisation to the probe 
occurred only when using high SDS buffer at 50 °C (figure 4, lane 2). It would appear 
that temperature is critical since only very slight hybridisation was observed at 42 °C 
(figure 4, lane 1).
Hybridisation of RNA to the DNA probes using other samples of fibroblasts and lung 
tissue was also unsuccessful using standard buffer either with or without formamide. In 
comparison, the use of high SDS buffer at 50 °C produced a distinct signal in both cell 
line and tissue samples, with no evidence of non-specific binding (see figures 5 and 19).
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1 2  3 4
Lane 1 High SDS buffer at 42°C
Lane 2 High SDS buffer at 50°C
Lane 3 Standard buffer at 42°C
Lane 4 Standard buffer (+50% formamide)
at 68°C
Figure 4. Optimisation of hybridisation conditions for DIG-labelled cDNA probes. 
RNA was extracted from 5xl06 guinea pig lung fibroblasts and divided equally between 
each lane. Following transfer, membrane lanes were incubated with gpEL-8 probe under 
the described conditions and bound probe was detected using anti-DIG Fab fragments 
and chemiluminescence substrate.
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3.2.3. Results from Northern blot analysis ofOA challenged whole lung tissue 
The kinetics of chemokine mRNA expression was examined in lung from OA-sensitised 
and naive guinea pigs at various time points following aerosol challenge with OA. Low 
levels of both RANTES and MCP-1 mRNA expression were observed in naive non­
challenged guinea pig lung (figure 5). RANTES mRNA was detected in naive lung 
samples following OA challenge at the time points examined. A slight increase was 
observed in sensitised lung tissue at 2 h post-OA challenge compared to time matched 
controls but this trend was not consistently seen in all sensitised lungs at later time 
points. The same lung samples were also examined for expression of MCP-1. In 
contrast with RANTES, MCP-1 message was greatly elevated in two of three sensitised 
lungs at 2 h following OA challenge compared to controls, and this increase was also 
observed at 6 and 12 h post challenge. At 24 h, levels of MCP-1 mRNA were elevated 
in naive OA challenged lungs. However accurate assessment of chemokine mRNA 
levels in sensitised tissue was not possible at this time point due to the under-loading of 
total RNA as assessed by the ribosomal 18 and 28 S bands (figure 5, lower panels). 
This may be due to RNA degradation since RNA from equal amounts of starting tissue 
(25 mg) was loaded in each gel lane. RNA degradation results from exposure to RNases 
but since intact total RNA was successfully purified from primary and cell line 
fibroblasts (for example see figures 18 and 19), it seem unlikely that the tissue 
degradation was due to exogenous RNase contamination. The purification technique 
may not have adequately remove all endogenous RNases from some tissue samples. In 
further studies, attempts to assess the comparative time course of expression of 
RANTES and other chemokine mRNA by Nothem blotting proved inconclusive due to 
RNA degradation in some samples. For this reason, a semi-quantitative RT-PCR 
method was developed.
116
N 2hC 2hOA 6hC 6hOA RANTES
12hC 12hOA 24hC 24hOA
N 2hC 2hOA 6hC 6hOA MCP-1





Figure 5. Northern blot analysis of RANTES and MCP-1 mRNA expression in OA 
sensitised (OA) and naive (C) guinea pig lung following OA-challenge. At all time 
points /i=3 animals except naive OA-challenge at 2 h which was n -2. Similar levels of 
RANTES expression was observed in both sensitised and naive lungs following OA 
challenge in comparison to MCP-1 which was upregulated at 2, 6, and 12 h in sensitised 
samples. ‘N’ represents mRNA levels in naive non challenged guinea pig lung. The 
lower panels show levels of total RNA loading through ribosomal 18 and 28S bands. 
Similar patterns of expression were obtained in a separate experiment using different 
sets of n=3 guinea pigs per treatment.
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3.3. Semi-quantitative analysis of OA challenged lung by Reverse-Transcriptase
Polymerase Chain Reaction (RT-PCR).
3.3.1. Optimisation o f PCR using chemokine reverse transcripts from guinea pig lung
Ovalbumin challenged guinea pig lung tissue was analysed by RT-PCR for the 
expression of chemokine message. mRNA was extracted from the tissue using Oligo 
(dT) columns and reverse transcribed into cDNA. In all cases, sufficient amounts of 
amplified cDNA to detect on a 1 % agarose gel were obtained following 35 PCR cycles 
and in the prescence of 2 mM MgCl2 . The concentration of Mg2+ appeared to be 
important for the amount of DNA produced since decreasing amounts of Mg2+ reduce 
the yield of DNA (figure 6A). Concentrations in excess of 2.5 mM may induce non­
specific amplifications (‘Introduction to PCR’ manual, Perkin Elmer). When total RNA 
was used as the starting material for the reverse transcription reaction, no amplified 
cDNA was detected following PCR.
A co-amplification of RANTES cDNA with house-keeping gene p-actin in the same 
PCR tube, was successfully achieved using the two sets of primers selected (figure 6B). 
Amplification of reverse transcripts for MCP-1 was only possible in the absence of the 
selected p-actin primers (figure 6B) and thus the p-actin amplification was run 
simultaneously in a separate tube. It is possible that the inability of MCP-1 to co- 
amplify with p-actin was due to primer dimerisation between the pairs selected. 
Interestingly, despite the use of two separate sets of guinea pig eotaxin primers (see 
sequences on page 87), no amplification of reverse transcribed cDNA from guinea pig 
lung was detected either when the eotaxin primers were used alone or in conjunction 
with P-actin.
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Figure 6. Initial RT-PCR analysis using mRNA from guinea pig whole lung tissue
0  -4-indicated that increasing amounts of Mg increased the yield of PCR product using 
primers for gpMCP-1 over 30 cycles (A). The example shown represents RNA from 
OA sensitised lung at 24 h following challenge. A similar effect was noted using RNA 
from a different lung sample from this treatment group. RANTES reverse transcripts (B 
right) could be co-amplified with p-actin and this effect was noted using 27 and 30 
cycles. However co-amplification of MCP-1 and p-actin using the selected primers was 
not successful (B left) although either could be amplified alone successfully. The same 
effects were observed on repeating these experiments. Amplifications with one primer 
set: R=RANTES, M=MCP-1, P=P-actin. Amplifications with two set: R/p=RANTES 
and p actin, M/p=MCP-l and p-actin.
119
3.3.2. Validation of method
For each lung sample, PCR amplification of 0.3 jlxI, 1.5 pi and 3 pi of the RT product 
yielded different amounts of final cDNA and when analysed by electrophoresis and the 
resulting bands measured by densitometry, this relationship was found to be linear 
(figure 7). It was observed that increasing amounts of RT product in the PCR reaction 
eventually caused a plateau in the amount of cDNA produced, highlighting the need to 
titrate each sample to allow accurate quantification. Product densities w'ere linear 
within the above range when amplified using primers for either RANTES, MCP-1 or 
house-keeping gene p-actin which served as a standard. The ratio of PCR product, as 
measured by densitometry between RANTES or MCP-1 and P-actin at a constant 
volume of RT product (1.5 pi was selected), allowed standardisation of the target cDNA 
levels relative to those of the house-keeping gene and thus enabled cross sample 
comparison using the Mann-Whitney U test.
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3.3.3. Results o f RT-PCR analysis o f OA challenged guinea pig lung
No differences in the levels of RANTES expression relative to P-actin were observed 
between naive or OA-sensitised guinea pig lung following OA-challenge at either 2 or 
24h. In contrast, the standardised levels of MCP-1 at 2 and 24h were elevated in 
sensitised OA-challenged lungs compared to time-matched controls (figure 8). Analysis 
using Mann-Whitney U test revealed that these differences in MCP-1 levels were 
significantly different (p<0.01) at both 2 and 24h.
To ensure that the DNA amplifications did not originate from genomic DNA carried 
over from the original mRNA extraction, an equivalent volume (ie. 3 |il) of the reverse 
transcription reaction mixture which had not undergone reverse transcription, was 
subjected to PCR amplification. Three or four lung samples were selected at random 
from each of the four treatment groups (naive and OA sensitised at 2 and 24h post-OA 
challenge). No samples demonstrated any evidence of amplification suggesting that the 
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Figure 7. Example of semi-quantitative PCR analysis of MCP-1 and p-actin reverse 
transcripts in guinea pig whole lung samples. Linearity of the amplification was 
identified by PCR of serial dilutions of the RT cDNA for each lung sample, yielding 
proportional amounts of product as detected by electrophoresis using a 1 % agarose gel. 
Examples of MCP-1 amplification from two lung samples are shown (top). PCR 
primers were selected to amplify a 470 base pair fragment of the MCP-1 sequence 
which could be readily distinguished from the 176 base pair product for p-actin. 
Amplifications of RANTES cDNA yielded a product of 223 base pairs using the 
selected primers. The ratio of densitometry measurements of the gel bands between 
MCP-1 and p-actin at a suitable midpoint along a best fit line (1.5 pi of RT cDNA) 






a  v °:
Z 0.8-





2hC 2hOA 24hC 24hOA











H  _  *






2hC 2hOA 24hC 24hOA
Time following OA challenge
Figure 8. Semi-quantitative RT-PCR analysis of RANTES and MCP-1 mRNA levels in 
guinea pig nai've (C) and sensitised (OA) lung at 2 and 24 h post OA-challenge. mRNA 
was extracted from whole guinea pig lung, reverse transcribed and the resulting cDNA 
amplified using selected primers. Levels of RANTES or MCP-1 amplified product 
were standardised through p-actin levels in the same sample. Each dot represents an 
individual animal and n=6 animals were analysed per time point per treatment. 
Standardised levels between treatments at the same time points were compared using 
Mann Whitney U test. Bars represent the median levels in each treatment group.
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Figure 9. PCR analysis of non-reverse transcribed RT reaction mixure (3 pi) using lung 
samples from each of the treatment groups selected at random. No evidence of MCP-1 
or P-actin amplification was observed using the selected primers, suggesting that there 
was no detectable carry-over of genomic DNA from the original mRNA preparation. 
Each lane represents a lung sample from a different guinea pig. This experiment was 
repeated with the same samples and again no amplifications were observed.
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3.4. In situ expression of chemokines in OA-challenged lung
In situ hybridisation was used to assess the effects of OA-challenge on chemokine 
production from individual cells types in the guinea pig lung. Histological examination 
revealed that the OA sensitisation and challenge procedure resulted in inflammation in 
the lung at 24 h, compared to nai've/OA challenged controls, since an eosinophilia was 
clearly present in the lung parenchyma and within the walls of the bronchi (figure 10).
When these samples were analysed by in situ hybridisation using DIG-labelled antisense 
riboprobes, prominent localisation of RANTES mRNA was observed in the mononuclear 
cells of naive OA-challenged lungs which was elevated in two of three sensitised OA 
challenged tissues studied. Weak staining was also evident in the luminal side of the 
bronchial epithelium, alveolar epithelium and endothelium (figure 11).
A similar pattern of expression of eotaxin mRNA was observed, with prominent 
localisation in the mononuclear cells. However, there was no evidence of upregulation in 
the sensitised guinea pig lung at 24 h post-OA challenged over time-matched controls 
(figure 12). It is possible that eotaxin mRNA expression in OA sensitised/challenged 
animals may have been more prominant at earlier time points (3-6h; Jose 1994b) but this 
was not examined in work for this project. The results were probe-specific since only 
minimal background staining was found in sense controls for each probe and these were 
comparable to the endogenous peroxidase activity observed in no-probe control samples.
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Figure 10. Histological examination of OA-sensitised guinea pig lung tissue revealed a 
marked monocytic and eosinophilic accumulation (E) especially within the bronchial 
wall (Bw) in OA sensitised samples at 24 h following OA challenge (lower photo) 
compared to naive, challenged controls (upper). Tissue was stained with haematoxylin 
and eosin (x200) and sections are shown from representative lungs of OA-sensitised and 
naive guinea pigs at 24 h following OA challenge; similar effects were also observed in 
lung sections from two other animals from each treatment group.
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Figure 11. Localisation of RANTES mRNA in the lung of OA-challenged guinea pigs 
by in situ hybridisation using a DIG-labelled antisense riboprobe. RANTES was 
strongly expressed in macrophages (M) and to a lesser extent in the bronchial lumen 
epithelium (LE), alveolar epithelium (AE) and endothelium (En) at 24 h in OA 
sensitised/challenged lung (A x400, B xlOOO) but less so in nai've/OA challenged 
animals (C x400, DxlOOO). Only minimal background staining was evident using 
RANTES sense probe (E xlOOO). Analysis of two other lungs from different 
naive/challenged animals indicated similar levels of RANTES as shown above. 
Analysis of the OA sensitised/challenged animals indicated that RANTES expression 
was also elevated in a second lung sample from a different animal but not in a third. 
The hybridisation signal for RANTES is expressed as dark brown and section were 
counter-stained with methyl green.
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Figure 12. Localisation of eotaxin mRNA in OA-challenged guinea pig lung using in 
situ hybridisation. Eotaxin message was expressed in mononuclear cells (M), bronchial 
lumen epithelium (LE) and alveolar epithelium (AE) at 24 h in OA 
sensitised/challenged lung (A x400) but at no stronger levels than in naive/challenged 
lungs (B x400). Only minimal background staining was evident for eotaxin sense (C 
xlOOO) and no-probe (D xlOOO) negative controls. Figure E shows localisation of 
mRNA for (3-actin (x400). All section are representative of n- 3 animals. Hybridisation 
signal is expressed as dark brown and sections are counter-stained with methyl green.
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3.5. Detection of RANTES protein in the whole guinea pig lung
In an attempt to examine RANTES protein levels in guinea pig whole lung tissue 
following OA challenge and to avoid the difficulties associated with the handling of 
RNA, extensive efforts were made to analyse tissue homogenates by Western blotting. 
A panel of monoclonals raised to human RANTES and polyclonal antisera raised to 
guinea pig RANTES were used, but in both cases required initial characterisation for 
their ability to recognise gpRANTES protein.
3.5.1. Characterisation o f monoclonal anti-human RANTES mAbs.
The panel of eleven monoclonals were initially screened for their ability to recognise 
guinea pig RANTES using an ELISA, by absorbing guinea pig RANTES (0.1-100 
ng/ml) onto ELISA plates and detecting using different concentrations of the 
monoclonals (0.1, 1 and 5 fig/ml). At an antibody concentration of 1 jig/ml, mAbs A, E 
and F recognised gpRANTES by ELISA but only at the highest concentration of 
gpRANTES examined, 100 ng/ml (figure 13). Absorbance values were no greater using 
a higher concentration of antibody (5 pg/ml), whilst 0.1 |ig/ml was insufficient to detect 
the protein.
Dot blot analysis (figure 14) confirmed the ability of monoclonal antibodies A and F at 
1 |ig/ml to recognise gpRANTES, and antibody B did not detect gpRANTES either by 
ELISA or dot blot analysis. However, antibody E did not detect gpRANTES by dot blot 
analysis despite a 4.5 fold increase over basal absorbance levels using ELISA.
The panel of antibodies was also used to detect human and gpRANTES run on a 15 % 
polyacrylamide gel under denaturing conditions (ie. in the presence of 2-
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mercaptoethanol). Antibodies A and F recognised both human and guinea pig RANTES 
but detected 0.1 jig of hRANTES with greater efficiency than 1 |ig gpRANTES, as 
assessed by the intensity of the Western detection band. All other monoclonals detected 
hRANTES but not gpRANTES except J, which recognised neither (figure 15).
A summary of the results for the characterisation of the anti-human RANTES 
monoclonals is given in table 3.1.
Anti-hRANTES
monoclonal
ELISA Dot blot analysis Western blot detection of 
proteins
A ++ +++ hRANTES>gpRANTES
B - + hRANTES only
E +++ + hRANTES only
F + ++ hRANTES>gpRANTES
D, G, H, I, J, L, K - Not tested hRANTES only except for J
Table 3.1. Summary of characterisation of anti-human RANTES monoclonal antibodies 
for their ability to recognise recombinant gpRANTES
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Figure 13. Detection by ELISA of gpRANTES using a panel of anti-human monoclonal 
antibodies. The ELISA was performed by absorbance of gpRANTES onto 96 well 
plates followed by incubation with 1 |Tg/ml of the monoclonal antibody and detecting 
with rabbit anti-mouse secondary antibody and substrate p-nitrophenylphosphate. Each 
bar represents mean ± SEM for n=3 wells.
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Figure 14. Detection by dot blot analysis of gpRANTES using four of the anti-human 
RANTES monoclonals. Serial dilutions of the chemokine were dotted as 1 pi, 
containing the indicated amounts, onto nitrocellulose membrane and incubated with 
lpg/ml of the respective monoclonal antibody. Bound antibody was detected using 
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Figure 15. Detection of gpRANTES and hRANTES by Western blot analysis using 
anti-human RANTES monoclonals. 0.1 pg rhRANTES and 1 pg gpRANTES were run 
on a 15 % polyacrylamide gel under denaturing conditions. The proteins were 
transferred and membranes incubated with 1 pg/ml of the respective monoclonal 
antibody. Bound antibody was detected using goat anti-mouse secondary antibody and 
ECL.
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3.5.2. Western blot analysis o f OA challenged lung tissue using selected anti-human 
RANTES monoclonal antibodies
Two of the anti-hRANTES monoclonal antibodies (A and F) were selected from the 
above characterisation studies in order to analyse lung tissue homogenates. Protein 
samples were prepared from OA-sensitised and naive guinea pig lungs at 2 and 24 h 
following OA challenge and separated by SDS-PAGE on a 15 % gel. The protein was 
transferred onto nitrocellulose and membranes were incubated with either antibody A or 
F (1 |Lig/ml) and bound antibody detected with goat anti-mouse IgG secondary antibody 
and ECL. Both antibodies apparently recognised protein of approximately 40-64 kDa 
(figure 15i. A) but further investigation, probing these same lung samples with 
secondary antibody only, revealed that these bands were detected because of non­
specific binding of the secondary antibody (figure 15i. B). The anti hRANTES mAbs 
also recognised protein running at approximately 10 kDa which was not due to non­
specific secondary antibody binding (15i. A and B). However, this protein ran at a 
higher molecular weight than recombinant gpRANTES. Furthermore analysis of total 
protein in these same samples using a Coomassie stained gel revealed that the protein 
was present in very large quantities in the guinea pig lung (figure 15i. C). This evidence 
suggested that the protein was probably not RANTES and N terminal sequencing of this 
band identified this protein to be a component of haemoglobin (E. Magnenat, Glaxo 
IMB, Geneva).
Despite the fact that both antibodies were able to detect recombinant guinea pig and 
human RANTES, no RANTES protein was detected in OA sensitised or naive lung 
samples either at 2 or 24 h following OA challenge (figure 15i. A). A number of 
possible reasons may explain this finding. RANTES protein may not be present in these 
samples, although the same samples did contain RANTES mRNA (see figure 5).
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Alternatively, RANTES protein may not be present in sufficient quantities in the 
extracts for detection and thus requiring purification of the samples, such as size 
exclusion gel filtration or heparin affinity binding. Furthermore, Western blot analysis 
demonstrated a marked difference in sensitivity of the antibodies between gpRANTES 
and hRANTES even though the proteins share 90 % homology (see chapter 5). The 
ability to raise monoclonals in the mouse against human RANTES that also cross react 
with gpRANTES probably depends on the monoclonal recognising an epitope which is 
the same in the human and guinea pig RANTES protein but different in the murine. 
Alignment of the amino acid sequences (refer to figure 20) shows that this occurs only 
at residue 3, where tyrosine in the guinea pig and human is replaced by threonine in the 
mouse, residue 15 (isoleucine is replaced by leucine), residue 17 (arginine is replaced by 
leucine), residue 24 (isoleucine is replaced by valine), residue 45 (lysine is replaced by 
arginine), and residue 59 (arginine is replaced by glutamine in the mouse). Further, 
other sites (residues 16,18 and 32) that differ between murine and human are conserved 
between murine and guinea pig and it may be that the antibodies raised were against 
these residues.
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3.5.3. Characterisation o f gpRANTES antiserum
In an attempt to over come these problems, antiserum raised in rabbits in response to 
gpRANTES was characterised for its ability to recognise gpRANTES. Serial dilutions 
of recombinant gpRANTES were dotted onto nitrocellulose as 1 |il and ‘strips’ of these 
dilutions were incubated with different dilutions of the antiserum. Bound antibody was 
detected using goat anti-rabbit secondary antibody and ECL reagent. The antiserum 
recognised gpRANTES, but not at amounts less than 100 ng (figure 16), which was 
comparable to that for the monoclonal antibodies (compare with figure 14). 
Furthermore, since there was no evidence of a dilution effect using decreasing amounts 
of antiserum, it is possible that the detection of gpRANTES was due to non-specific 
binding of antibody. For these reasons, analysis using the polyclonal antiserum was not 
continued.
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Figure 15i. Western blot analysis of OA sensitised and naive guinea pig whole lung at 
24 h following OA challenge using anti-hRANTES mAb ‘A ’ at 1 p,g/ml. Lung 
homogenates were separated on a 15 % polyacrylamide gel (A). Protein bands detected 
between 40-64 kDa (B) were due to non-specific binding of secondary antibody (C). 
Protein of approximately 10 kDa was detected by mAb ‘A ’ but not by secondary 
antibody alone. This protein was also visible on a Coomassie gel showing total protein 
(A). Sequencing identified this band to be a component of haemoglobin. No evidence 
of RANTES protein was detected in any lung samples. Each lane represents lung 
homogenate from one guinea pig. Similar results were obtained using tissue at 2 h post 
OA challenge and using the antibody ‘F* at 1 p,g/ml.
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Figure 16. Dot blot analysis o f  gpRANTES detected using antiserum raised against 
gpRANTES in the rabbit. Bound antibody was detected using goat anti-rabbit 
secondary antibodies and ECL.
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3.6. Detection o f chemokines in isolated guinea pig cells
3.6.1. Expression of RANTES in guinea pig peritoneal macrophages
Isolated guinea pig peritoneal macrophages were stimulated in culture with either LPS, 
recombinant gpRANTES or vehicle and extracted after 24 h. Preliminary northern blot 
analysis (this experiment was performed only once) revealed no expression in vehicle 
control cells but RANTES mRNA was observed following LPS stimulation at all time 
points tested and at 4 h and 12 h following stimulation with 50 nM recombinant 
gpRANTES (figure 17).
C R L C R L
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Figure 17. Northern blot analysis for RANTES mRNA from isolated peritoneal 
macrophages at various times following stimulation. Approximately 10 pg of total 
RNA extracted from 4 x l0 6 cells was loaded per lane. Cells were stimulated at 2 x l0 6/ml 
with 50 nM gpRANTES (R), 1 pg/ml LPS (L) or PBS-vehicle (C) as shown.
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3.6.2. Kinetic expression of chemokine mRNA in a guinea pig lung fibroblast cell 
line and in primary cell cultures.
In an attempt to elucidate other cell types contributing to chemokine production, 
expression of mRNA was investigated using Northern blot analysis in a guinea pig lung 
fibroblast cell-line JH4-C11 and in cultured cells grown from collagenase digests of 
guinea pig lung tissue. Outgrowth of adherent cells from the digests was observed at 
days 2-4 after start of culture and the colonised cells rapidly grew to confluence within a 
week. Since these cells could only be successfully passaged using trypsin/EDTA 
solution up to passage 10, experiments were performed on cells between passage 2-6. 
In the absence of staining techniques these primary cells can not be catagorically 
identified. However, these cells displayed a spindle shaped morphology typical of 
cultured fibroblasts and akin to the guinea pig fibroblast cell line, JH4 Cl-1. 
Furthermore, their morphology was not characteristic of the organised ‘swirling’ nature 
of smooth muscle cell cultures or the pavemental appearance of epithelial cells (see 
below). In addition, analysis of all cultures by light microscopy failed to identify any 
regions of contaminating cell growth.
Attempts to establish primary cultures of guinea pig airway tracheal epithelium were 
successful by incubating lung digests with Bronchial Epithelial Growth Medium 
(Clonetics), but since the cells could not be successfully passaged, sufficient numbers 
could not be grown. These cells were also adhesive but portrayed a characteristic 
pavemental appearance in contrast to the cultured fibroblasts.
Confluent cultures of the JH4-C11 cells did not constitutively express mRNA for IL-8, 
MCP-1 or RANTES and no induction was observed following stimulation with human
140
recombinant TNFa (30 ng/ml) and/or rhIL-1 (10 ng/ml). However, incubation with 
medium from LPS-stimulated guinea pig peritoneal macrophages, which was assumed 
to be a rich source of guinea pig cytokines (‘cytokine supernatant’), stimulated a time- 
dependent expression of MCP-1 in the JH4-C11 cells. Evidence of a biphasic 
expression was observed peaking at 2 and 24 hours compared to the negligible 
expression in time matched controls. A similar pattern of expression was observed for 
IL-8 (figure 18).
MCP-1 expression was observed in primary lung fibroblasts at 4 and 12 h which was 
not increased following stimulation with the cytokine supernatant from LPS-stimulated 
macrophages and Con A-stimulated spleen cells. However, at later time points (24 and 
48 h) expression of MCP-1 was stimulus-dependent (figure 19). This difference could 
reflect a time dependent response to FCS used in the medium which indueced MCP-1 
expression at early but not later time points. As for the JH4-C11 cell line, only weak 
expression of MCP-1 was observed at time points post 24 h stimulation although this 
effect did not seem to be related to cytotoxicity as assessed by trypan blue exclusion. 
Examination of the same primary fibroblasts for the presence of RANTES and M IP-la 
mRNA revealed no expression at any time point analysed even following stimulation 
with the cytokine supernatant. To assess the expression of eotaxin, a DIG-labelled 
oligoprobe (R&D systems, Abingdon, UK) was used. The eotaxin probes did detect 
some distinct bands but on closer inspection these were found to align with ribosomal 
28 and 18 S RNA and therefore are probably due to non-specific binding (figure 19). 
This experiment was attempted a further two times. In each case, expression of MCP-1 
but not RANTES, eotaxin or M IP-la was observed.
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Figure 18. Time course o f  expression o f  IL- 8  and MCP-1 mRNA in a guinea pig lung 
fibroblast cell line, JH4-C11 stimulated with cytokine supernatant (S) or vehicle (C). 
Ribosomal 18 and 28S bands show loading o f  total RNA. Chemokine mRNA was 









Figure 19. Chemokine expression in primary lung fibroblast-like cells following 
stimulation and detected by DIG-labelled full length cDNA probes, except for eotaxin, 
where a DIG-labelled oligo probe was used. MCP-1 mRNA expression was observed at 
4 and 12 h (lanes 1-4) and also at 24 h (7 & 8 ) and 48 h (5 & 6 ) but only following 
stimulation with cytokine supernatant (S). ‘N S ’ represents mRNA levels in the absence 
o f cytokine supernatant. In comparison, RANTES, eotaxin (bands correlate with 18/28S 
ribosomal RNA) or M IP -la  mRNA expression was not detected in these cells.
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3.7. Summary of results: chemokine detection in the guinea pig lung
•  Both RANTES and MCP-1 mRNA were expressed in the naive guinea pig lung
• In a guinea pig model of allergic lung inflammation, RANTES and MCP-1 mRNA 
were differentially expressed. RANTES mRNA was not increased in OA 
sensitised/challenged lungs compared to levels in nai’ve/challenged lungs. In 
comparison, MCP-1 mRNA was upregulated in OA sensitised samples following 
challenge.
•  Attempts to use murine and human RANTES monoclonal antibodies or rabbit anti­
guinea pig RANTES antiserum to analyse guinea pig RANTES protein in lung 
lysates were unsuccessful.
•  In situ hybridisation identified mononuclear cells and to a lesser extent bronchial 
epithelium and endothelial cells as potential sources of both RANTES and eotaxin.
•  However, no expression of RANTES, eotaxin or M IP-la mRNA was detected in 
primary fibroblast-like cells. These cells and the guinea pig lung fibroblast cell line, 
JH4-C11, did express MCP-1 and IL-8 mRNA in response to cytokine supernatant 
derived from LPS-stimulated guinea pig macrophages.
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CHAPTER 4: RESULTS
The expression and purification of recombinant guinea pig RANTES 
protein
4.1. The cloning o f gpRANTES cDNA
The gpRANTES cDNA was isolated from a library constructed from concanavalin A- 
stimulated guinea pig spleen cells. As shown in figure 20, the gpRANTES cDNA 
comprises 516 base pairs with an open reading frame encoding a 92 amino acid protein. 
This includes a presumably cleavable leader sequence akin to that described for 
hRANTES (Schall et al. 1988) and it was assumed that the point of cleavage in the 
guinea pig protein is the same. This gives rise to a 68 amino acid protein with a 
predicted molecular weight of 7901 Da for gpRANTES. gpRANTES shows 90% 
nucleotide sequence identity with hRANTES (Schall et a l 1988). The deduced amino 
acid sequence has 87% and 86% homology to human and murine RANTES (Schall et 
al 1988; Schall et a l 1992) respectively (figure 20) with 91% identity to hRANTES in 
the region encoding the presumed 68 amino acid mature protein.
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guinea pig SSKCSNLAW FVTRKNRQVC ANPEKKWVRE
human SGKCSNPAW  FVTRKNRQVC ANPEKKWVRE








Figure 20. Full length nucleotide sequence for gpRANTES protein (top). The coding 
region begins at position 20 and ends at position 292 and is underlined. Residues 20-43 
are a presumed signal sequence. This sequence has been submitted to Genbank under 
the accession code U77037. Amino acid sequence alignment for guinea pig RANTES 
with human and murine sequences (below), showing presumed leader sequence (-23 to 
1) and secreted proteins (1-68). Underlined amino acids highlight the differences in 
composition between guinea pig and human RANTES.
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4.2. Protein expression and purification
Initial attempts to express the guinea pig RANTES protein in E. coli using the 
gpRANTES cDNA proved unsuccessful. No detectable expression of an 8-10 kDa 
protein was observed with or without the N terminal hexapeptide sequence either in the 
cell pellet or supernatant following cell breakage (figure 21). However, extremely high 
levels of expression were obtained when the human RANTES construct carrying the 
hexapeptide at the amino terminus underwent base substitution. Mutations were made 
at the following positions numbered according to the sequence in figure 20; 98(T-»G), 
134(G—>T), 140(C-»G), 152(G-»A), 182(G->A), 197(C-»T), 198(C->T), which 
resulted in the substitution of the 6 amino acids responsible for the difference in primary 
sequence of the two species (figure 20). Mutations were performed by B. Allet, Glaxo 
IMB, Geneva. All protein purification was performed by myself at Glaxo IMB.
The purification of gpRANTES was very similar to that described by Proudfoot et al 
(1995) for human RANTES, although where differences arose, details are outlined 
below. The guinea pig RANTES fusion protein was expressed in inclusion bodies (see 
figure 25A, lanes 2-4) which were separated from the remaining E. coli proteins by size 
exclusion gel filtration (Sephacryl HR200) after solubilisation in guanidium HC1 
(figures 22A and 25A, lane 5). Fractions containing proteins between 5-20 kDa on 
SDS-PAGE were pooled, renatured and concentrated by cation exchange 
chromatography using a HL26/10 SP column. The major protein peak eluted between 
1.3 M and 1.6 M sodium chloride (figure 22B). It is unlikely that any non-renatured 
protein was carried over at this stage since this is generally insoluble and hence removed 
by centrifugation prior to separation. If any non-renatured protein remains soluble, this 
would elute at a different salt concentration.
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Endoproteinase Arg-C digestion was used to remove the fusion peptide from both 
human and guinea pig RANTES proteins. In the case of human RANTES, the products 
were easily separated using cation exchange chromatography. SDS-PAGE analysis of 
fractions from this column (figure 23) show that most of the product was cleaved 
hRANTES, running at a lower molecular weight compared to a hexapeptide-hRANTES 
standard. In comparison, Arg C cleaved the hexapeptide guinea pig protein at more than 
the required site (25A, lane 6). The cleaved product underwent initial separation by 
cation exchange chromatography as above with the addition of 6 M urea in the buffers. 
Under these conditions, cleaved gpRANTES eluted at 0.5 M NaCl, preceding uncleaved 
gpRANTES at 0.7 M NaCl (figure 22D). However, the mature full length guinea pig 
protein was isolated from selected fractions by reverse phase HPLC (figure 24, peak b) 
giving a yield of 0.1 mg per mg fusion protein, and 0.2 mg/g E. coli cells. In 
comparison the yield of huamn RANTES was higher at 0.8 mg/g cells, which may 
reflect differences in the ease of hexapeptide separation following Arg C cleavage. 
However, reverse phase HPLC purification for gpRANTES resulted in a single band on 
SDS-PAGE analysis under denaturing conditions (figure 25A, lane 7). The authenticity 
of this final product was verified by amino acid composition of the amino terminal 
(SPYASD) by Edman degradation which was performed by E. Magnenat, Glaxo IMB, 
Geneva. In addition, electrospray ionisation mass spectroscopy analysis gave a mass of 
7897Da which corresponds with the expected mass of 7901Da calculated from the 
amino acid sequence, with the formation of two disulphide bonds. The final product 
contained no detectable levels of endotoxin. Bioassay of fractions during the different 
purification steps indicated that renatured gpRANTES was inactive before removal of 
the hexapeptide leader, whilst mature full length gpRANTES mobilised [Ca2+]i in THP- 
1 cells (figure 25B).
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1 2  3 4 5 6 7 8
Lane 1 Molecular weight markers
Lane 2 10|Lig rhRANTES
Lane 3 non-induced total cells
Lane 4 1/20 dilution of cell break supernatant
Lane 5 1/20 dilution of induced total cells
Lane 6 1/10 dilution of cell break supernatant
Lane 7 1/10 dilution of induced total cells
Lane 8 1/5 dilution of cell break pellet
Figure 21. SDS-PAGE analysis of cell pellet and supernatant following cell breakage of 
E. coli transfected with gpRANTES cDNA. No detectable expression of a protein 
running at approximately 8-10 kD (compare with rhRANTES standard in lane 2) was 
observed in either cell pellet or supernatant.
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Figure 22. Purification steps of gpRANTES from E. coli. (A) Separation from 
inclusion body components using size exclusion gel filtration (Sephacryl HR 200) under 
denaturing conditions. Fractions 52 to 65 containing 5-20 kD protein were pooled, 
renatured and concentrated by cation exchange chromatography (figure B and SDS- 
PAGE of fractions in C). Fractions 61-77 containing approx 8 kD protein eluting 
between 1.3-1.6 M NaCl (B), were pooled and digested with Arg C. Digested products 
were initially separated by cation exchange chromatography (D). Most cleaved protein 
eluted within fractions 45-61 (0.5 M NaCl), preceding uncleaved gpRANTES (#62-80).
150
1 2 3 4 5 6 7 8
Lane 1 Molecular weight markers (kDa)
Lane 2-6 Predominant peak HPLC products from
cation exchange column fractions
Lane 7 rhRANTES*
Lane 8 hexapeptide hRANTES*
Figure 23. SDS-PAGE analysis of fractions from cation exchange chromatography 
resulting from the separation of Arg C digestion of hexapeptide-human RANTES. 
Digestion products were separated by applying to a HiLoad S (26/10) column 
equilibrated with 50 mM sodium acetate pH 4.5 and eluting with a linear gradient of 
NaCl. Fractions from this column (lanes 2-6) contained cleaved hRANTES which ran 
at a lower molecular weight than the uncleaved protein (lane 8). Lane 1; molecular 















Figure 24. Reverse-Phase HPLC trace to show separation of Arg C-digested 
hexapeptide-gpRANTES. Peak a represents the uncleaved fusion protein, peak b 
represents gpRANTES (cleaved) as confirmed by N terminal sequencing (b=SPYAS) 
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Figure 25. (A) SDS-PAGE analysis of the purification of gpRANTES protein from E. 
coli. Lane 1 shows molecular weight markers, lane 2; total E. coli products, lane 3; 
supernatant from E. coli extraction, lane 4; E. coli inclusion body, lane 5; size exclusion 
gel filtration pool (Sephacryl HR 200), lane 6; products following Arg C digestion, lane 
7; recombinant gpRANTES. (B) Recombinant gpRANTES was able to induce changes 
in [C a2+]j in monocytic THP-1 cells whilst a similar concentration of fusion-protein- 
gpRANTES was completely inactive (below). This assay was used as a routine ‘screen’ 
at each step following the Arg C cleavage process to identify fractions containing 
cleaved gpRANTES.
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4.3. Attempts to identify RANTES in guinea pig platelets
Guinea pig RANTES could not be expressed in E. coli using the gpRANTES cDNA 
(figure 21). Mutation of a human RANTES construct, as described above, yielded high 
quantities of gpRANTES but with the same N-terminal start point as hRANTES. The 
identification of a native form of guinea pig RANTES would allow confirmation of the 
N terminal sequence and since thrombin-stimulated human platelets are a source of 
RANTES (Kameyoshi et al. 1992), guinea pig platelets were examined for the possible 
presence of the chemokine.
Guinea pig platelets were isolated from acid-citrated whole blood and stimulated with 
2U/ml thrombin under similar conditions as described for human platelets (Kameyoshi 
et al. 1992). Thrombin induced a marked aggregation of the platelets, as assessed by a 
increase in light transmission using an aggregometer (figure 26). Over n- 4 platelet 
preparations from separate animals, this dose of thrombin induced a mean increase in 
the light transmission of 76 %.
Thrombin-stimulated platelet supernatants were assayed for their ability to increase 
[Ca2+]i in guinea pig peritoneal macrophages. Results in chapter 5 of this thesis 
demonstrate the ability of RANTES to activate these cells. The supernatant did induced 
changes in [Ca2+]i in these cells whilst an equivalent carry-over amount of thrombin 
(O.lU/ml) did not. However this effect was completely inhibited by 1 jiM of the PAF 
antagonist, WEB 2086. This dose of WEB 2086 completely inhibited the increase in 
[Ca2+]i induced by 100 nM PAF in these cells (figure 27). Thus no ‘RANTES-like’ 
activity was detected in guinea pig thrombin-stimulated platelet supernatants.
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1 mM Ca2+ 2U/ml thrombin
o%n
321
Minutes post addition of Ca2+
Figure 26. An example trace of platelet aggregation induced by thrombin (2U/ml).
Q
Aggregation of platelets at an initial density of 2x10 /ml was assessed by increased light 
transmission. The mean change in light transmission using n=4 platelet preparations 







WEB2086 (luM) with TSPS
50 -
0 --------- 1--------- 1--------- 1--------- 1--------- 1--------- 1______ i______I______i______ I______i
0 20  40 60 80 100
Time (sec)
Treatment of gp peritoneal M 0 Mean change in [C a2+]i ±SEM nM
TSPS 112.3±15
TSPS + 1 pM WEB 2086 5.5±1.6
0.1 U/ml thrombin 4.1 ± 1.8
100 nM PAF 343.8±98.2
100 nM PAF + 1 pM WEB 2086 17.8±7.2
Figure 27. Above Representative trace to show increases in [C a2+]i observed following 
addition of thrombin-stimulated platelet supernatant (TSPS) to fura-2 loaded guinea pig 
peritoneal macrophages ( l x l 0 6/ml). The effect was inhibited by pre-addition o f 1 pM  
WEB 2086. Below. Mean±SEM changes in [Ca2+]j following addition of TSPS with or 
without WEB 2086. Responses are from macrophage preparations from n=3 animals 
and using TSPS prepared from platelets from different guinea pigs.
156
4.4. Summary of results: expression and purification of recombinant gpRANTES
• gpRANTES is highly homologous to hRANTES at both the nucleotide (90%) and 
amino acid level (87%).
• gpRANTES protein would not express in E. coli using the gpRANTES cDNA. 
However, high levels of expression were obtained when the human RANTES 
construct encoding a hexapeptide tail was mutated to obtain the substitution of the 6 
amino acids responsible for the difference in primary sequence of the two species.
• The gpRANTES-hexapeptide protein was expressed in the inclusion body of E. coli. 
Following cleavage to remove the hexapeptide sequence, full length mature 
gpRANTES was purified to single-peak RP-HPLC purity and was able to induce 
changes in [Ca2+]j in THP-1 cells.
• No evidence was observed for the presence of RANTES in thrombin-stimulated 
platelet supernatant. The supernatant was able to increase [Ca2+]i in guinea pig 




Biological characterisation of recombinant gpRANTES
5.1. In vitro biological activity
Guinea pig peritoneal eosinophils and macrophages and human peripheral blood 
eosinophils were used to assess the biological activity of gpRANTES. The efficiency of 
cell isolation procedures were confirmed by histological analysis of Diff-Quik stained 
cytospins (figure 28). The purity and viability of isolates was >93 %.
Figure 28. Representative cytospins of guinea pig peritoneal lavage cells (A), peritoneal 
macrophages (B) and eosinophils (C) and human peripheral blood eosinophil (D) 
isolations. Contaminating cell types were no greater than 4 % of the total cells counted, 
m = macrophage, e = eosinophil, xlOOO.
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Guinea pig peritoneal eosinophils were initially examined for their ability to migrate in 
response to recombinant human C5a. C5a induced a bell-shaped response with maximal 
response at 30 nM. Figure 29 shows the migratory response in n=3 different eosinophil 
preparations. Since C5a was always an effective chemotactic agent, it was routinely 
used as a positive control in the experiments examining the migratory effects of the 
chemokines. However, the extent of the response to C5a varied between different sets 
of experiments.
Guinea pig RANTES was able to induce a pronounced chemotactic response in human 
eosinophils with similar potency to hRANTES. Both proteins caused a maximal 
response at 30 nM but higher concentrations caused a decrease in the migratory 
response (figure 30). However, neither protein was able to stimulate a significant 
chemotactic response of guinea pig eosinophils, although cells were responsive to C5a.
It has previously been shown that IL-3 and GMCSF-primed guinea pig eosinophils are 
able to respond to the CXC chemokine IL-8 (Burrows et al. 1991) and thus it was 
important to determine whether primed guinea pig eosinophils might be RANTES- 
responsive. In order to determine a suitable concentration of a priming cytokine, guinea 
pig eosinophil chemotactic responses to human recombinant IL-5, IL-3 and GMCSF 
were assessed (figure 31). IL-3 and GMCSF were unable to induce the migration of 
these cells at the concentrations tested (1-100 nM). In comparison, IL-5 caused a slight 
concentration-dependent increase in migration, inducing the chemotaxis of 35±8 
eosinophils compared to a basal value of 4±2 eosinophils. In an attempt to unveil a 
RANTES response to IL-5, a threshold concentration of this cytokine (ie. a 
concentration at which the cytokine alone did not induce eosinophil chemotaxis), 3 nM, 
was tested together with gpRANTES. As can be seen in figure 32, guinea pig
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eosinophils did not migrate over vehicle basal levels in response to IL-5 alone, 
RANTES alone, or RANTES plus IL-5. This was in contrast to the CXC chemokine IL- 
8, which alone appeared to cause a very slight chemotaxis of guinea pig peritoneal 
eosinophils. This response was substantially potentiated in the presence of IL-5. The 
lack of response of guinea pig eosinophils to RANTES in the chemotaxis bioassay was 
mirrored by an inability to increase [Ca2+]i. The maximal response of [Ca2+]i observed 
with either gpRANTES or hRANTES was negligible in guinea pig eosinophils. 
Conversely, gpRANTES caused a rapid increase in [Ca2+]i in human eosinophils (figure 
33). In marked contrast, guinea pig peritoneal macrophages were strongly activated by 
gpRANTES, as assessed by changes in [Ca2+]i (figure 34A) and chemotaxis (figure 
34B). In the same sets of macrophages, hRANTES demonstrated similar levels of 
potency. An increase of 321 ±56 nM in [Ca2+]i was observed following addition of 100 
nM hRANTES and 61 ±5 nM [Ca2+]j following addition of 10 nM.
Guinea pig peritoneal macrophages were also activated using recombinant human MIP- 
la . rhM IP-la induced a dose dependent increase in [Ca2+]i in these cells as is shown in 












Figure 29. Chemotactic response of guinea pig eosinophils induced by recombinant 
human C5a as assessed by cells migrated per high power field (x400). The response of 
these cells towards hRANTES is also shown. Values represent the mean±SEM using 
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Figure 30 In vitro chemotaxis towards gpRANTES and hRANTES of human peripheral 
blood eosinophils (top) and guinea pig peritoneal eosinophils (bottom), as assessed by 
cells migrated per high power field (x400). Responses are compared to that for 100 nM 
rhC5a and basal migration to buffer. In each experiment 4 replicates of each test sample 
dilution were performed. Results are expressed as mean±SEM for n=3 eosinophil 
preparations from different donors.
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Figure 31. Chemotactic responses of guinea pig peritoneal eosinophils in response to 
IL-5, IL-3 and GMCSF with rhC5a as positive control. A slight migratory response was 
noted using IL-5 but not IL-3 or GMCSF. 3 nM IL-5 was selected as a priming dose for 
subsequent experiments since this concentration alone did not induce the migration of 
these cells. Points represent mean±SEM for n- 3 eosinophil preparations from different 
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Figure 32. Chemotactic response of guinea pig eosinophils towards RANTES (left) and 
rhIL-8 (right) in the presence and absence of 3 nM IL-5, 100 nM rhC5a and vehicle 
migration or to 3 nM IL-5 alone. In each experiment 4 replicates of each test sample 
were performed. The chemotactic response was assessed by cells migrated per high 

















Figure 33. Representative time course trace to show the effect o f  100 nM gpRANTES 
addition at time=22 s on [C a2+]j in human and guinea pig eosinophils. The mean peak 
change in [Ca2+]j ±SEM in eosinophils following addition o f  100 nM gpRANTES for 
«=3 different human donors was 121±40nM compared to 10±4nM for eosinophils from 
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Figure 34. Dose dependent effect of gpRANTES on the migration (A) and on changes
i
in [Ca ]i (B) in guinea pig peritoneal macrophages. Points represent mean±SEM for 
«=3 macrophage preparations from different animals. The chemotactic response was 

















Figure 35. Dose dependent changes in [Ca ]i in guinea pig peritoneal macrophages 
induced by rhMIP-la. Data represents mean peak ± SEM using cells from n=3 separate 
guinea pigs. Using the same cell preparations 100 nM rhMIP-lp induced peak changes 
in [Ca2+]i of 210±35 (mean ± SEM). Responses represent mean±SEM for «=3 
macrophage preparations from different animals.
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Generation of hydrogen peroxide in guinea pig macrophages.
Guinea pig macrophages were analysed for their ability to generate hydrogen peroxide 
in response to human and gpRANTES. Table 4.2 summarises the results of hydrogen 
peroxide generation in two sets of macrophages from different guinea pigs. Since only a 
minimal response was observed using either human or guinea pig RANTES compared 
to the positive control, C5a, this experiment was not repeated.
[Agonist] nM Experiment 1 Experiment 2
gpRANTES 3 nM 1.07±0.05 3.28±0.16
gpRANTES 10 nM 1.57±0.04 3.92±0.06
gpRANTES 30 nM 1.97±0.03 4.54±0.28
gpRANTES 100 nM 2.33±0.19 3.36±0.42
hRANTES 3 nM - 4.28±0.34
hRANTES 10 nM 2.22±0.11 4.76±1.06
hRANTES 30 nM - 5.70±1.23
hRANTES 100 2.48±0.04 4.14±0.62
rhC5a 100 5.20±0.09 7.80±1.23
Basal (vehicle) 0.9±0.07 3.01±0.75
Table 5.1 Hydrogen peroxide generation from two guinea pig macrophage preparations 
using different donor animals. Values are expressed as mean±SEM from n -4 wells per 
agonist dilution.
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Responses of blood derived eosinophils in vitro
Guinea pig whole blood from was collected from animals 1 h after injection with 18.3 
pmol/kg rhIL-5. Blood eosinophilia has previously been shown to be maximal at this 
time point following injection of the same dose of rhIL-5 in the guinea pig (Collins et a l 
1995). Citrated blood was separated using dextran and upper layer centrifuged to pellet 
the cells. These cells were then separated on a discontinuos Percoll gradient as 
described for peritoneal cells. However, this separation step was not found to be 
effective and most cells were banded between a density of 1.080-1.085 g/ml. Cytospins 
of this band revealed that 35±7 % were mononuclear cells, 39±9 % were neutrophils, 
18±9 % were bilobed cells (presumably eosinophils but with weak granular staining) 
and 7±3 % were eosinophils with intense granular staining (mean±SEM for n=4 
leukocyte preparations from different animals).
The mixed cell population from the Percoll gradients was analysed for an ability to 
migrate toward gpRANTES using the microchemotaxis chamber. At the concentrations 
of gpRANTES tested (1-100 nM), no significant differences in the number of migrated 
cells were count compared to saline/BSA control wells. In comparison, 100 nM rhC5a 
induced a significant increase (p<0.01) in the number of cells that migrated compared to 
controls using cells from n- 4 different animals. Examination of the filter following 
chemotaxis revealed that the migrated cells were predominantly neutrophils in C5a- 
treated wells.
These results are detailed in table 5.2. Raw data was compared to control (basal) using 
two-way ANOVA followed by Dunnett’s test. Since basal migration varied 
considerably between each experiment, results are expressed as chemotactic index (Cl)
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which is calculated by dividing the mean number of cells migrated to a given 
concentration of gpRANTES by the mean basal migration to saline/BSA.








rhC5a 100 2.97±0.8 *p<0.01
Saline/BSA (basal) - 136.8±47.4 (cell nos.)
Table 5.2. Summary of chemotactic responses of blood leukocytes to gpRANTES and 
rhC5a. No significant migration was observed for gpRANTES compared to basal 
migration. In comparison, C5a induced a significant increase in cells migrated over 
basal levels. Results are using blood cells from n- 4 preparations from different 
animals. Chemotaxis was assessed by number of cells migrated per high power field 
(x400). However, results are assessed as chemotactic index except for basal migration.
* Significant difference (p<0.01) in comparison to basal migration using two-way 
ANOVA with Dunnett’s test on raw data.
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5.2. In vivo macrophage recruitment in the guinea pig
5.2.1. Effects o f tracheal instillation of gpRANTES
Cellular recruitment into the lung following tracheal instillation o f gpRANTES was 
assessed by changes in total B AL cell numbers and differential cell counts. gpRANTES 
caused a dose dependent increase in the total cells in the BAL 24 h after instillation. 
This effect was predominantly due to increased numbers o f macrophages, with no 
detectable increase in recruitment of eosinophils, neutrophils or T lymphocytes (figures 
36, 37A). Time course studies revealed that an increase in cell numbers was observed 
as early as 6  h and was maintained until at least 48 h (B). The predominant cell type at 
all the time points was the macrophage, although at 48 h a small increase in eosinophils 
and neutrophils was evident.




Figure 36. Representative cytospins o f BAL cells from guinea pigs at 24 h following  
tracheal instillation o f either saline (A) or 10 |ig  gpRANTES (B). In all cases, lungs 


























Figure 37. Tracheal instillation of gpRANTES induced a dose and time-dependent 
increase in number of BAL M 0 but not eosinophils. (A) Dose-dependent increases in 
total BAL M 0 number. Results are mean±SEM cell number at 24 h for n=3 animals 
(0.1, 0.3, 3, and 10 jig) and for n=9 (1 pg and vehicle control V). Lymphocyte and 
neutrophil numbers did not significantly rise above those for control animals (data not 
shown). *Significant difference (p<0.05, ** p<0.01) in comparison to control 
macrophage numbers using ANOVA with post-hoc Dunnett’s test. (B) Time dependent 
increases in M 0 number following instillation of 1 pg gpRANTES or vehicle. Results 
are mean+SEM total macrophage number in BAL for n=3 animals at 6 h, n=6 at 48 h 
and n=9 at 24 h for both RANTES and saline instilled animals. * Significant difference 
(p<0.05, ** p<0.01) in comparison to time-matched control using Student’s t test.
172
5.2.2. Dermal response to injection o f gpRANTES
5.2.2.1 in In eosinophil accumulation in response to chemokines. The leukocyte 
migratory responses in the guinea pig in vivo were assessed using a model as described 
by Faccoli et al (1991), whereby in In -labelled cells accumulate at skin sites injected 
with inflammatory mediators. Work done as part of this study demonstrated that n iIn- 
labelled guinea pig peritoneal eosinophils did not accumulate above basal levels in 
response to rhRANTES, rhMCP-1 or rhIL-8. In comparison, the positive control, 
guinea pig zymosan activated plasma - a rich source of C5a-des-Arg did induce the 
accumulation of these cells (figure 38A). Concurrent analysis of 125I albumin 
accumulation in these skin sites in the same guinea pigs indicated that these chemokines 
alone did not induce increases in plasma leakage over that observed for vehicle-injected 
sites. However, plasma leakage was observed using the positive control, histamine, of 
87±8.6 jul/site compared to 21±5 pl/site for saline (figure 38B). In these experiments 
mean±SEM represents responses of 11 ^ -eosinophil accumulation and plasma leakage 
for n=4 donor eosinophil preparations from different animals with each cell preparation 
injected into a separate recipient guinea pig.
In further experiments using two different donor with two different recipient guinea 
pigs, no m In eosinophil accumulation was observed in sites injected with these 
chemokines alone or in conjunction with the potent vasodilator, PGEi (lO'10 mol/site; 
figures 39 and 40). In addition, IL-5 also failed to induce 11 ^ -eosinophil accumulation 
(figure 39). In these experiments the numbers of 11 ^ -eosinophils per site were 2.5-4 
fold less compared to those in figure 38. It is possible that the activation of the donor 
eosinophils during their purification might cause their sequestration at sites such as the 
lung, in the recipient animals. In one set of animals (n=2) a slight increase in plasma 
leakage in sites injected with 10'10 mol/site rhRANTES and PGEi was observed (figure
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39) . The reason for this is not known, however it is possible that this was associated 
with a RANTES-induced histamine release from basophils as previously reported (Kuna 
et al. 1992) and Alam and colleagues (1992) have demonstrated a similar role for MCP- 
1. Furthermore, the action of histamine has been demonstrated to be potentiated in the 
presence of vasodilators such as PGEi (Williams and Morley 1973). In work presented 
for this thesis, plasma leakage was investigated in response to IL-8 and MCP-1 in the 
presence of 10'10 mol/site PGEi. Plasma leakage was no greater than for PGEi alone 
(figure 40).
This model was not used to further analyse the activity of gpRANTES since in vitro data 
indicated that both gpRANTES and hRANTES were not able to active guinea pig 
peritoneal eosinophils (figure 30). Since peritoneal cells were used in these in vivo 
experiments, this would account for the inability of hRANTES to induced m In 
eosinophil accumulation in this model. Furthermore, a pertinent question at that stage 
of my work was whether gpRANTES might induce the migration of blood-derived 
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Figure 38 A. 11'in-labelled eosinophil accumulation in skin sites injected with guinea 
pig ZAP, but not in response to rhRANTES, rhMCP-1 or rhIL-8. In the same animals, 
plasma leakage was also monitored by accumulation of 125I albumin (B), although 
increases over saline-injected sites were only observed using histamine. In both figures 
the dotted line represents mean basal accumulation. Each mediator was injected in 
duplicate per guinea pig. All bars represent the mean ± SEM of n=4 donor eosinophil 
preparations in 4 different recipient guinea pigs. Histamine was used at 2.5x108 
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Figure 39 A. 1HIn-labelled eosinophils accumulated in skin sites in injected with guinea 
pig ZAP, but not in response to rhRANTES +/- PGEi (10'10 mol/site) or IL-5. In the 
same animals, plasma leakage was also monitored by accumulation of 125I albumin (B). 
In both figures the dotted line represents mean basal accumulation for ease of 
comparison. Each mediator was injected in duplicate sites per guinea pig. All bars 
represent the mean ± SD from 2 recipient animals, each animal having received 
eosinophils from different donor guinea pigs. Histamine was used at 2.5x10 mol/site 
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Figure 40 A. 11 ^ -labelled eosinophil accumulation in skin sites injected with guinea
pig ZAP, but not in response to rhIL-8 and rhMCP-1 +/- PGEi (1010 mol/site). In the 
same animals, plasma leakage was also monitored by accumulation of 125I albumin (B). 
In both figures the dotted line represents mean basal accumulation for ease of 
comparison. Each mediator was injected in duplicate sites per guinea pig. All bars 
represent the mean ± SD from 2 recipient animals, each animal having received
Q
eosinophils from different donor guinea pigs. Histamine was used at 2.5x10 mol/site 
and ZAP used as 100 pi of a 1/5 dilution.
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5.2.2. 1. Migratory responses o f blood derived leukocytes to i.d. injections o f gpRANTES
Guinea pig naive skin sites were injected i.d. with gpRANTES or saline and examined 
histologically for evidence of cellular infiltration. Injection of gpRANTES induced a 
time and dose-dependent inflammatory response, and the cell counts of extravascular 
leukocytes are summarised in table 5.3. Within 2 h of gpRANTES injection some 
evidence of monocytic cuffing around dermal vessels was observed but no overall 
increase in dermal leukocyte numbers compared to time-matched control samples 
(figure 41, A-C). A slight neutrophil infiltrate in both the gpRANTES and saline- 
injected sites at 2 h demonstrated evidence of an acute inflammatory reaction. 
gpRANTES did not induce eosinophilia whilst sites injected with guinea pig ZAP at this 
time point were characterised by an eosinophilic and neutrophilic infiltrate (D). At 24 h 
post injection of 10'11 mol/site gpRANTES, an increase in the number of mononuclear 
cells was observed within the dermis compared to saline-injected sites. At higher doses 
(10'10 mol/site), an increased severity of inflammation was noted with the accumulation 
of pockets of mononuclear cells in the dermis. At 24 h, only small numbers of 
eosinophils and neutrophils were present (figure 42). All preparation of histological 
sections and photography was performed by myself.
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Treatment (mol/site) Time (h) Sites counted Leukocyte count
Vehicle 2 4 21±5
gpRANTES 1 0 10 2 4 30±3
Vehicle 24 6 16±4
gpRANTES 1 0 “ 24 6 40±2
gpRANTES 1010 24 6 110±10
Table 5.3 The numbers of extravascular leukocytes in the guinea pig dermis at various 
times following intradermal injection of gpRANTES or saline. Results reflect cell 
counts from duplicate skin sites in n- 3 (24 h) or n-2  (2 h) guinea pigs. Cell counts are 
expressed as mean ± SEM of cell numbers per hpf (x400). For sites injected with 10'10 
mol/site gpRANTES (24 h) where pockets of mononuclear infiltrate were observed, 
counts reflect cell numbers within these areas. No such areas were found in vehicle 
injected sites.
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Figure 41. Haematoxylin and eosin-stained representative sections of guinea pig dermal 
responses to gpRANTES. At 2 h post gpRANTES (10 ‘ 1 0  mol/site) injection (figure A, 
x2 0 0 ) no overall increase in dermal infiltrate was observed compared to saline injected 
sites (figure B, x200), despite some monocytic accumulation around blood vessels 
(figure C, x400). Only small numbers of eosinophils were observed in gpRANTES and 
saline-injected sites compared to gpZAP injected sites which was characterised by a 
granulocytic infiltrate (figure D, x200).
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Figure 42. Haematoxylin and eosin-stained representative sections of guinea pig dermal 
responses to gpRANTES at 24 h. In comparison to saline control sites (figure A, x200), 
injection of 1 0 11 mol/site gpRANTES caused an increase in the number of monocytes 
in the dermis (figure B, x200). At higher doses of 10'10 mol/site (figure C, x200) large 
pockets o f cells (M) and marked perivascular cuffing (PC) were observed which were 
predominantly mononuclear (figure D, xlOOO). Perivascular cuffing was not present in 
saline controls (figure E, xlOOO).
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5.3. Summary of results:
Characterisation of recombinant gpRANTES protein
• gpRANTES was an effective stimulus of human eosinophils as assessed by increases 
in [Ca2+]i in fura-2 loaded cells and chemotaxis responses in vitro
• Neither gpRANTES nor hRANTES were able to activate guinea pig peritoneal 
eosinophils in these assays, even in the presence of IL-5, in vitro. Furthermore, in 
vivo studies demonstrated th a t11 ^ -labelled guinea pig peritoneal eosinophils did not 
accumulate in skin sites injected with RANTES.
• However, both guinea pig and hRANTES were potent stimulators of guinea pig 
peritoneal macrophages.
• gpRANTES exhibited similar potency and efficacy to hRANTES
• A similar profile of activity was observed in vivo. Following tracheal instillation of 
gpRANTES, a dose and time-dependent increase was observed in the number of 
macrophages but not eosinophils
• In guinea pig skin sites injected with gpRANTES, a monocytic accumulation was 
observed at 24 h, with no increases in eosinophil numbers above saline-injected sites.
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CHAPTER 6. DISCUSSION
The guinea pig has been widely used in the study of allergic airway inflammation. Since 
the CC chemokine RANTES has been implicated as an important mediator of leukocyte 
recruitment in allergic asthma (Strieter et al. 1996), it is of interest to characterise its 
role in this species. The work presented in this thesis describes the expression of 
RANTES in the guinea pig lung as well as the cloning, expression and purification of 
gpRANTES protein to assess its biological activities.
6.1. The expression o f RANTES in the guinea pig lung
RANTES and MCP-1 were expressed in the guinea pig lung and low levels of both 
chemokines were detected even in non-sensitised/non-challenged animals. Studies by 
Schall et al. (1988) and MacLean (1996a) indicated that such ‘constitutive’ RANTES 
expression was also present in the mouse but not in the normal human lung. In the case 
of the guinea pig, it is possible that chemokine expression in naive lungs may be 
indicative of on-going inflammation in these animals.
In a guinea pig model of allergic inflammation, RANTES and MCP-1 appear to be 
differentially expressed in the lung (figure 5). The use of Northern blot analysis 
revealed similar levels of message in naive and OA sensitised guinea pig lung following 
OA challenge. In contrast, MCP-1 mRNA was clearly upregulated at 2, 6 and 12 h 
compared to time-matched controls. It was not possible to assess chemokine expression 
at 24 h in this model using Northern blot analysis since degradation of the RNA in these 
samples appeared to be extensive. Whilst a high susceptibility to RNA degradation 
appeared to be a feature of guinea pig lung tissue it is possible that the prominent 
eosinophilia at this time point in sensitised samples might be responsible for excessive
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RNase activity. In an attempt to verify chemokine mRNA levels at 24 h post challenge, 
RT-PCR analysis was performed on a separate group of similarly treated guinea pigs. 
Using this technique, samples are standardised and therefore comparable by reference to 
internal levels of a housekeeping gene such as p-actin. As for the Northern blot 
analysis, no consistent difference was observed in RANTES mRNA levels between 
naive and sensitised animals at 2 or 24 h following OA challenge. In comparison, 
MCP-1 levels increased by almost four fold in the sensitised group compared to 
controls, at both times (figure 8). The assessment of standardisation levels of 
chemokines using RT-PCR thus appears to be a suitable alternative to Northern blot 
analysis.
The kinetic expression of RANTES and MCP-1 in the guinea pig allergic lung has not 
been previously reported. However, a similar analysis of allergic inflammation in the 
murine lung by MacLean et al (1996) also demonstrated non-variable RANTES 
expression over 3 to 48 h post OA challenge. In comparison, expression for the CC 
chemokine eotaxin was strongly induced over a similar time course in OA sensitised but 
not sham sensitised lungs. Eotaxin is a potent and specific eosinophil attractant 
originally identified in BAL of OA sensitised guinea pigs at 3-6 h post challenge, by 
Jose et al (1994b). Furthermore this group (Jose et al. 1994a) and others (Rothenberg et 
al. 1995b) have demonstrated that OA sensitisation of the guinea pig lung induces 
increased expression of eotaxin mRNA notably at 3 h following challenge, whilst the 
chemokine is only weakly expressed in non-sensitised controls.
During clinical asthma however, increased RANTES expression in the lung compared to 
levels in normal control subjects, implies a more important role in the development of 
an allergic response, although a number of other CC chemokines are also upregulated.
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Bronchial tissue from asthmatics has been reported to express increased levels of 
RANTES and MCP-3 (Humbert et a l 1997) as well as MCP-1 mRNA (Sousa et a l 
1993). Alam et al (1996) demonstrated elevated levels/activity of RANTES, M IP-la 
and MCP-1 protein in the BAL of asthmatics, although Teran and colleagues (1996) 
identified RANTES as the sole eosinophil chemoattractant in BAL fluid and observed a 
six fold increase in RANTES protein levels at sites of allergen challenge compared to 
saline challenged sites. In contrast, recent studies by Fahey et al (1997) failed to detect 
any differences in expression of RANTES mRNA between atopic asthmatics and 
healthy subjects using in situ hybridisation. Studies by Kurashima et al (1996) have 
suggested that increased levels of M IP-la and MCP-1 in the sputum precede and are 
indicative of the development of a late phase response during acute asthma attacks.
6.2. Potential sources of guinea pig chemokines in the lung
Guinea pig lung tissue was analysed by in situ hybridisation to identify cells potentially 
responsible for the production of RANTES. Initial examination of the sections revealed 
that overall RANTES mRNA expression was increased in two of three OA sensitised 
lung sections compared to naive lungs at 24 h post OA-challenge (figure 11). Analysis 
of the same samples for eotaxin expression showed no such increases (figure 12). This 
data appears to conflict with the fairly constant RANTES expression observed using 
Northern blot analysis. It is particularly surprising since these lungs were also analysed 
by RT-PCR and overall standardised levels of RANTES or eotaxin were representative 
of their treatment group. Furthermore other groups (Jose et al. 1994b; Rothenberg et a l 
1995b) have demonstrated variable levels of eotaxin using similar guinea pig models of 
allergic asthma. Peak expression of eotaxin was detected at 3h following OA challenge
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and chemokine expression using in situ hybridisation was not analysed at this time 
point. However, in situ hybridisation identifies particular cell types responsible for 
chemokine expression and studies of expression in the whole lung (even RT-PCT) 
might not be sufficiently sensitive to detect such subtle changes. Whilst the expression 
of RANTES appears more strong than for eotaxin, such comparisons based on the 
intensity of staining are not necessarily accurate. The antisense RANTES riboprobe 
labelled at twice the efficiency of the antisense eotaxin probe and although a 
correctional dilution into the hybridisation buffer was made, this also introduces 
proportionally more unlabelled probe which competes for target mRNA.
In situ hybridisation was successfully used to identify the potential source of RANTES 
and for comparison, eotaxin. Both chemokines portrayed a similar pattern of 
expression, predominantly within the alveolar macrophage and less so in the 
endothelium, bronchial epithelium and cells lining the alveoli.
6.2.1. RANTES and eotaxin expression in the alveolar macrophage
In situ analysis indicated that the alveolar macrophage expressed RANTES and eotaxin 
mRNA in guinea pig lung tissue. Although the number of BAL macrophages was 
increased in the animals which were sensitised to OA (A.-M. White, personal 
communication) increased numbers of macrophages within the lung section were not 
observed. The identification of guinea pig mononuclear cells as a potential source of 
RANTES was supported by Northern blot analysis of total RNA extracted from 
peritoneal macrophages cultured in vitro (figure 17). No constitutive expression was 
observed in these cells but was prominent following LPS-stimulation at all time points 
analysed. Since LPS has been shown to induce rapidly TNFa mRNA within 1 h in
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rodent alveolar macrophages (Ulich et al. 1991), it is possible that at least some of the 
observed RANTES expression in guinea pig peritoneal macrophages was TNFa 
mediated. Furthermore, work in this thesis indicates that recombinant gpRANTES itself 
induces RANTES expression in these cells and although it is not clear whether the 
expression is associated with production of the protein, it does raise the possibility of a 
RANTES-mediated positive feedback mechanism. Further work is needed to 
investigate the expression of RANTES and eotaxin in the guinea pig alveolar 
macrophage especially since Van Otteren et al (1994) demonstrated that M IP-la 
appears to be secreted at far greater levels from LPS-stimulated murine alveolar 
macrophages compared to those isolated from the peritoneum.
A number of other workers have identified the macrophage as a source of RANTES. 
Schall et al (1992) initially isolated mRANTES from the macrophage cell line PU5-1.8. 
Devergne et al (1994) reported RANTES in alveolar macrophages (and epithelial cells) 
in delayed-type hypersensitivity granulomas and confirmed this finding by observing 
RANTES expression and protein release in IFNy-treated BAL macrophages. In 
contrast, Van Otteren et al (1995b) implicate the endothelial cell but not the alveolar 
macrophage as a source of RANTES in rodent models of endotoxaemia. Such 
variations could reflect the nature of the stimulus, for example TNFa has been shown to 
be a key mediator of sepsis and is also the most potent inducer of RANTES expression 
in a number of cells including the epithelium. In contrast the upregulation of IFNy, IL- 
1 (3 and TNFa is a specific feature of DTH granulomas and might favour stimulation of 
macrophages and endothelial cells (Devergne et al. 1994). Interestingly, a recent study 
by McKee and colleagues (1996) reported that alveolar macrophages from patients with 
idiopathic pulmonary fibrosis express RANTES as well as M IP-la and p and MCP-1
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mRNA following stimulation with fragments of the glycosaminoglycan, hyaluronan. 
Such fragments are generated from the high molecular weight parent polymer, which did 
not induce expression, during chronic inflammation although it is not clear whether such 
fragments are present in allergic lung inflammation.
6.2.2. RANTES and eotaxin were not expressed in other leukocytes o f the lung
Alveolar macrophages were the only leukocytes identified in the guinea pig lung to 
express RANTES or eotaxin (figures 11 and 12). Schall et al (1990) originally 
identified RANTES expression in IL-2 dependent human T cell lines and studies by 
Conlon and colleagues (1995) showed that a number of human peripheral blood 
lymphocytes especially CD8 + CD45RO+ T cell, secreted RANTES as well as M IP-la. 
It is feasible that the scant numbers of these cells in the lung made analysis of their 
chemokine expression difficult. In this study, all eosinophils identified in the guinea pig 
lung did not express RANTES or eotaxin. In contrast, a recent study by Ying and 
colleagues (1996) concluded that human eosinophils synthesis RANTES through de 
novo gene transcription, identifying over 50% of the immunopositive cells for RANTES 
during allergen-induced late-phase cutaneous reaction as EG2+ eosinophils. The authors 
confirmed the human eosinophil to be a source of RANTES by demonstrating the 
release of biologically active protein from human peripheral blood eosinophils after 
stimulation with serum-coated particles, findings supported by Lim et al (1996) using 
GM-CSF stimulated cells. Recent work by Garcia-Zepeda (1996) suggests that the 
human eosinophil might also be a source of eotaxin.
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6.2.3. The epithelium and endothelium express RANTES and eotaxin mRNA
Our in situ hybridisation studies suggest evidence of RANTES and eotaxin expression 
in airway epithelium and less so in the endothelium (figures 11 and 12). These proteins 
join an ever expanding list of other chemokines produced by these cells, including IL- 8  
(Standiford etal. 1990a; Hebert et al. 1990) and MCP-1 (Sousa et al. 1994). In terms of 
leukocyte migration, these cells could be thought of as ‘gate keepers’, dictating which 
cells pass into the bronchial lumen and extravascular spaces through the generation of 
high, localised concentrations of chemokines. It seems feasible that RANTES and 
eotaxin production at these sites contributes towards leukocyte accumulation in the BAL 
and lung of the guinea pig and characterisation of the biological activity of these 
chemokines suggests that RANTES mediates macrophage accumulation, whilst eotaxin, 
eosinophil accumulation (this work and Jose et al. 1994b). Since both endothelial and 
epithelial cells seemingly secrete a similar array of chemokines, the balance of 
leukocytes in the lung tissue itself (compared to the bronchial lumen) might be mediated 
by the differential expression of adhesion molecules. Studies by Weg et al (1993) 
demonstrated that an antibody to VLA-4 inhibited eosinophil accumulation in the guinea 
pig skin following a passive cutaneous anaphylaxis reaction, implying that VLA-4- 
mediated adhesion might be important for transendothelial migration. Milne and Piper
(1993) suggested that CD18/ICAM-1 interactions control migration across the 
epithelium into the bronchial lumen, since pretreatment of OA sensitised guinea pigs 
with anti-CD 18 mAbs decreased the number of eosinophils in the BAL but not in the 
lung tissue. Das and colleagues (1995) also reported that the administration of 
antibodies to both VLA-4 and CD 18 were required to inhibit BAL eosinophilia in the 
guinea pig but suggested that both eosinophils and monocytes could use both 
mechanisms to cross either barrier. However, it is clear that chemokines themselves can
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influence adhesion molecule expression; RANTES upregulates CD1 lb/CD 18 on 
eosinophils (Alam et a l 1993) and appears to induce eosinophil transendothelial 
migration through HUVEC via CD 18 and VLA-4-dependent mechanisms (Ebisawa et 
a l 1994). However, recent work by Burke-Gaffney (1996) suggests that eotaxin, but 
not RANTES or M IP-la, mediates VLA-4-dependent eosinophil adhesion to human 
lung micro vascular endothelial cells.
Our observations of RANTES and eotaxin production from endothelial and epithelial 
cells supports those of a number of other workers. Marfaing-Koka et al (1995) reported 
RANTES expression in human endothelial cells following synergistic induction with 
TNFa and IFNy which could be inhibited with IL-4 and IL-13. Rothenburg and 
colleagues (1995a) similarly described eotaxin expression in a murine endothelial cell 
line, although interestingly, this group also showed that eotaxin production was 
associated with IL-4 production from transfected tumours in vivo. The expression of 
RANTES in cultured epithelium similarly seems to require cytokine stimulation. Kwon 
et al (1995) observed RANTES but not M IP-la expression in the epithelial cell line 
A549 upon induction by TNFa or IL-1 (with peak expression at 24 and 48 h 
respectively) with RANTES immunoreactivity increasing for both stimuli at 48 h. 
Wang and colleagues (1996) observed TNFa-induced RANTES release from primary 
bronchial epithelial cells peaking slightly earlier at 24 h. This group also demonstrated 
epithelial RANTES protein expression in bronchial biopsy sections from mild 
asthmatics although in situ hybridisation studies by Humbert et al (1997) fail to support 
their findings. Many of these investigators have demonstrated reduced RANTES 
expression in vitro and in vivo following glucocorticoid treatment (Kwon et a l 1995;
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Wang et al. 1996; Stellato et al. 1995) It has been suggested that a down regulation of 
transcription factors, notably NF-kB, could be responsible for these effects (Wang et a l 
1996). The 5'-flanking region of the human RANTES gene contains an array of 
transcription factor binding sites and the rapid induction of RANTES following IL-lp 
stimulation in these cells is concurrent with increased binding activity of NF-kB 
(Danoff et a l 1994).
The in situ analysis also revealed weak positive staining for RANTES and eotaxin 
mRNA within the alveolar wall (figures 11 and 12). Increased expression, particularly 
for eotaxin, may have been observed at 3 h in sensitised tissues, although this time-point 
was not investigated. This layer consists primarily of an epithelium of type I and II 
pneumocytes (although type I cells are infrequently visible in histological section by 
virtue of their extremely flattened morphology), endothelial cells, connective tissue 
including fibroblasts as well as the readily identifiable macrophage, embedded within 
the wall. In absence of double staining procedures, the precise stromal/parenchymal 
cells expressing these chemokines are not readily identified in situ, although Van 
Otteren at al (1995b) reported TNF-induced RANTES protein release from rat type II 
pneumocytes and Lukacs and colleagues observed RANTES expression predominantly 
in these cells during allergic inflammation in the mouse lung (Lukacs et a l 1995b).
6.2.4. Expression o f chemokines in guinea pig lung fibroblasts
The fibroblast has been reported as a source of a number of chemokines and although 
these cells are not readily identified in situ, they are proliferative in culture. Using 
Northern blot anaysis, no detectable expression of RANTES or eotaxin was observed in 
a guinea pig fibroblast cell line, JH4-C11, or fibroblast-like primary cells grown from
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lung explants. This suggests that the lung fibroblast does not play a key role in the 
production of these chemokines (figures 18 and 19). In contrast, RANTES production 
has been reported from cytokine-stimulated human dermal fibroblasts as a truncated 
form, [Tyr-RANTES]68 (Noso et a l 1995). Furthermore, rheumatoid synovial 
fibroblasts expressed RANTES mRNA following TNFa or IL-lp stimulation 
(Rathanaswami et a l 1993). No chemokine expression was observed in guinea pig 
fibroblasts following stimulation with these recombinant human cytokines, presumably 
a consequence of differences in species specificity. Given that the human macrophage 
is a rich source of IL-1 and TNFa (Ulich et a l 1991), supernatant from LPS-stimulated 
guinea pig peritoneal macrophages was assumed to contain guinea pig TNF and IL-1 
and small amounts of IFNy, although the exact levels of these were not determined. 
However Rolfe et al (1992) demonstrated that chemokine expression in human 
pulmonary fibroblasts stimulated with LPS-treated alveolar macrophages could be 
obliterated using anti TNF and anti IL-lp antibodies. Rathanaswami et a l (1993) 
demonstrated that RANTES expression in synovial fibroblasts was inhibited by dual 
TNFa and IL-lp stimulation but augmented by co-stimulation with IFNy. It seems 
unlikely that the possible presence of both TNFa and IL-1 would have diminished any 
RANTES message in the guinea pig fibroblasts, since stimulation with recombinant 
guinea pig TNFa in a later experiment also did not induce expression. Furthermore, 
even in the presence of conditioned media from Con A-stimulated spleen cells, that was 
assumed to contain guinea pig IFNy (Trinchieri & Perussia, 1985), no RANTES 
expression was induced although it is possible that IFNy was not present at optimal 
doses.
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The guinea pig lung fibroblast appears to be important in the production of other 
chemokines such as MCP-1 and IL-8 , and their expression at early time points is 
consistent with descriptions of these chemokines being rapidly induced following 
stimulation (Miller & Krangel, 1992). It is not clear why a high expression of MCP-1 
was seen at early time points in vehicle-treated primary fibroblasts which became 
stimulus dependent after 12 h (figure 19). This might reflect a time dependent response 
to the addition of fresh medium containing FCS. However the ‘early’ expression of 
MCP-1 in the guinea pig fibroblast corresponds with that observed in the sensitised 
whole guinea lung notably at 2 h post OA challenge and it is possible that this cell is a 
key contributor of the overall expression of MCP-1. A similar time-course for MCP-1 
expression was reported by Rolfe and colleagues (1992) in human pulmonary fibroblasts 
following TNFa or IL-lp stimulation. This group also demonstrated MCP-1 expression 
after stimulation with conditioned media from LPS-treated human alveolar macrophages 
and suggested that a positive feedback loop between monocyte and fibroblast involving 
MCP-1, might maintain infiltration of monocytic cells into the lung. gpMCP-1 is able 
to stimulate guinea pig peritoneal macrophages (Yoshimura 1993), and it is possible 
such a system exist in the guinea pig.
6.3. The characterisation o f gpRANTES protein
6.3.1. Sequence homology o f gpRANTES
gpRANTES is highly homologous with hRANTES at both the nucleotide (90%) and 
amino acid (91%) level, as well as with murine RANTES (89% and 8 8 % respectively) 
over the region of the secreted protein (figure 20). In comparison to other guinea pig 
CC chemokines cloned to date, gpRANTES shares 28% amino acid homology with
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eotaxin, 37% with gpMCP-1 and these latter proteins are considerably less well 
conserved with their human counterparts (62% and 56% respectively, Ponath (1996), 
Yoshimura (1993). Furthermore, the high homology of gpRANTES with mRANTES is 
quite distinct from other chemokines. Eotaxin and gpMCP-1 are only 63% and 45% 
identical with their murine counterparts (Rothenberg et al. 1995a; Yoshimura, 1993) 
whilst IL- 8  has not been identified in mouse or rat (Yoshimura & Johnson, 1993). 
Yoshimura (1993) suggested that these observations might support the theory that the 
guinea pig has evolved from a separate lineage from other rodents (Graur et al. 1991).
6.3.2. Expression o f gpRANTES by mutation o f hRANTES cDNA 
High levels of expression in E. coli were obtained by mutating the hRANTES cDNA at 
6  positions to achieve the predicted amino acid sequence for gpRANTES (figure 25), 
although expression systems utilising gpRANTES cDNA were unsuccessful (figure 21). 
It is clear that the N terminus is important in conferring activity for human CC 
chemokines. Proudfoot and colleagues (1996) demonstrated that retention of 
methionine at the N terminus of the mature hRANTES protein, a phenomenon common 
to E. coli derived proteins, renders the protein inactive as an agonist but effective at 
inhibiting RANTES and MIP-la-induced responses in THP-1 cells. Methionine 
retention by gpRANTES was successfully prevented by expressing the protein with a 
cleavable N terminal hexapeptide leader sequence ending in Arg at the 5' end, as 
previously described (Proudfoot et al. 1995). Amino terminal sequencing showed that 
the initiating methionine was removed from the mature gpRANTES and this protein 
induced changes in [Ca2+]i in the pro-monocytic cell line THP-1 (figure 25B), which has 
been reported to be RANTES-responsive by virtue of CCR1 receptor expression (Wang
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et a l  1993; Proudfoot et al. 1995). In comparison, hexapeptide-gpRANTES failed to 
induce any response in these cells.
A number of groups have also demonstrated that N terminal deletions of the mature 
chemokine itself can vastly alter activity of the protein. Studies by Clarke-Lewis and 
co-workers (Gong et al. 1996) indicated that N terminal truncations to hRANTES (9-68) 
as well as MCP-1 (9-76) and MCP-3 (10-76) abolished agonist activity but conferred 
inhibitory action towards monocytic responses induced by all three parent chemokines. 
Interestingly, a single amino acid deletion from the N terminal residue of MCP-1, 
changed the target cell selectivity from a basophil to an eosinophil activator (Weber et 
al. 1996). However, Noso and colleagues (1995) recently reported that an N terminally 
truncated form of hRANTES was the major eosinophil attractant (as well as GMCSF) 
released from dermal fibroblasts which showed identical potency and efficacy in a 
chemotaxis assay system to the natural [Ser-RANTES]6 8-
Clearly the identification of a native source of gpRANTES protein would allow 
confirmation of the N terminus (i.e. the position at which removal of the presumed 
signal sequence takes place). Human platelets harbour stable mRNA species for a 
number of CXC chemokines in addition to MCP-3 and RANTES (Power et a l 1995) 
and are a rich source of RANTES protein (Kameyoshi et al. 1992) which appears to be 
localised, along with M IP-la, within the a  granules (Klinger et a l 1994). Extensive 
attempts for this project to detect RANTES in guinea pig platelets (figures 26 and 27) 
and independently by J.-M. Schroder (University of Kiel, personal communication), 
who analysed platelet HPLC fractions for human eosinophil chemoattractant activity, 
have proved unfruitful. Furthermore, although the guinea pig macrophage expresses 
RANTES mRNA, it was not clear whether this is utilised for protein synthesis.
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Therefore, it had to be assumed that gpRANTES has the same N terminus as 
hRANTES.
6.3.3. gpRANTES activates monocytic cells but not eosinophils in the guinea pig 
RANTES demonstrates selectivity between guinea pig peritoneal eosinophils and 
macrophages. gpRANTES and hRANTES were not able to cause migration (figure 30) 
or an increase in [Ca2+]i (figure 33) in guinea pig peritoneal eosinophils. m Indium- 
labelled guiena pig peritoneal cells did not accumulate in skin sites in donor guinea pigs 
injected with human RANTES (figure 38). Furthermore, it would appear that these cells 
do not migrate towards RANTES even when co-incubated with IL-5 (figure 32). In 
contrast, IL-5 has previously been demonstrated to enhance the chemotactic response of 
human eosinophils to different chemokines, including RANTES (Ebisawa et al. 1994; 
Schweizer et al. 1994). However, both human and gpRANTES were potent activators 
of human blood eosinophils. It was not possible to assess the RANTES responsiveness 
of blood derived guinea pig eosinophils (or indeed monocytes) directly in vitro mainly 
due to the low circulating numbers of these cells in normal animals. Thus, attempts 
were made to boost the eosinophil count by i.v. injection of IL-5, which induces 
eosinophil release from the bone marrow according to a method by Collins et al. (1995). 
However, analysis of blood smears and leukocyte preparation cytospins from these 
animals showed that many cells were not well differentiated. Separation of the 
leukocyte subtypes proved difficult using a Percoll gradient and furthermore, guinea pig 
neutrophils did not recognise the human CD 16 mAb bound to MACS beads, which 
allowed effective separation of human peripheral blood eosinophils through negative 
selection. Examination of the chemotactic response of the blood leukocytes from these 
animals revealed a similar migratory response towards RANTES as for the control.
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Macrophages from the guinea pig peritoneum were responsive to RANTES as 
demonstrated by changes in [Ca2+]i and chemotaxis (figure 34). RANTES induces an 
immediate and transient rise in [Ca2+]i, and the chemotaxis studies were performed over 
a relatively short (2-4 hours) incubation period. Therefore, it seems reasonable to 
assume that RANTES acts directly on these cells, rather than inducing an intermediate 
effector. The profile of RANTES activity in the guinea pig is clearly different from 
human peripheral blood cell populations, where RANTES is a potent activator of both 
eosinophils and monocytes (this work and references by Schall et a l (1990) and Rot et 
a l (1992). This difference does not appear to be accounted for by species variation 
between the primary sequence of guinea pig and human RANTES since, where tested, 
these proteins have almost identical biological activity.
It could be argued that differences between the human and guinea pig eosinophil 
populations used in these in vitro experiments reflect the use of blood-derived cells 
compared to cells isolated from an inflammatory site. Receptor desensitisation may 
occur following extravasation. However, guinea pig peritoneal eosinophils are able to 
respond to other chemoattractants such as C5a and LTB4 (Faccioli et a l  1991) and when 
primed with IL-5, to IL-8 . Moreover, Jose et al (1994b) have demonstrated 
responsiveness of elicited guinea eosinophils towards eotaxin. Furthermore, it is clear 
that the use of elicited cells per se does not preclude stimulation by RANTES, as it is an 
effective activator of peritoneal macrophages.
The in vivo analysis indicates that, as in vitro, gpRANTES has a selective action as a 
monocyte/macrophage attractant. Following instillation of gpRANTES into the guinea 
pig airways, a significant increase in BAL macrophage numbers, but not eosinophils, 
was observed. This effect was dose-dependent and the mononuclear cell accumulation
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was detectable at 6  hours and sustained for at least 48 hours (figure 37). Similarly, 
injection of gpRANTES into naive guinea pig skin sites, induced a monocytic 
infiltration which was dose and time dependent. No evidence of an increase in 
eosinophil numbers compared to saline-injected sites was observed at 2 or 24 hours post 
injection, whilst large areas of dermal macrophages were observed at 24 hours (figures 
41, 42). Intradermal injections have been shown to be a valid model of blood-derived 
eosinophil migratory responsiveness towards RANTES by Meurer et al (1993) who 
reported eosinophilic and monocytic infiltration in skin sites of the dog in response to 
hRANTES at 4 h post injection which was vastly elevated at 24 h. Interestingly, the 
authors observed a six fold increase in dermal macrophage numbers using a dose of 500 
pmol/site hRANTES compared to saline sites. Results from this thesis show that 
RANTES injection into guinea pig skin sites induces a similar fold increase using only 
1 0 0  pmol/site although no larger doses were injected to assess whether the response was 
maximal at 100 pmol/site. RANTES has been shown to be an important mediator of 
macrophage recruitment in vivo in a murine model of endotoxemia. Passive 
immunization with anti-RANTES antibodies resulted in a significant reduction in 
macrophage infiltration into the lung at 24 hours following intraperitoneal 
administration of lipopolysaccharide (VanOtteren et a l 1995a).
A number of recent reports have shed light on factors which mediate eosinophil 
accumulation in the guinea pig in vivo. The CC chemokine eotaxin induces eosinophil 
activation in vitro (Jose et al. 1994b) and Collins et al (1995) demonstrated eosinophil 
accumulation in guinea pig skin sites injected with eotaxin. This accumulation was 
increased six fold in animals preinjected i.v. with IL-5. The authors proposed a 
systemic effect of IL-5 to mobilise large numbers of bone marrow eosinophils into the 
blood which would subsequently be recruited by high concentrations of local
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chemokine. Eosinophil migration might also be facilitated by the effects of EL-5 
priming (Schweizer et a l 1994). However, it seems unlikely that the use of IL-5 would 
unveil such a role for RANTES in vivo in the guinea pig under similar circumstances, 
since RANTES-induced migration of guinea pig EL-5-primed eosinophils was not 
observed in vitro, and eotaxin itself is a potent eosinophil attractant (Jose et al. 1994b). 
IL-5 is associated with a Th2 response and pretreatment of OA sensitized guinea pigs 
with anti-EL-5 antibody TRFK-5, prior to challenge reduces airway hyperreactivity and 
the associated eosinophilia (Van Oosterhout et al. 1993). In the mouse, a number of 
groups have reported that IL-4 rather than IL-5 is causally related to the eosinophilia of 
allergic inflammation (Lukacs et a l 1994) and disruption of the murine IL-4 gene 
blocks Th2 cytokine responses (Kopf et a l 1993).
In addition to these cytokines, murine allergic responses are associated with TNFa 
(Lukacs et a l 1995a) which probably acts through a combination of adhesion molecule 
upregulation, initiation of cytokine cascades and induction of key chemokines such as 
eotaxin and M IP-la (Lukacs et a l 1996a). Most recently White et al (1996) have 
demonstrated gpTNFa-induced eosinophilia in the guinea pig B AL, although the precise 
chemoattractants have yet to be elucidated since gpTNFa itself has no direct eosinophil 
attractant ability.
6.3.4. Evidence for chemokine receptors on guinea pig peritoneal cells 
Studies as part of this project indicate that gpRANTES activates guinea pig peritoneal 
macrophages with similar potency to hRANTES, and hM IP-la and hMIP-lp are also 
agonists for these cells (figure 35). However, possible receptors that bind RANTES on 
guinea pig monocytic cells have yet to be identified, although Van Riper et al have
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shown some specific binding of hRANTES to guinea pig mononuclear cells (1993). All 
five human CC chemokine receptors cloned to date are expressed on monocytic cells 
and of these all but the MCP receptor, CCR2, bind RANTES (reviewed by Power and 
Wells 1996) although the reason for such biological redundancy is not clear. Of 
particular note is the CCR5 which binds M IP-la and p as well as RANTES and may be 
important in the selective recruitment of monocytic cells since it is expressed on primary 
adherent monocytes but not eosinophils or neutrophils (Combadiere et al. 1996). It is 
also noteworthy that of the four murine CC receptors which have been cloned 
(homologues of human receptors CCR1-4) all preferentially bind M IP-la and most also 
bind RANTES (Post et al. 1995; Meyer et al. 1996; Hoogewerf et al. 1996).
Marleau and colleagues (1996) demonstrated that hRANTES and hMCP-3 were able to 
bind receptors on guinea pig peritoneal eosinophils, displacing eotaxin. However, 
unlike eotaxin they were unable to induce changes in [Ca2+]i in these cells. M IP-la/p 
did not bind or activate these eosinophils. Furthermore hRANTES inhibited the 
accumulation of 11’in-labelled eosinophils in eotaxin-injected guinea pig skin sites. 
This implies that a common receptor on these cells binds RANTES, eotaxin and MCP- 
3, and has lead to the suggestion that hRANTES could antagonise and regulate eotaxin 
responses in the guinea pig. gpRANTES is also inactive towards these cells (this 
thesis), although its ability to displace eotaxin and thus inhibit eotaxin-induced 
responses remains to be established. However, should such a role exist, then the co­
localised production of eotaxin with RANTES in the guinea pig lung as demonstrated 
by in situ hybridisation mRNA distribution, might facilitate such inhibition. On the 
bases of binding data it would appear that this receptor is the guinea pig homologue of 
the human eotaxin receptor, CCR3 which also binds eotaxin, MCP-3 and RANTES with
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Kd of 0.1, 2.7 and 3.1 nanomolar respectively (Daugherty et a l 1996). This receptor is 
expressed at high levels on the human eosinophil. However since RANTES as well as 
MCP-3 and eotaxin are able to induced changes in [Ca2+]i in AML.3D10 cells 
transfected with the receptor, RANTES is presumably able to induce human eosinophil 
responses by signalling through this receptor. Human eosinophils also express the 
CCR1 receptor (Proudfoot et al. 1995) which binds RANTES at a higher affinity than 
CCR3 (Kd of 0.6 nM) but is present at much lower levels (Daugherty et a l 1996). It is 
not known whether guinea pig eosinophils express CCR1. However since neither 
RANTES, hM IP-la or MCP-3 (own observations and Marleau et al. 1996), the ligands 
for human CCR1, activate guinea pig eosinophils it is tempting to speculate that this 
receptor is absent on these cells. A summary of postulated guinea pig and known 
human receptors for eosinophils and macrophages are summarised in diagram 6 .1 .
The inability of RANTES to induce eosinophil activation is not confined to the guinea 
pig; eosinophils from IL-5 transgenic mice are also unresponsive to RANTES (Post et 
al. 1995). However, homologues of CCR1 and CCR3 have been identified on murine 
eosinophils (Post et a l 1995; Gao & Murphy, 1995; Meyer et a l 1996) which bind 
RANTES as well as M IP-la and MIP-lp, and M IP-la is a potent activator of these 
cells (Lukacs et a l 1996c). It is possible that the CC chemokines (RANTES, MCP-3, 
eotaxin and M IPl-a) bind homologues of the same eosinophil receptors with differing 
affinities or efficacies according to the species. Such a rationale would explain the 
species differences in CC chemokine involvement in allergic inflammation, since the 
expression of an eosinophil attractant appears to correlate with induction of pulmonary 
eosinophilia. In a model of murine airway inflammation induced by challenge with 
Schistosoma mansoni egg antigen, Lukacs et al (1996c) demonstrated increases in MIP-
l a  expression at 8 h post-challenge. Pretreatment with anti-M IP-la neutralising 
antibody prior to challenge decreased BAL eosinophil numbers by 50 %, consistent with 
the role of M IP -la  as a murine eosinophil attractant. In the human, a number o f  
eosinophil-attracting chemokines are upregulated during allergic responses in the lung, 
including RANTES (Teran et al. 1996).
human Eosinophils Guinea pig Eosinophils
CC CKR1 CC CKR3 C C  C KR 3
human Macrophages
CC CKR1 CC CKR5
Diagram 6.1. Postulated guinea pig and known human CC chemokine receptors on 
eosinophils and macrophages.
gp Macrophages
C C C K R l  C C C K R 5
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Work presented in this thesis demonstrates that the expression of RANTES mRNA was 
not induced in response to antigen sensitisation/challenge in the guinea pig and is not an 
eosinophil attractant in this species. gpRANTES is however a potent activator of guinea 
pig monocytic cells and since macrophages are the predominant cell type in BAL in the 
absence of inflammation and a low level expression of RANTES mRNA was detected 
in normal guinea pig lung, it is tempting to speculate that RANTES may contribute to 
the maintenance of resident lung macrophages. Other authors have shown that gpMCP- 
1 activates guinea pig elicted, but not resident macrophages, and eotaxin is a potent 
guinea pig eosinophil-attractant and may be particularly effective in conjunction with 
Th2-type cytokine IL-5. Since these two chemokines are both upregulated in the OA- 
challenged lung they may be more important than RANTES in cell recruitment during 
allergic inflammation in the guinea pig.
A central role for chemokines in asthma remains to be established and the determination 
of the action of any one chemokine in allergic airway inflammation can only be made in 
an appropriate animal model. Although these results indicate that RANTES has 
differing cellular selectivity in the guinea pig compared to the human, the guinea pig 




This thesis has demonstrated evidence for RANTES as a macrophage attractant in the 
guinea pig. This would appear to be relevant to monocyte recruitment in the lung since 
tracheal instillation of gpRANTES increases BAL macrophage numbers. However, the 
in vitro characterisation of gpRANTES centred around the responses of peritoneal cells. 
It may be more relevant to assess the RANTES responsiveness of guinea pig alveolar 
macrophages, as well as CC chemokine expression in these cells.
Recent work by Marleau and colleagues (1996) suggests the presence of a shared 
eotaxin/RANTES/MCP-3 receptor on guinea pig peritoneal eosinophils. Cloning of 
such a receptor would allow a full characterisation of chemokine responses and cast 
light on reasons for the ability of RANTES and MCP-3 to bind but not activate guinea 
pig eosinophils. As for other chemokines, key sequences for receptor binding can be 
elucidated by the synthesis and biological characterisation of truncated forms of the 
protein and in this way receptor antagonists designed. A feature of the chemokines is 
the multiplicity of proteins binding to any one receptor although the reasons for this 
redundancy are unclear. A number of authors have therefore questioned the likelihood 
that inhibition of an individual chemokine would adequately affect the overall 
inflammatory process, leading to suggestions that antagonism at the level of the receptor 
is a more prudent target for therapeutic intervention (Teixeira et al. 1995). 
Alternatively, the inhibition of central cytokines, particular IL-5, IL-4 and TNFa, might 
inhibit production of a number of down-stream chemokines.
Work in this thesis indicates that RANTES might not be central to eosinophil 
recruitment in allergic inflammation in the guinea pig. However, studies of RANTES as 
a histamine releasing factor from human basophils (Kuna et al. 1993) and mast cells
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(Mattoli et a l 1995) suggest that RANTES might indirectly induce bronchoconstriction 
and other features of the immediate phase of an allergic response. Studies are currently 
underway to determine whether such a role exists for RANTES in the guinea pig 
(M.Watson, personal communication).
It remains to be seen what relative contribution the chemokines make to the overall 
development and maintenance of allergic inflammation. How, for example, might they 
interact with the non-specific leukocyte attractants PAF and the leukotrienes, equally 
implicated in the pathogenesis of asthma by virtue of their upregulation? Studies that 
embrace the many inflammatory molecules deciphered over the last few decades will 
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Appendix 1: Media and Solutions
Where appropriate, media and solutions were sterilised by autoclaving for 20 min at 15 
lbs/sq inch (121 °C) on a liquid cycle. All concentrations are final.
DNA loading buffer: 0.5 % SDS, 25 % glycerol, 0.25 % bromophenol blue, 0.05 M 
EDTA
Hybridisation solution for cDNA probes: High SDS buffer contains 7 % SDS, 50 mM 
sodium phosphate buffer pH 7.0, 2 % blocking reagent, 5x SSC, 0.1 % Sarcosyl, 50 % 
formamide. Warm to 50°C to dissolve.
Hybridisation solution for riboprobes: 50 % deionised formamide with 5x SSC 
warmed to 50 °C before addition of 10 % dextran sulphate. After complete 
solubilisation at 50 °C the following reagents were added; 5x Denhardt’s solution, 0.5 % 
SDS, 1 % denatured sheared herring sperm DNA and DEPC-treated water to required 
volume.
Miniprep solution I: 25 mM Tris containing 50 mM glucose and 10 mM EDTA
Miniprep solution II: 0.2 N NaOH containing 1 % SDS prepared from sterile stocks 
of 10 N NaOH and 20 % SDS on day of experiment.
Miniprep solution III: 3 M potassium acetate containing 11.5 ml glacial acetic acid
MOPS buffer (x20): 0.8 M MOPS, 0.02 M EDTA, 0.2 M sodium acetate, adjusted to 
pH 7.0 with NaOH pellets.
NBT/BCIP alkaline phosphatase substrate: 0.03 % NBT and 0.015 % BCIP in 100 
mM Tris HC1 adjusted to pH 9.5, containing 5 mM MgCl2 and 100 mM NaCl.
Northern blot maleic acid buffer: 0.1 M maleic acid, 0.15 M NaCl adjusted to pH 7.5 
with NaOH pellets, DEPC-treated overnight then autoclaved.
Northern blot blocking buffer stock: 10% blocking reagent for nucleic acids in
maleic acid buffer. Microwaved until boiling to dissolve.
Northern blot chemiluminescence substrate buffer: 0.1 M Tris, 0.1 M NaCl, 50mM 
MgCl2 . Adjusted to pH 9.5.
238
Paraformaldehyde solution (4 %): 4 % paraformaldehyde, 2 % sucrose, 5 mM
MgCl2, 0.02 % DEPC in lx PBS, pH 7.4.
RNA loading buffer: 33 % glycerol in DEPC-treated water with 0.25 % bromophenol 
blue
RNA sample buffer: 8  % formaldehyde (from stock of 37 %), 5x MOPS, 0.6 % w/v 
ethidium bromide, 60 % v/v formamide.
LB medium (Luria-Bertani medium): 1 % w/v Bacto tryptone, 0.5 % Bacto yeast
extract, 1 % NaCl, pH 7.0 with NaOH. LB plates were made from 2 % agar in LB 
medium.
Recovery medium: 2 % w/v Bacto tryptone, 0.5 % Bacto yeast extract, 10 mM NaCl, 
2.5 mM KC1, 10 mM MgCl2, 10 mM MgS0 4 , 20 mM glucose.
Sodium acetate solution (3 M): 40.8 % sodium acetate solution (in DEPC-treated 
water) was adjusted to pH 5.2, by addition of an approximately equal volume of glacial 
acetic acid.
SSC (x20): 3 M NaCl, 0.3 M trisodium citrate, pH 7.0. DEPC-treated and autoclaved. 
TBE (x5): 54 g/L Tris base, 27.5 g/L boric acid, 4.65 g/L Na2EDTA.H20 , pH 8.3 
TBS: 0.9 % w/v NaCl in 10 mM Tris HC1 pH 7.4
Tris-saturated phenol/chloroform commercial preparation containing: Tris (0.1 M) - 
saturated phenol:chloroform:isoamyl alcohol, 25:24:1
Western blocking buffer: 5 % non-fat powdered milk (Marvel), 0.05 % azide in lx 
TBS
Western electrophoresis running buffer: 25 mM Tris containing 192 mM glycine and 
0.1 % SDS
Western protein sample buffer x5: 50 % glycerol, 10 % SDS, 1.5 % 2- 
mercaptoethanol and 0.5 mg bromophenol blue in lA dilution of the stacking gel buffer
Western transfer buffer: 25 mM tris containing 192 mM glycine and 20 % methanol
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Western gel components:
Component Running gel (15%) Stacking gel (4%)
Distilled water 1.175 ml 2.15 ml
10 % SDS (w/v) 50 jil 37.5 pi
1.5 M Tris buffer pH 8.8 
(Running gel buffer)
1.25 ml ”
0.5 M Tris buffer pH 6.8 
(Separation gel buffer)
” 1 ml
Protogel* 2.5 ml 0.63 ml
TEMED 5 JLtl 5 pi
10 % Ammonium 
persulphate
50 pi 37.5 pi
* Protogel (national Diagnostics, Atlanta, USA) consists of 30 % w/v acrylamide and 
0.8 % bisacrylamide
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Appendix 2: Components of commercial reagents
Denhardt’s solution: contains BSA, Ficoll, PVP in water, as a 50x concentrate
DiffQuik: Solution I contains Eosin G in phosphate buffer pH 6.6 (1.22 g/L)
Solution I contains thiazine dye in phosphate buffer pH 6.6 (1.1 g/L)
Fixative contains fast green in methanol (0.002 g/L)
Euthatal: sodium pentobarbitone (60 mg/ml)
Hypnorm: fentanyl citrate (0.315 mg/ml) with fluanisone (10 mg/ml)
m Indium Chloride (inInCl3): 10 jiCi/ml in pyrogen-free 0.04 N HC1
125Iodine labelled human serum albumin (125I-HSA): 20 mg albumin/ml of sterile 
isotonic saline 50 |iCi/ml
Lambda DNA-EcoR I and Hind III digests for molecular weight markers
Double stranded DNA was digested with EcoR I and Hind III restriction endonucleases 
and dialysed against lOmM Tris-HCL pH 7.8 containing 1 mM EDTA. The digest 
consisted of 13 fragments from 125 base pairs to 21,226 bases.
Mark 12, wide-range protein standards from 2.5kDa to 200kDa
Protein Molecular weight
Myosin (rabbit muscle) 200,000 Da
(3 galactosidase (E. coli) 116,300 Da
Phosphorylase b (rabbit muscle) 97,400 Da
Bovine serum albumin 66,300 Da
Glutamic dehydrogenase (bovine liver) 55,400 Da
Lactate dehydrogenase (porcine 
erythrocyte
36,500 Da
Carbonic anhydrase (bovine 
erythrocyte)
31,000 Da
Trypsin inhibitor (soybean) 21,500 Da
Lysozyme (Chicken egg white) 14,400 Da
Aprotinin (bovine lung) 6,000 Da
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Percoll: silica particles, at a density of 1.120±0.005 g/ml 
Protogel: 30 % w/v acrylamide, 0.8 % bisacrylamide
RNAsol B: contains unspecified amounts of guanidine thiocyanate and phenol 
Sagatal: pentobarbitone sodium (60 mg/ml)
Transcription buffer (x5) commercial preparation containing: 200 mM Tris-HCl, pH 
7.5, 30 mM MgC^, 10 mM spermidine, 50 mM NaCl.
Bronchial epithelial growth medium (BEGM). contains hydrocortisone, epidermal 
growth factor, epinephrine, transferrin, insulin, retinoic acid, and BSA; unspecified 
amounts
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